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ABSTRACT 
 
Endothelial cells line all of our blood vessels. They monitor and respond to 
signals generated during injury, infection and disease by releasing a wide range of 
molecules  that  regulate  blood  flow,  coagulation,  inflammatory  responses  and 
vessel  growth.  Protein  mediators  are  released  by  exocytosis  of  intracellular 
organelles,  and  a  major  trigger  for  this  type  of  secretion  is  an  increase  in 
intracellular free calcium ion concentration ([Ca
2+]i). Mitochondria are thought to 
influence  Ca
2+  homeostasis  through  local  Ca
2+  buffering.  Due  to  a  lack  of 
sensitive and time-resolved assays for endothelial exocytosis little is known about 
the precise relationship between Ca
2+-signalling and exocytosis, and the influence 
of Ca
2+ buffering by mitochondria.  
Using  fluorescence  and  biochemical  techniques  I  have  investigated  the 
relationship  between  secretagogue-evoked  Ca
2+-signalling  and  the  influence  of 
mitochondrial function on the exocytosis of two distinct organelle populations in 
cultures of Human Umbilical Vein Endothelial Cells (HUVEC); 1) the Weibel-
Palade  body  (WPB)  the  main  storage  organelle  for  pro-coaguland  and 
inflammatory mediators, and 2) the non-WPB, a non-stored and morphologically 
distinct  organelle  that  can  contain  a  range  of  inflammatory  and  anti-coagulant 
molecules.  
These  two  distinct  organelle  populations  were  labeled  for  fluorescence 
microscopy by targeted expression of chimeras of green (EGFP) or red (mRFP) 
fluorescent  proteins  in  living  HUVEC.  Exocytosis  was  evoked  by  both 
physiological and pharmacological secretogogues that increase [Ca
2+]i. The times 
of exocytosis of individual organelles were monitored by flashes of light from 
granule EGFP, produced by pH changes within the organelle upon fusion. In the 
same experiments, [Ca
2+]i and intra-mitochondrial Ca
2+ concentration ([Ca
2+]m) 
were monitored using fluorescent Ca
2+-indicators. 
The  data  obtained  has  defined  more  precisely  the  relationship  between 
agonist-evoked changes in [Ca
2+]i and secretory vesicle exocytosis in HUVEC. 
These  studies  will  contribute  to  a  better  understanding  of  the  processes  that 
regulate secretion of biomolecules from the endothelium. 
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1.1  Outline 
This thesis focuses on the use of optical techniques to study exocytosis of 
secretory  granules  from  cultured  Human  Umbilical  Vein  Endothelial  Cells 
(HUVEC). Two granules were studied; the Weibel Palade Body (WPB), a true 
storage organelle of endothelial cells (EC), and a less well characterised granule 
called  for  the  purposes  of  this  thesis  the  non-WPB  organelle.  This  chapter 
includes a brief introduction to the endothelium followed by a description of the 
two secretory organelles studied, the secretagogues used to study exocytosis and 
the pathways of intracellular Ca
2+ release and sequestration that drive secretion. A 
detailed description of the secretory pathway and formation of the WPB follows 
including what is known about the regulation of WPB fusion. Then the role of the 
main WPB cargo protein von Willebrand Factor (vWF) and a non-WPB cargo 
protein  the  tissue  plasminogen  activator  (t-PA)  is  summarised  in  regulating 
vascular homeostasis, injury and inflammation. Finally the role of mitochondria in 
endothelial cells and in other systems is reviewed.  
1.2  The Endothelium 
1.2.1  Historic background 
The vascular endothelium forms the lining of blood vessels, a monolayer of 
cells that separates blood from vascular muscle (see review [2]). In 1628 the first 
observation of circulating blood took place by William Harvey and later on in 
1660 Malphigi discovered the existence of a network of vessels separated from 
tissue [3]. The existence of cells lining blood vessels was discovered in the 1800s 
by von Recklingausen [2]. At that time the endothelium was characterized as an 
inert semi-permeable barrier that controls traffic of substances between plasma 15 
and tissue by osmotic pressures [3]. It wasn’t until the 1950s when George Palade 
performed  electron  microscopic  studies  of  the  endothelium  [4],  and  James 
Gowans  studied the interaction between lymphocytes and the endothelium [5] 
that the idea of the endothelium being a specialized organ emerged. Subsequent 
studies  led  to  the  characterization  of  the  endothelium  as  a  dynamic  secretory 
organ  [3, 6] with great heterogeneity arising from variations in local environment 
and  vessel  size  [7].  Phenotypic  endothelial  differences  across  the  vasculature 
include  intracellular  continuity,  degree  of  fenestration  [8],  susceptibility  to 
undergoing  apoptosis  [9]  and  differential  protein  expression  such  as  of  von 
Willebrand  factor  (vWF)  [7]  and  tissue  plasminogen  activator  (t-PA)  [10]. 
Detailed study of the function of the endothelium first became feasible with the 
development of techniques to culture endothelial cells (EC)
 in vitro in the 1970s 
[11-13]. However, it has been established that the EC phenotype is altered under 
culture conditions [14]. Yet, EC in culture retain  many properties of EC in vivo, 
making them a useful, practical model for the study of the endothelium and its 
properties (reviewed in [15]).  
1.2.2  The endothelium as a secretory organ 
The  regulatory  role  of  the  endothelium  on  its  two  contact  surfaces;  the 
circulating  blood  and  the  smooth  muscle  layer  is  immense.  This  role  is 
accomplished  by  secretion  of  factors  responsible  for  mediating  vessel  growth, 
blood coagulation, regulation of blood flow, vessel permeability and nutrient and 
leukocyte traffic (reviewed in [16]). EC help control blood pressure and blood 
flow by the constitutive and regulated release of vasodilators such as nitric oxide
 
(NO) and prostacyclin (PGI2) [17] and vasoconstrictors such as endothelin (ET) 
and  platelet-activating  factor  (PAF)  [18,  19].  Moreover  EC  express  or 16 
constitutively release/secrete mediators to maintain normal blood fluidity under 
resting conditions [16]. The antithrombotic mediators of the endothelium can be 
divided into three groups; the mediators that prevent platelet aggregation and thus 
thrombus  formation  (primary  haemostasis)  such  as  PGI2,  NO  and  surface 
proteoglycans;  the  anticoagulants  which  act  to  suppress  the  activation  of  the 
coagulation  pathway  (secondary  haemostasis),  such  as  tissue  factor  pathway 
inhibitor  (TFPI),  protein  C  and  annexin  V;  and  those  that  act  to  dissolve  the 
formed  clot  (fibrinolysis)  such  as  tissue  plasminogen  activator  (t-PA)  and 
plasminogen activator inhibitor 1 (PAI-1) [16]. Some of these processes will be 
considered later in more detail. Furthermore the endothelium is responsible for 
promoting  blood  coagulation  by  regulated  exocytosis  during  vascular  injury, 
inflammation,  hypoxia  [20],  ischemia,  radiation  or  mechanical  stimuli  such  as 
high shear stress [21, 22]. EC release pro- and anti-coagulant factors to promote 
and at the same time localise and limit blood coagulation under conditions of 
stimulation. Some of these factors are produced “on demand” for instance PGI2, 
NO  and  PAF  and  others  such  as  von  Willebrand  Factor  (vWF)  and  tissue 
plasminogen activator (t-PA) reside in preformed secretory organelles such as the 
Weibel  Palade  Body  (WPB)  and  the  non-WPB  respectively.  In  all,  the 
endothelium can be described as a specialised secretory organ.  
1.3  Secretory Organelles of ECs 
1.3.1  The Weibel Palade Body and its cargo 
The WPB is a secretory organelle made exclusively in EC, discovered in 
1964 by Weibel and Palade from lung electron microscopy studies [23, 24]. The 
organelles were characterised as rod shaped of about 0.15µm in diameter and 2-17 
3µm in length consisting of tightly packaged fine tubules of approximately 15nm 
thick. Biochemical, immunofluorescence and structural studies suggested that the 
fine tubules in WPBs are von Willebrand factor (vWF) [25-27], the major protein 
of  WPBs,  comprising  more  than  95%  of  its  cargo  [28].  Figure  1.1A  is  a 
fluorescence image of a single HUVEC immune-labelled with an antibody against 
vWF  illustrating  the  rod-shaped  WPB  organelles.  The  paracrystalline  storage 
property  of  vWF  [26]  is  thought  to  be  necessary  for  the  rapid  release  and 
simultaneous unravelling of the 100µm vWF filaments upon exocytosis [29], to 
efficiently capture platelets along their lengths [30, 31] in response to fluid shear 
[32, 33]. The role of vWF in haemostasis is considered later on in more detail. 
The nascent vWF protein consists of a pro-peptide (proregion) which is cleaved 
during maturation but remains non-covalently linked to the mature vWF protein in 
the  WPBs  [24,  34].  Upon  exposure  of  the  WPB  lumen  to  physiological  pH, 
proregion dissociates from mature vWF and rapidly disperses from the site of 
exocytosis [35]; whereas vWF adheres to the endothelial cell membrane or the 
exposed sub-endothelium [36-39]. Under conditions of low extracellular pH such 
as  ischemia,  proregion  remains  associated  with  secreted  vWF  [34].  The 
extracellular role of proregion is still under investigation. In vitro it can act as a 
ligand for the Very Late Antigen -4 integrin (VLA-4) present on monocytes [40], 
suggesting  a  potential  role  in  chemotaxis.  Other  sources  suggest  proregion 
associates with IL-8 to promote neutrophil adhesion [41] and may play a role in 
platelet aggregation [42] as it contains a binding site for platelets [43].  
Other core and membrane proteins in the WPB are co-packaged during the 
organelles’ formation at the trans-Golgi-network (TGN) or are recruited during 
post-Golgi  maturation  of  the  organelle.  The  WPB  membrane  can  contain  the 18 
leukocyte  adhesion  molecule  P-selectin,  also  present  in  platelets  [44,  45].  P-
selectin  translocates  to  the  EC  plasma  membrane  during  WPB  exocytosis  and 
mediates neutrophil and monocyte rolling along activated endothelium by binding 
via the P-selectin glycoprotein ligand-1 (PSGL-1) in a Ca
2+ dependent interaction 
[46].  P-selectin  deficient  mice  exhibit  an  absence  of  leukocyte  rolling  on  the 
endothelium  [47].  About  20min  after  its  secretion,  P-selectin  is  thought  to 
endocytose via a clathrin associated mechanism [48, 49] and recycle to the Golgi 
where it can be re-incorporated into newly forming WPB or sent to lysosomes for 
degradation [50]. P-selectin is not expressed in all endothelial cells and in those 
that do express it, it may not be found in all WPBs [51]. In addition, expression of 
P-selectin alone in an epithelial cell line does not lead to formation of pseudo-
WPBs, but rather requires  co-expression with vWF [52], suggesting no role for P-
selectin in the formation of the WPB. 
Small membrane GTP-binding proteins [53] that take part in transport or 
exocytosis, Rab27a [54], rab3D [55] and ralA [56] are thought to be recruited to 
the WPB membrane at some stage post-budding from the trans-Golgi network 
(TGN) and reflect maturation of the granule. Recently it has been suggested that 
Rab27a prevents exocytosis of mature WPBs in the absence of a stimulus, by 
anchoring the granules to the actin matrix in a complex with its effector molecule 
MyRIP  [57].  Another  component  of  the  WPB  membrane  is  the  glycoprotein 
CD63 or lamp3 [58]. CD63 is also found in late endosomes and in lysosomes and 
is constitutively expressed at the cell surface of HUVEC. After internalization it 
can be delivered via endosomal structures to post-Golgi WPBs [59]. The function 
of CD63 on the WPB is unclear. The fact that the WPB contain Rab27a and CD63 
on their membrane, both markers of secretory lysosomes in other cells [60-62], 19 
has led to the suggestion that both organelles are somehow evolutionary related 
[63, 64]. 
In addition to the WPB membrane proteins, soluble core proteins include 
small  chemokines  such  as  IL-8  a  neutrophil  chemoattractant  [41,  65,  66]  and 
eotaxin-3 an eosinophil chemoattractant [67], which are up-regulated by tumour 
necrosis factor-α (TNF-α), Il-1 (IL-8) and Il-4 (eotaxin-3) [68]. In other cell types 
that do not form WPB, Il-8 is found in the Golgi [41].  
Under  certain  conditions  WPBs  have  been  reported  to  contain  the 
vasoconstrictor  endothelin-1[69],  anti-coagulant  molecule  tissue  plasminogen 
activator (t-PA) [70], angiopoietins-1 and 2 [71, 72], osteoprotegerin [73, 74] and 
factor VIII [75].  
1.3.2  The non-WPB- secretory organelle for t-PA 
  Tissue  plasminogen  activator  (t-PA)  is  a  serine  protease  important  in 
fibrinolysis, discussed in more detail later. Although t-PA is continuously secreted 
by the endothelium under resting conditions, its rate of secretion increases during 
stimulation  [76-78].  The  secretory  organelle  for  t-PA  has  long  been  under 
investigation,  initially  to  understand  whether  spontaneously  secreted  t-PA  was 
derived from a different population of secretory granules than that responsible for 
stimulated secretion of t-PA. It was found that t-PA was stored in WPBs from co-
localization studies of t-PA and vWF in cultured EC [79]. Secretion studies further 
showed coordinated release of the two proteins in response to various secretagogues 
[70, 79, 80]. T-PA was targeted to pseudo-WPBs in co-expression studies of vWF 
and  t-PA  in  ECV304,  a  cell  line  that  does  not  endogenously  express  vWF, 
suggesting targeting of t-PA to the regulated pathway of secretion in the presence of 20 
vWF [81]. Other biochemical studies however showed differential release of t-PA 
and vWF to Ca
2+-raising agonists such as thrombin [82], bradykinin [82], histamine 
[83] and ionomycin [84] possibly via a CaM/Ca
2+-dependent pathway [84] and to 
cAMP  raising  agents  [85,  86],  suggesting  t-PA  exists  in  a  non-WPB  type  of 
granule. Using density gradient centrifugation Emeis (1997) identified a separate 
secretory granule for t-PA, small dense vesicles that underwent exocytosis when 
stimulated with high concentrations of thrombin [87]. Other reports also identified a 
population of granules morphologically distinct from WPBs, appearing as small 
punctuate structures of  0.1-0.2µm diameter [88, 89]. A controversy  exists as to 
whether t-PA is packaged in WPBs or in a distinct small organelle called the “non-
WPB organelle” for the purposes of this thesis. Work in our lab has shown that t-
PA is found in both the WPB and the non-WPB organelle. Figure 1.1B shows a 
single HUVEC immuno-labelled with an antibody against t-PA demonstrating the 
punctate non-WPB organelles.  
The  non-WPB  organelle  lacks  vWF,  CD63  and  P-selectin  and  does  not 
recruit Rab27a (T Carter personal communication) or rab3D [55], but can contain 
a  wide  variety  of  molecules,  depending  on  the  status  of  the  cell.  Such  cargo 
molecules may include protein S [90, 91], and t-PA [76]. The chemokines GRO-α 
and  MCP-1  [92]  have  recently  been  identified  in  a  population  of  secretory 
granules  distinct  from  the  WPB  that  can  undergo  stimulated  exocytosis.  That 
study  did  not  show  co-localisation  of  the  GRO-α  positive  granules  with  t-PA 
positive granules; however evidence from unpublished work in our lab suggests 
that these organelles are indeed the same.  
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Figure 1.1 Immuno-labelled WPBs or non-WPBs in single HUVEC 
Immunofluorescence image showing a single HUVEC stained with an antibody 
specific  for  vWF  (A),  the  major  protein  of  the  endothelial  specific  storage 
granules Weibel Palade Bodies, typically rod-shaped organelles and an antibody 
specific for endogenous t-PA (B), labelling the non-WPB organelles, appearing as 
small puncta. 
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1.4  Signalling pathways leading to WPB release 
WPB  exocytosis  can  be  triggered  by  mechanical  and  chemical  stimuli, 
during physical exercise [93], by fluid shear stress [21, 94], and by physiological 
agonists  [95,  96].  The  physiological  agonists  can  be  crudely  divided  into 
secretagogues that increase intracellular free calcium ion concentration ([Ca
2+]i), 
such as histamine [97-99], ATP [100, 101], vascular endothelial growth factor 
(VEGF)  [102],  PAR2-activating  peptide  [51]  and  thrombin  [103-105];  or 
intracellular cyclic adenosine monophosphate concentration (cAMP) [101] such 
as serotonin [106], vasopressin [107] and epinephrine [108].  
Agonists such as histamine and thrombin, raise [Ca
2+]i by binding to G-
protein coupled receptors (GPCRs) of the Gq-type on the EC membrane, leading 
to  activation  of  phospholipase  Cβ  (PLCβ)  [109].   PLC  hydrolyzes 
phosphoinositide 4, 5 bisphosphate (PIP2) to yield the soluble messenger inositol 
1,4,5-trisphosphate  (IP3)  and  diacylglycerol  (DAG)  [110-113].  DAG  activates 
protein kinase C (PKC) in the presence of Ca
2+ [114] which may act as a feedback 
mechanism to regulate raised [Ca
2+]i but does not appear to be involved in vWF 
secretion [115-117]. IP3 diffuses in the cytosol and acts on IP3 Receptors (IP3R) on 
the ER [118, 119] to trigger Ca
2+ release. There are three IP3R isoforms [120] and 
most cell types express more than 1 isoform of IP3R [121, 122]. Endothelial cells 
have highest expression levels for type 1 IP3R [123]. Intracellular Ca
2+ rise is 
coupled to calmodulin activation (Ca
2+/CaM), which is thought to play a role in 
WPB exocytosis [84, 115], possibly via activation of molecules involved in the 
exocytotic machinery [124-126]. 
cAMP raising agonists bind to GPCRs of the Gs-type which results in the 
activation  of  adenylate  cyclase  (AC)  and  thus  the  formation  of  the  second 23 
messenger cAMP from ATP. cAMP is known to bind and activate protein kinase 
A (PKA) in ECs [108]. Inhibition of cAMP-activated PKA in HUVEC results in 
reduced vWF secretion [101, 107] suggesting a role for PKA in WPB exocytosis. 
cAMP is degraded by cyclic nucleotide phosphodiesterases (PDE).  
cAMP-  raising  agents  are  slower  and  less  efficient  in  triggering  WPB 
exocytosis than Ca
2+-raising agents [127]. Moreover the two types of signaling 
pathways are also thought to have opposing effects on the cytoskeleton. While 
Ca
2+ drives the recruitment of granules from the periphery and the center of the 
cell to the plasma membrane, intracellular cAMP rises drive only the recruitment 
of granules from the periphery and tend to trigger the formation of clusters of 
granules around the nucleus [127, 128]. Moreover Ca
2+-raising agents cause cell 
retraction  and  intercellular  gap  formation,  whereas  cAMP-raising  agents 
strengthen the cortical actin network and preserve cell-cell contacts [127]. It is 
generally  thought  that  cAMP-raising  agents  act  in  a  more  systemic  manner, 
important in the physiological regulation of plasma vWF levels [93, 129], whereas 
Ca
2+ elevating agents may  evoke acute responses involved in inflammation or 
thrombosis.  
1.5  WPB Secretagogues used in this thesis  
In this thesis, WPB and non-WPB kinetics of exocytosis were determined 
for  the  physiological  Ca
2+-elevating  agonists,  histamine  and  thrombin.  The 
response  to  these  agonists  was  compared  to  the  receptor-independent 
pharmacological secretagogue ionomycin. Figure 1.2 shows a schematic of the 
action of the three secretagogues at the membrane receptor level. 24 
1.5.1  Histamine 
Histamine is a major mediator of acute inflammation and hypersensitivity 
responses. It is a hydrophilic vasoactive amine derived from the decarboxylation 
of the amino acid histidine, catalyzed by the enzyme L-histidine decarboxylase 
[130]. Histamine is broken down by histamine-N-methyltransferase and diamine 
oxidase [130]. 
Histamine  has  pleiotropic  actions  and  is  involved  in  smooth  muscle  cell 
proliferation  [131],  lymphocyte  differentiation  [132]  and  hematopoiesis  [133]. 
The majority of histamine is stored in granules in mast cells [134] and basophils 
[135],  leukocytes involved in allergic reactions. While basophils are only found 
in the circulation, mast cells migrate into the tissues. Mast cells and basophils are 
stimulated  to  secrete  histamine  when  their  IgE  plasma  membrane  receptor  is 
activated by the appropriate allergen cross-linked to IgE immunoglobulin [136]. 
Mast cell stimulation in tissue is thought to be involved in atherogenesis, while 
activation of mast cells in the human heart and coronary arteries are linked to 
coronary artery disease [137]. 
There are four subtypes of histamine receptors (HR), HR1, HR2, HR3 and 
HR4; all of which are aminergic G-protein coupled receptors (GPCRs), comprised 
of a heptahelical transmembrane protein that transduces extracellular signals via G 
proteins and intracellular second messenger systems [109]. HR1 couples to Gq and 
leads to PIP2 hydrolysis, HR2 couples to Gs to activate adenylate cyclase and HR3 
and HR4 couple to Gi to inhibit the adenylate cyclase pathway (reviewed [138]). 
Molecular  properties,  distribution  and  functional  characteristics  of  histamine 
receptor  subtypes  differ  in  various  species  and  tissues  [139].  Across  the 
endothelium HRs occur at high densities in venules whereas in arterioles, veins 25 
and muscular arteries they have been found at lower densities with capillaries and 
the aorta showing the lowest levels [140]. The distribution and density of receptor 
subtypes is an important factor defining  cellular responses [141]. Site-directed 
mutagenesis studies have identified the binding pocket of histamine on the human 
HR1  receptor  to  be  Asp
107  in  transmembrane  domain  3,  a  conserved  residue 
among all aminergic receptors, responsible for an ionic interaction with the amino 
group  of  histamine  [142,  143].  The  active  and  inactive  states  of  HRs  exist  in 
equilibrium. HR agonists such as histamine, have a higher affinity for the active 
state of the receptor and antagonists for the inactive one. Specific binding to HR1 
by mepyramine, an HR1 selective antagonist, has been used to study the binding 
characteristic  of  HR1  agonists  and  antagonists.  The  association  constant  of 
mepyramine for the HR1 is 1.6±0.4nM [144]. The affinity of histamine for the 
HR1, measured as [
3H]mepyramine displacing ability (inhibition constant Ki), was 
determined by competition binding assays to be 16.9±0.1µM [143].  
Receptor homologous desensitization is characterized by a loss of receptor 
responsiveness in the continuous presence of high concentrations of an agonist 
[145]. It was early established that the HR is prone to homologous desensitization 
[146]  and  PKC  phosphorylation  of  HR1  is  thought  to  play  a  role  in  this 
mechanism  [147].  Additional  evidence  of  homologous  desensitization  of  HR1 
came from studies in various cell lines including BC3H-1 cells, Hela cells and 
1321N1  human  astrocytoma  cells  [147-149]  and  smooth  muscle  preparations 
[150, 151]. These studies reported that prolonged or repetitive exposure of cell 
cultures to high histamine concentrations decreased the Ca
2+ response, attributing 
this  effect  to  the  temporary  inactivation  of  HR1  leading  to  a  reduced  agonist 
affinity. On the contrary prolonged stimulation of human umbilical endothelial 26 
cells with low concentrations of histamine induced [Ca
2+]i oscillations that were 
maintained unaffected by the duration of histamine stimulation [152]. Subsequent 
stimulations with higher histamine concentrations for a short period of time before 
returning back to low histamine concentrations did not affect the amplitude of  the 
[Ca
2+]i spikes suggesting no apparent desensitization of the HR1 in those studies 
[152]. 
Histamine released in the circulation results in transient, regional activation 
of endothelial cells. Endothelial cells express both HR1 and HR2 [153, 154]. In 
vivo HR1 mRNA is found to be up-regulate during inflammatory conditions such 
as  atherosclerosis  and  allergic  rhinitis  [155,  156].  In  vitro,  histamine  HR1 
activation in human umbilical endothelial cells leads to [Ca
2+]i rises [152, 157] in 
a dose-dependent manner [97]. Downstream effects of histamine binding to EC 
include an increase in vascular permeability, first discovered by Dale and Laidlaw 
[158] and further characterised using electron microscopy by Majno and Palade in 
1961  who  demonstrated  histamine  creates  junctional  gaps  between  adjacent 
endothelial cells that could facilitate plasma to leak into the basement membrane 
[159].  Contraction  in  endothelial  cells  for  the  formation  of  junctional  gaps  is 
driven by the contractile proteins actin and myosin [160]. Moreover, histamine is 
a potent secretagogue stimulating PGI2 [161] and vWF release [97], both in a dose 
dependent manner [97]. Histamine also stimulates secretion in a variety of other 
cell types including neurons [162] and adrenal gland cells [163].  
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1.5.2  Thrombin 
Thrombin is a serine protease of the coagulation cascade [164] derived from 
the  proteolytic  cleavage  of  the  zymogen  pro-thrombin  by  the  pro-thrombinase 
complex consisting of serine protease factor Xa and its cofactor Va, end products 
of the coagulation cascade [165]. Production of thrombin is regulated by thrombin 
itself in a positive feedback mechanism where thrombin activates factor V and 
factor  VIII  to  propagate  the  coagulation  cascade  [166-168].  Thrombin  also 
negatively  regulates  its  production  by  activating  protein  C,  via  binding  to 
thrombomodulin.  Protein  C  acts  to  damp  down  the  coagulation  cascade,  by 
inactivating  many  of  the  serine  proteases  involved  in  the  cascade  [169].  The 
ultimate  role  of  thrombin  is  the  conversion  of  the  soluble  plasma  protein 
fibrinogen  into  insoluble  fibrin.  Thrombin  also  activates  many  cells  including 
platelets, endothelial cells, epithelial cells, smooth muscle cells and hemopoietic 
cells  to  promote  haemostasis  [170-173].  Thrombin-activated  platelets  secrete 
many  molecules  that  will  act  autologously  to  induce  platelet  shape  change, 
aggregation and adhesion to the sub-endothelium to promote fibrin clot formation.  
Thrombin acts through Proteinase Activated Receptors (PARs), which like 
the  HR  receptors,  are  G-protein  coupled  receptors  [174,  175].  There  are  four 
PARs (PAR-1-4), of which thrombin activates PAR-1, 3 and 4 whereas PAR-2 is 
activated by trypsin or mast cell tryptase [176]. Thrombin activates PAR-1 and 3 
with high potency and PAR-4 with low potency. Endothelial cells constitutively 
express  PAR-1  and  PAR-2  [177,  178]  which  play  a  functional  role  in  the 
endothelium whereas PAR-3 and PAR-4 are limited to regulating platelet function 
[179]. The half maximal effective concentration (EC50) of thrombin on PAR-1 
activation was found to be 50 pM [180]. The interaction between thrombin and 28 
PAR-1  on  endothelial  cells  takes  place  between  the  anion  binding  site  of 
Thrombin, a sequence of positively  charged basic residues, and a sequence of 
negatively  charged  acidic  residues  on  the  amino-terminus  of  PAR-1  [176]. 
Thrombin cleaves the amino-terminus, an irreversible process, to expose a new 
amino-terminus and render the receptor active. Low concentrations of thrombin 
will eventually cleave and activate all the receptors on a cell; however the rate of 
receptor  cleavage  will  depend  on  thrombin  concentration.  Studies  in  human 
pulmonary artery endothelial cells showed that both duration and concentration of 
thrombin stimulation regulate endothelial cell surface PAR-1 expression [181]. 
PAR-1 desensitization occurs by receptor inactivation and internalization during 
long exposures (>60min) to low doses (25nM) of thrombin [181]. The internalized 
receptors are sorted to lysosomes in endothelial cells and fibroblasts [182]. The 
recovery  of  the  receptor  responsiveness  occurs  by  de  novo  synthesis  and 
translocation of PAR-1 to the cell surface [181]. 
Following thrombin induced PAR-1 activation, PLC is activated through Gq 
to  produce  IP3  which  mobilises  [Ca
2+]i  and  DAG  which  activates  PKC  [179]. 
Thrombin has been shown to produce a dose-dependent [Ca
2+]i rise and dose-
dependent patterns of [Ca
2+]i signalling in endothelial cells [97, 183]. Thrombin-
induced PAR-1 stimulation in endothelial cells leads to secretion of NO and PGI2 
[103] which may cause smooth muscle cell contraction [184]; reversible increase 
of microvascular permeability by formation of inter-endothelial gaps [185, 186] 
due to cadherins junction disassembly [187, 188] and vasoconstriction [189, 190] 
due to myosin light chain phosphorylation which results in mechanical contraction 
of the endothelium [191]. Histamine also induces endothelial gap formation but 
with  less  potency  than  thrombin  [187].  Thrombin-induced  secretion  of  von 29 
Willebrand  factor  is  thought  to  be  due  to  [Ca
2+]i  elevations  instead  of  PKC- 
mediated signal transduction [115]. 
1.5.3  Ionomycin 
Ca
2+ ionophores such as ionomycin are often used as experimental tools to 
stimulate Ca
2+-dependent processes such as exocytosis [1, 83, 116] or to discharge 
intracellular  Ca
2+  stores  [192,  193]  independently  of  cell  surface  receptor 
activation.  Ionomycin  belongs  to  the  family  of  polyether  carboxylic  acid 
antibiotics  [194]  isolated  from  the  bacterium  Streptomyces  conglobatus  [195]. 
Due to its dibasic acidic properties it selectively forms positively charged 1:1 lipid 
soluble  complexes  with  divalent  cations  [196-201],  with  a  high  selectivity  for 
Ca
2+  over Mg
2+ [201], to transport Ca
2+ across membranes [202, 203]. Ionic or pH 
differences may induce variations in the affinity of ionomycin for Ca
2+ [201, 204]. 
Ionomycin is a Ca
2+ transporter in both directions between membranes such that 
Ca
2+  equilibrates  uniformly  in  all  vesicles  within  a  cell  at  all  ionomycin 
concentrations  used  [205].  The  ionomycin-induced  Ca
2+  transport  across 
membranes can be influenced by plasma membrane depolarisation [204].  
In EC ionomycin-induced emptying of the ER leads to a sustained [Ca
2+]i 
rise. This sustained rise is due to a store-regulated Ca
2+ entry process, activated by 
ER Ca
2+ depletion, which refills the intracellular Ca
2+ store via the action of the 
Sarco-ER-Ca
2+ ATPase (SERCA) pump on the ER [206]. Supporting evidence 
come from experiments where blocking the store-regulated Ca
2+ entry pathway 
showed no change in the initial mobilization of Ca
2+ observed but showed an 
inhibition of the plateau phase of ionomycin-evoked [Ca
2+]i responses [206]. 
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Figure 1.2 Histamine, thrombin and ionomycin cell membrane action 
Schematic of histamine (A), thrombin (B) and ionomycin (C) action at the cell 
membrane. Histamine in endothelial cells acts via the histamine receptor HR1 and 
thrombin  via  the  Proteinase-Activated  Receptor  1  (PAR-1),  both  G-protein 
coupled receptors. Thrombin cleaves PAR-1 at the NH2 terminus for the receptor 
to be activated. Ionomycin bypasses the receptor level and translocates Ca
2+ ions 
into the cytosol mainly from the internal Ca
2+ store.  
C 
Ca
2+ 
store
s 
[Ca
2+]i 
Ionomycin 
Ca
2+ 
Ca
2+ 
Ca
2+ 
A  B 
 INACTIVE 
 
 
Hist 
Hist 
NH2 
GDP  GTP 
Gq 
 
COOH  COOH 
 ACTIVE 
NH2 
INACTIVE   ACTIVE 
￿
 
GDP  GTP 
Gq  Gq 
COOH 
Thr 
Gq 
PAR-1: Thrombin  HR1: Histamine 
NH2 
COOH 31 
1.6  Regulation of intracellular Ca
2+ homeostasis 
Ca
2+  is  a  major  intracellular  messenger  in  eukaryotic  cells  [207].  The 
regulation of Ca
2+ levels is important for  controlling cellular processes and to 
ensure that [Ca
2+]i does not reach cytotoxic levels [208]. The major Ca
2+ store in 
the cell is the ER constituting approximately 75% of the total intracellular Ca
2+ 
reserve  in  endothelial  cells  while  the  remaining  25%  is  handled  by  the 
mitochondria  [209].  Both  ER  and  mitochondria  have  high  capacities  for  Ca
2+ 
storage, reaching  as high as 3mM in the ER most of which is bound to Ca
2+ 
binding proteins (see review [210, 211]) such as calreticulin [212] or BiP [213]. 
The  cytosolic  Ca
2+  response  is  biphasic;  firstly  an  initial  transient  increase  of 
[Ca
2+]i due to IP3-evoked release from intracellular stores [214], followed by a 
prolonged phase, that can take the form of either a maintained [Ca
2+]i
 elevation, a 
decline to basal levels (~0.1µM) or periodic Ca
2+ spikes (oscillations) [100, 105, 
215-217]. The major pathways of intracellular Ca
2+ sequestration are illustrated in 
Figure 1.3 and dissected below. 
1.6.1  The initial phase of the [Ca
2+]i  response and Capacitative Ca
2+ entry 
The  initial  phase  of  the  [Ca
2+]i  rise  evoked  by  histamine  or  thrombin 
depends  on  the  generation  of  IP3  and  the  activation  of  the  IP3R  on  the  ER 
membrane. 
Early studies suggested that the agonist dependent depletion of the internal 
stores  is  a  trigger  for  extracellular  Ca
2+  entry  via  plasma  membrane  channels. 
These  studies  used  Mn
2+  entry,  monitored  as  quenching  of  cytosolic  Fura-2 
fluorescence in thrombin stimulated platelets [218] and endothelial cells [219]. 
This mechanism was described by Putney in 1986 as store-operated-Ca
2+-entry 32 
(SOC)  or  capacitative  Ca
2+  entry  (CCE)  [220,  221]  and  is  responsible  for 
accomplishing long lasting Ca
2+ influx in endothelial cells [222-224] and other 
non-excitable cell types [225-227]. Extensive studies have taken place to try and 
identify the Ca
2+ entry channels. In 1992 Hoth et al discovered a non-voltage-
gated Ca
2+ selective current in mast cells activated by store depletion, which was 
called  the  ICRAC  (Ca
2+-release  activated  Ca
2+-current)  [192,  228].  The  ICRAC, 
conducted by the CRAC channel, is a small inwardly rectifying current with a 
very positive reversal potential (>+60mV) suggesting a high selectivity for Ca
2+ 
[229]. The CRAC channel is thought to be under negative feedback regulation by 
high local concentrations of Ca
2+ and the extent of store depletion [230, 231]. 
ICRAC currents activated by depleting intracellular Ca
2+ stores by ionomycin or 
administrating the SERCA blocker thapsigargin have also been described in EC 
[232, 233].  
Later on it was suggested that the CRAC channels are encoded by the Trp 
(transient  receptor  potential)  genes  [234],  originally  identified  in  a  Drosophila 
photoreceptor  mutant  [235].  The  sequence  of  Trp  [236]  was  found  to  be 
homologous to mammalian voltage-dependent Ca
2+ channels [237]. Heterologous 
expression of Trp in mammalian systems demonstrated enhanced CCE [238]. In 
vascular  EC  at  least  19  Trp  isoforms  are  expressed  with  diverse  functions, 
including modulation of EC permeability, cytoskeleton rearrangement, oxidative 
stress  induced  responses  and  vascular  tone  activated  by  different  stimuli 
(reviewed in [239]). TRP activation in EC is thought to fine-tune the membrane 
potential (PM) leading to altered driving force for Ca
2+ entry (reviewed [240]). 
Due to the importance  of TRP channels in controlling [Ca
2+]i signalling, their 
malfunction may lead to cardiovascular disorders [241]. TRP channels 1 (TRPC1) 33 
[242,  243]  or  4  (TRPC4)  [244]  have  been  proposed  to  mediate  CCE  in  EC, 
however this is debatable due to their non-selectivity for Ca
2+ [245].   
Although  research  has  led  closer  to  the  identity  of  CCE  channels,  the 
signalling  pathways  that  couple  intracellular  store  depletion  to  the  plasma 
membrane to activate the Ca
2+ entry channels remain unclear. Three mechanisms 
have been proposed by different groups (reviewed [246, 247]). Firstly a diffusible 
messenger pathway has been proposed [248] in which a small mobile factor is 
released from the stores upon their depletion, termed Ca
2+- influx factor (CIF) 
[249] which directly opens CRAC channels [250]. A likely proposed molecule to 
act as a diffusible messenger is microsomal P450 mono-oxygenase  (P450MO) 
metabolites  such  as  epoxyeicosatrienoic  acid  (EET).  EET  is  synthesized  from 
arachidonic  acid  which  is  produced  by  Ca
2+  activation  of  Phospholipase  A2 
(PLA2)  and  acts  as  an  endogenous  ligand  on  CCE  channels  [251].  Ca
2+  entry 
induced  by  EET  has  been  reported  previously  in  EC  [252-255].  The  second 
mechanism proposed for CCE signalling was the vesicle secretion model [256] in 
which CRAC channels are transported from the ER and inserted into the plasma 
membrane upon store depletion [257]. Finally the conformational coupling model 
was proposed which suggests the interaction between ER and plasma membrane 
for  direct  Ca
2+  entry  [258].  Originally  IP3Rs  were  thought  to  be  physically 
attached to CRAC channels on the plasma membrane and function as messengers 
via direct protein-protein interactions [258, 259]. Recently two molecules have 
been  identified  as  key  players  in  the  CCE  mechanism  in  immune  cells  and 
HEK293 cells, Orai1 and STIM1 [260]. STIM1 is thought to reside on the ER 
membrane where it acts as a Ca
2+ sensor and is activated upon ER Ca
2+ depletion 
to  redistribute  into  clusters  that  approach  the  plasma  membrane  [261].  These 34 
aggregates were found to interact with Orai1 molecules on the plasma membrane 
and subunits of CRAC channels [262], leading to their activation and the direct 
entry of Ca
2+ from the extracellular space into the ER (reviewed in [263]). Orai1 
and STIM1 have recently been implicated to play a role in EC CCE mechanism 
[264]. 
1.6.2  The prolonged phase of the [Ca
2+]i response and [Ca
2+]i oscillations 
In EC Ca
2+ oscillations were first observed in cultured Human Umbilical 
Endothelial cells stimulated with histamine by Jacob et al [152] and later on with 
thrombin [183, 265], ATP [100, 215] and bradykinin [216, 266]. The mechanism 
underlying  Ca
2+  oscillations  in  non-excitable  cells  involves  complex  feedback 
behaviour by IP3 and Ca
2+ acting on the IP3R [267, 268]. The open probability of 
the brain type I IP3R Ca
2+ channel, also found in endothelial cells [123], shows a 
bell shape relationship to local [Ca
2+]i [269]. Thus in the presence of IP3, local 
[Ca
2+]i acts as a co-agonist to modify IP3R activation in a biphasic manner; low 
concentrations  increase  the  open  probability  of  the  channel  whereas  higher 
concentrations  reach  inhibitory  levels  terminating  Ca
2+  efflux  into  the  cytosol 
[270, 271]. The interaction between Ca
2+ and the IP3R is thought to account for 
the abrupt up-stroke and rapid termination of the first period of Ca
2+ release that 
gives rise to the spike-like appearance of the Ca
2+ release profile [267]. Following 
IP3R activation and Ca
2+ release, cellular buffering mechanisms remove cytosolic 
Ca
2+ [272] returning [Ca
2+]i levels back to resting levels (described in more detail 
below); allowing the slow recovery from Ca
2+-inhibition of the IP3R by high Ca
2+ 
[267]. After a period of time (that depends on the cell type and types of IP3Rs 
expressed), a regenerative cycle of IP3R receptor activation may occur, driven by 
the co-agonist effect of low Ca
2+ in the continued presence of IP3, leading to a 35 
second round of Ca
2+ release from the ER. Subsequent Ca
2+ spikes arise in the 
same  way  and  can  be  repeated  as  long  as  the  cell  is  exposed  to  agonist  that 
generates IP3 [152]. The Ca
2+-dependency of the open probability of the IP3-gated 
channels shifts according to the IP3 concentration ([IP3]i), so that at low [IP3]i the 
IP3R  is  inhibited  at  lower  local  Ca
2+;  whereas  at  high  [IP3]i  the  IP3R  activity 
persists in the face of high Ca
2+
 [273]. Thus following stimulation with very high 
agonist concentrations sustained rises in Ca
2+ rather than Ca
2+ spikes are often 
observed  [152].  Refilling  of  the  ER  for  maintaining  the  cytoplasmic  [Ca
2+]i 
oscillations is achieved by capacitative entry of extracellular Ca
2+ in endothelial 
cells [222-224] (1.6.1). 
The  Ca
2+  released  from  a  cluster  of  IP3Rs  propagates  locally  in  the 
cytoplasm  promoting  nearby  IP3R  clusters  to  release  Ca
2+  giving  rise  to  a 
propagating wave of [Ca
2+]i within single cells. Such behaviour is observed in a 
wide  variety  of  cells  including  pancreatic  acinar  cells  [274],  SMC  [275], 
hepatocytes [276] and EC [277, 278]. 
Agonist-induced  [Ca
2+]i  oscillations  may  function  to  regulated  cellular 
processes.  In  excitable  cells  [Ca
2+]i  spikes  coincide  with  exocytosis  [279],  for 
instance  gonadotropin  release  in  pituitary  gonadotropes  [280],  catecholamine 
release  from  adrenal  chromaffin  cells  [281,  282]  and  insulin  secretion  from 
pancreatic β-cells [283]. In non-excitable cell types [Ca
2+]i oscillations mediate 
cellular functions including fluid secretion and cell volume changes in salivary 
gland cells [284], fertilization of mouse oocytes [285], secretion from mast cells 
[286], cell migration in neutrophils [287], glycogenolysis in hepatocytes [227] and 
cell  contraction  in  smooth  muscle  cells  [288].  It  is  not  clear  what  cellular 
functions are regulated by [Ca
2+]i oscillations in EC however the regulation of 36 
secretion  of  vasoactive  molecules  such  as  NO,  endothelin  or  PGI2  has  been 
suggested [289]. Interestingly it has been suggested that WPB exocytosis may not 
be regulated by [Ca
2+]i oscillations although a direct analysis was not carried out 
in that study [183].  
Early  work  in  hepatocytes  showed  that  spike  frequency  during  [Ca
2+]i 
oscillations  is  dependent  on  agonist  concentration  [227,  290].  A  similar 
relationship between stimulus strength and Ca
2+ oscillation frequency was also 
noted in endothelial cells [100, 152, 183, 215, 266]. These observations led to the 
idea that the frequency of Ca
2+ oscillations might provide the means to regulate 
different cellular processes. Indeed the frequency of Ca
2+ oscillations was found 
to elicit either long-term potentiation or depression in neurons [291], differential 
gene transcription and cell differentiation in T-cells [292], differential secretory 
patterns from exocrine pancreatic gland cells [293] and epithelial cells [294]. 
In  addition  to  the  sensitivity  of  the  IP3R  to  IP3  and  [Ca
2+]i  levels,  the 
frequency of Ca
2+ oscillations is also regulated by several factors including the 
rate  of  cytoplasmic  Ca
2+  removal  by  Ca
2+  pumps  (see  1.6.3)  and  protein 
phosphorylation  as initially suggested by Goldbeter et al [295]. Phosphorylation 
of the IP3R by a series of kinases including protein kinase C (PKC) [296-298], 
Ca
2+/Calmodulin-dependent protein kinase II (CaMKII) [298], protein kinase A 
(PKA)  [299-301]  and  cyclic  GMP-dependent  protein  kinase  [302]  have  been 
shown to regulate the potency of IP3-evoked Ca
2+ release in a feedback regulation. 
The activity of CaMKII [303] and PKC [266, 296] on the IP3R is determined by 
the Ca
2+ oscillation frequency and amplitude.  37 
1.6.3  The decay phase of the [Ca
2+]i response; cytoplasmic [Ca
2+]i removal 
mechanisms 
The decline in [Ca
2+]i following release from the stores is achieved by the 
action of membrane pumps responsible for intracellular Ca
2+ homeostasis. These 
include  the  plasma  membrane  Ca
2+-ATPase  (PMCA)  [304]  and  the  Na
+/Ca
2+ 
exchanger  (NCE)  [272,  305,  306]  on  the  plasma  membrane;  the  Sarco-
Endoplasmic  Reticulum-Ca
2+  ATPase  (SERCA)  on  the  ER  [307]  and  the 
mitochondrial uniporter  in endothelial cells (reviewed in [308]). The uniporter 
will be considered in more detail below (1.10). The PMCA and SERCA function 
at low transport rates, both with high affinities for Ca
2+, maintaining in this way 
resting [Ca
2+]i levels during the inter-spike period and are thought to play a role in 
determining  the  frequency  of  [Ca
2+]i  oscillations  in  EC  [304,  307].  The  NCE 
however has low affinities for Ca
2+ but can transport Ca
2+ at much higher rates, 
able  to  extrude  high  concentrations  of  Ca
2+  from  the  cytoplasm  rapidly  [309]. 
Different  isoforms  of  pumps  with  specific  rates  of  transport  are  thought  to 
determine the time-course of Ca
2+ transients in different cells [310].  
The NCE is found on the plasma membrane but also on other intracellular 
organelles including mitochondria [311].  Its direction mode  and rate of action 
depends  on  the  Na
+  and  Ca
2+  gradient  and  the  membrane  potential  across  the 
plasma membrane [309]; thus reduction of the Na
+ gradient leads to an increase in 
[Ca
2+]i via NCE Ca
2+ entry in EC [304, 306]. Inhibition of either the PMCA or 
NCE  pump  delays  the  decay  phase  of  the  agonist-stimulated  [Ca
2+]i  response 
suggesting both play a role in shaping Ca
2+ transients in EC [193, 312]. 
The SERCA pump is responsible for clearing high cytosolic Ca
2+ levels by 
pumping Ca
2+ into the ER and maintaining ER Ca
2+ levels constant during IP3-38 
evoked Ca
2+-release [313]. The activity of the SERCA and PMCA Ca
2+-ATPases 
compete for the raised [Ca
2+]i and either pump accounts for the falling phase of 
Ca
2+ spikes during Ca
2+ oscillations in different cells. In HUVEC the SERCA 
pump is thought to be responsible for the decay phase of agonist-evoked Ca
2+ 
release [307], whereas in rat microvascular EC the PMCA and NCE pumps play 
this role [314]. The SERCA is also suggested to contribute to the initial shape of 
the  Ca
2+  rise  of  individual  spikes  as  it  transports  local  Ca
2+  into  the  ER 
suppressing the Ca
2+ positive feedback mechanism on the IP3Rs (1.6.2) [307].  
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R=G-protein coupled Receptor 
G= G-protein 
PLC= Phospholipase C 
IP3= Inositol 1,4,5-trisphosphate 
PKC= Protein kinase C 
IP3R= IP3 Receptor 
DAG= Diacylglycerol  
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2+ ATPase 
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2+ 
ATPase 
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+/Ca
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CRAC=  Ca
2+-release  activated  Ca
2+ 
channel 
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Figure 1.3 Endothelial cell [Ca
2+]i sequestration 
When  a  Ca
2+-raising  agonist  reaches  the  cell,  it  binds  to  and  activates  a  G-
protein  coupled  receptor  (GPCR)  which  in  turn  interacts  with  a  G-protein  to 
activate PLC. In turn PLC catalyzes the formation of IP3 and DAG. The later 
activates  PKC  which  can  regulate  [Ca
2+]i  via  feedback  mechanisms  such  as 
phosphorylation and inactivation of the GPCR. IP3 diffuses to the ER to bind and 
activate IP3R leading to an intracellular Ca
2+ rise. Local Ca
2+ regulates the IP3R 
open  probability.  Increased  [Ca
2+]i  is  sequestered  from  the  cytoplasm  via 
different pumps; the SERCA pump which drives Ca
2+ into the ER, the PMCA and 
NCE  which translocate Ca
2+ outside the cell in parallel and the mitochondria 
uniporter. The NCE on the mitochondria functions to slowly discharge [Ca
2+]m.. 
Emptying of the ER triggers capacitative Ca
2+ entry via CRAC channels, however 
their nature and signal for activation is under investigation. 
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1.7  The secretory pathway: From ER to fusion 
Endothelial cells  are complex secretory  cells that function to  control the 
processes  of  haemostasis,  inflammation,  vasoregulation  and  angiogenesis  by 
secreting  or  releasing  a  wide  range  of  molecules.  Therefore  it  is  important  to 
understand  the  secretory  pathways  of  EC  and  the  route  by  which  different 
mediators  are  trafficked  and  released.  The  two  secretory  granules  that  are  the 
focus of this thesis have been described above. Here a brief overview of what is 
known  about  the  formation  and  fusion  of  these  endothelial  organelles  will  be 
made. 
1.7.1  Secretory vesicle formation in EC 
1.7.1.1  VWF biosynthesis and WPB formation 
The  Weibel-Palade  bodies  (WPBs)  are  a  population  of  rod-like  storage 
granules, found in EC [23, 24, 315] (Figure 1.1A). The formation of the WPB is 
thought to be driven by its main cargo protein von-Willebrand factor (vWF) [28], 
as heterologous expression of vWF in other cell systems induced the formation of 
rod-like organelles that resembled the WPB [316, 317] and knock down of the 
protein  inhibits  WPB  formation  in  EC  [318].  The  vWF  gene  is  located  on 
chromosome 12 [319, 320]. Direct amino acid sequence analysis of vWF [321] 
and cloning from EC cDNA libraries [319, 320] determined a 9kb mRNA coding 
for  2813  amino  acid  polypeptide  [322]  composed  of  a  22  amino  acid  signal 
peptide, 741 amino acid pro-peptide and 2050 amino acid mature vWF [323].  
The cellular trafficking pathways for different secreted proteins all start with 
their synthesis by ribosomes attached to the membrane of the rough endoplasmic 
reticulum  (rER)  [324],  an  interconnected  network  of  membrane  tubules  and 42 
cisternae continuous with the nuclear envelope [325]. Ribosomes are attached to 
the ER membrane by their large subunit which holds the nascent peptide [326]. 
The  newly  synthesized  polypeptides  are  transported  through  the  translocon 
complex  [327]  on  the  ER  membrane  into  the  cisternal  space  of  the  ER,  an 
irreversible  step  called  segregation  [328].  Various  sugar  modifications  occur 
during translation and protein-protein interactions within the lumen of the ER that 
help facilitate protein folding, protein quality control and oligomerization [329].  
During entry of  vWF into the ER lumen, it is processed by removal of the 
signal peptide and addition of N-linked carbohydrates [330] before dimerizing by 
forming  disulfide  bonds  between  the  C-terminus  cysteine  knot  domains  [331-
333]. Dimerization allows the vWF protein to proceed from the cisternal space of 
the rough ER to the Golgi network [334, 335] in an energy dependent fashion via 
a  carrier-mediated  mechanism  facilitated  by  COP-I  in  conjunction  with  ARF1 
[336].  
The Golgi complex is a series of membrane compartments consisting of 
three discrete groups of cisternae, the cis, medial and trans [337]. The cis-Golgi 
network (CGN) serves as a port of entry to the Golgi stack for secretory proteins 
excluding ER resident proteins. Proteins are thought to move from one station to 
the next via the budding and fusion of small transport vesicles with subsequent 
cisternae,  where  they  undergo  various  modifications  such  as  carbohydrate 
modifications, acylation and sulfation catalysed by resident enzymes [337, 338]. 
VWF undergoes further modifications in the Golgi such as addition of O-linked 
carbohydrates [331].  
Sorting of secretory proteins destined for the plasma membrane, secretory 
vesicles and lysosomes occurs in the Trans-Golgi Network (TGN) [339, 340], a 43 
specialised reticulum of tubules derived from the trans-most cisterna of the Golgi 
involved  in  the  final  protein  processing  steps  [337].  The  TGN  was  firstly 
discovered by Novikoff in the 1960s and was thought to be a part of the ER that 
formed lysosomes (GERL- Golgi endoplasmic reticulum lysosomes) [341]. It was 
later renamed as the TGN by Griffiths and Simons [342]. The proteins reach the 
lumen of the TGN in a dilute solution and are progressively concentrated in a 
Ca
2+- and pH-dependent manner [343]. The TGN is thought to be slightly more 
acidic (~pH6.2-6.58 [344-347]) than the previous compartments, a feature that has 
a role in facilitating protein aggregation. 
In  the  TGN  the  disulphide  linked  vWF  dimer  undergoes  sulfation  by 
sulfotransferases [348] and the endoproteolytic cleavage of proregion from the 
mature vWF by a furin-like activity [349]. The cleavage step was earlier thought 
to take place in the WPB where proregion and mature vWF are found in a 1:1 
stoichiometry [350, 351]. However it was later found that the cleavage step occurs 
in the slightly more acidic TGN environment where a non-covalent association 
occurs between proregion and vWF [24, 34]. The vWF dimers then polymerise 
via  disulfide  bonds  formed  between  the  N-termini  to  generate  high  molecular 
weight  multimers.  The  multimerization  process  also  requires  the  acidic 
environment of the Golgi, high Ca
2+ and the presence of proregion [334, 352, 
353]. The latter may act as a disulfide isomerase at low pH, able to catalyze thiol 
protein disulphide interchange and support N-terminal disulphide bond formation 
essential for vWF multimerisation [354, 355].  
The  vWF  tubules  are  packaged  into  the  WPBs  at  the  TGN  in  a  highly 
ordered paracrystalline structure [26, 29]. The heterotetrameric adaptor protein 1 
(AP-1)  and  clathrin  coated  membranes  are  reported  to  be  important  for  WPB 44 
biogenesis from the TGN [356] however the relationship between clathrin coat 
and formation of tubules is yet to be precisely determined. Clathrin is present on 
newly  formed  secretory  granules  including  the  WPB  but  is  lost  during  their 
maturation.  Clathrin  mediated  membrane  budding  is  thought  to  lead  to  the 
removal of soluble and membrane proteins not needed in the mature organelle as 
well as recycling excess membrane back to the TGN [339]. This process of core 
and  membrane  remodelling  leads  to  secretory  granule  maturation.  The  mature 
WPBs accumulate within the cytoplasm, ready to undergo exocytosis in response 
to secretagogue stimulation. There is evidence that vWF undergoes progressive 
condensation during WPB maturation as observed by EM of high-pressure frozen 
WPBs [27]. 
1.7.1.2  T-PA biosynthesis and non-WPB formation 
The optical studies of the non-WPB secretion described in this thesis utilize 
a fluorescent  fusion protein of one of its cargo molecules, tissue plasminogen 
activator (t-PA). The amino acid sequence of the t-PA precursor comprises 563 
residues, including a signal sequence of 20-23 hydrophobic amino acids and a 
hydrophilic pro-sequence of 12-15 amino acids at the N-terminus [357]. In the ER 
the t-PA polypeptide chain is glycosylated and the signal and pro-sequence are 
cleaved from the newly synthesized enzyme [358]. No detailed data exist for the 
sorting at the TGN and formation of the t-PA containing non-WPB organelle. The 
cargo  and  regulation  of  secretion  of  the  non-WPB  organelle  is  less  well 
understood and is discussed below.  45 
1.7.2  Constitutive and regulated secretion 
Segregation of proteins destined for constitutive or regulated secretion takes 
place  at  the  TGN  [359].  In  contrast  to  the  regulated  pathway  clathrin  is  not 
involved in the exit of constitutively secreted proteins from the TGN [360]. It is 
thought  that  upon  arrival  of  material  at  the  TGN  destined  for  constitutive 
secretion, a signalling cascade involving protein kinase D (PKD) is triggered to 
locally produce diacylglycerol (DAG) [361]. The cargo is packaged into budding 
transport carriers which grow in size to encapsulate the cargo molecules, and the 
accumulated DAG catalyzes membrane fission to dissociate the transport carriers 
from the TGN (reviewed in [362]). The transport carriers are then trafficked to the 
plasma membrane. It was first though that secretion via the constitutive pathway 
was not altered by secretagogue stimulation [339, 359] however, there is evidence 
that  under  some  conditions  regulation  of  the  constitutive  pathway  does  occur 
[363],  and  other  Ca
2+  dependent  trafficking  steps  [364-366].  Constitutively 
secreted proteins by definition are not stored within the cell, and consequently 
they do not accumulate within the cell in a time dependent fashion [359]. The 
release of constitutively secreted proteins can be rapidly blocked by inhibitors of 
protein  synthesis  [367,  368],  by  disruption  of  ER  to  Golgi  trafficking  by  the 
antibiotic Brefeldin-A [369-371] or by decreasing the temperature below 20°C 
[372], while leaving regulated secretory storage granules largely unaffected. The 
half  time  for  constitutive  delivery  to  the  plasma  membrane  of  a  GFP-tagged 
transmembrane protein expressed in COS cells was approximately 3.8min [373] 
and pulse labelling of constitutively secreted glycosaminoglycan chains (GAG) in 
CHO cells exhibited a half time for secretion of 12-14min [374]. Evidence from 
pulse-chase experiments shows that newly synthesized t-PA can be retained in the 46 
cell for up to 4h [375]. Studies utilizing GAG chains have shown that constitutive 
secretion does not require any newly synthesized proteins suggesting recycling of 
components of the vesicle machinery [376]. 
Certain  cell  types  also  utilise  the  regulated  secretory  pathway  [339]. 
Proteins destined for the regulated secretory pathway  form  a dense membrane 
bounded core of aggregated protein at the TGN, that becomes enveloped by a 
clathrin coat and buds off the TGN in an ATP dependent manner to yield a dense 
core  immature  secretory  granule  [340].  Regulated  secretory  proteins  are 
concentrated  into  specialised  membrane  bound  storage  organelles,  which  are 
retained in large intracellular pools and their release is coupled to an extracellular 
stimulus [359]. Regulated exocytosis takes place in a controlled manner in which 
the  time  course,  rates  and  quantity  of  bioactive  molecules  released  varies  in 
response to the strength or duration of stimulation. A fraction of protein sorted 
into  the  regulated  pathway  can  be  spontaneously  secreted  in  the  absence  of  a 
stimulus and this is called basal secretion [377].  
VWF is sorted into both the constitutive secretory pathway [95] and the 
regulated secretory pathway (stored into WPB) [350] at the TGN. Constitutively 
secreted vWF appears to be in the form of smaller multimers originating from the 
ER  [350].  It  was  originally  thought  that  only  5-10%  of  vWF  synthesized  in 
cultured  EC  is  stored  in  WPB  and  the  rest  is  secreted  constitutively  [350]. 
Recently however it has been shown that the sorting efficiency is much higher, 
with  perhaps > 50% of vWF sorted into the WPB [371]. There is not a clear 
distinction about which pathway the non-WPB belongs to.  47 
1.7.3  The role of the cytoskeleton in exocytosis 
The microtubules extend asymmetrically from the microtubule organizing 
centre around the nucleus (minus end) to the cell periphery (plus end) [378]. The 
microfilament network may anchor and stabilise the plus ends of microtubules at 
the plasma membrane [379]. It is thought that vesicle movement to the plasma 
membrane  is  facilitated  by  transport  on  microtubules  [380],  and  vesicle 
interactions with microtubules have been observed in electronmicrographs [381]. 
Following microtubule depolymerisation, the secretion and polarization of newly 
synthesized  material  [382]  along  with  regulated  secretion  of  WPBs  [383]  is 
inhibited  suggesting microtubules are important in trafficking of constitutive and 
regulated  secretion.  The  viscous  gel  of  the  actin  cortex  acts  to  hinder  vesicle 
motion  at  the  subplasmalemmal  area  [384,  385]  and  prevent  docking  to  the 
plasma membrane and subsequent fusion in the absence of a stimulus [359, 386-
388]. Involved in this process are Rab27a and its effector protein MyRIP, which 
are thought to anchor WPBs to the actin cortex [57]. Disassembly of the cortical 
F-actin allows translocations of vesicles to the plasma membrane for fusion [389]. 
Both  WPB  and  non-WPB  trafficking  is  thought  to  be  co-ordinated  between 
microtubules and the actin cytoskeleton [390]. 
1.7.4  Pools of granules 
In a population of regulated secretory granules different pools of granules 
are likely to exist at different stages in the secretory pathway. Immature secretory 
granules are found near the centre of the cell, in the vicinity of the TGN and 
mature secretory granules tend to be located in the periphery of the cell. Early 
work on neuronal synaptic vesicles has classed distinct granule pools depending 48 
on their readiness to be released upon stimulation [391, 392]. In chromaffin cells 
these different pools of granules were seen as distinct components in membrane 
capacitance recordings [393-395]. It is thought that a pool of granules can be pre-
docked  at  “active”  sites  on  the  plasma  membrane,  waiting  for  the  appropriate 
stimulus for fusion. In many neuronal cells “active” sites have been shown to be 
enriched  in  Ca
2+  channels  [396].    This  pool  of  granules  is  termed  the 
“immediately readily releasable” pool, as opposed to the “slowly releasable” or 
“reserved” pools of  granules that are  found  further away  from the membrane, 
however there is a controversy surrounding the nature of the different pools of 
granules [397, 398].  
It is suggested that Ca
2+ is the messenger of communication between the 
pools of granules regulating their readiness to be released. Synaptotagmin 1 is 
thought to be the Ca
2+ sensor only on the “immediately readily releasable” pool in 
adrenal chromaffin cells, regulating their fusion [399]. 
1.8  Molecular fusion machinery 
1.8.1  Regulated exocytosis 
Secretion, the discharge of the granules content into the extracellular space 
was  originally  called  “membrane  fusion”  by  Palade  (1959)  and  later  on 
“exocytosis” by de Duve (1963). Early work on stimulated secretion by Jamieson 
and Palade [343] revealed it is not the rates of synthesis and intracellular transport 
of  secretory  proteins  that  are  enhanced  by  stimulation  in  vitro,  but  the  final 
discharge steps and the preceding storage steps. This data implied that stimulated 
secretion  is  regulated  at  stages  close  to  the  point  of  fusion.  The  molecular 
machinery for exocytosis has been studied extensively in excitable cells. Although 49 
the WPB and non-WPB fusion apparatus remains largely unknown, the classical 
view of exocytosis in neuroendocrine cells will be briefly described here. The 
granules  are  transported  towards  the  plasma  membrane  where  they  undergo 
tethering, docking, priming, triggering and finally fusion. 
Tethering describes the initial attachment between vesicles and the target 
membrane, required prior to docking. Docking involves SNARE proteins (soluble 
N-ethylmaleimide-sensitive  factor  (NSF)  attachment  protein  receptors).  These 
include  a  vesicular  SNARE  (v-SNARE)  VAMP  (vesicle  associated  membrane 
protein) (or synaptobrevin) [400]; a target membrane SNARE (t-SNARE) on the 
plasma membrane, such as SNAP-25 (Synaptosome Associated Protein) [401] and 
syntaxin [396]. These SNARE proteins assemble into a helix bundle to form the 
SNARE complex [402]. The SNARE complex assembly is prevented by Munc-18 
(mammalian homologue of UNC-18 gene), which bind syntaxin stabilizing it in a 
closed conformation [403, 404]. Priming is considered to be the process which 
renders  the  vesicles  fusion-competent  and  this  includes  the  ATP-  independent 
disruption of the Munc-18- syntaxin interaction by PKC phosphorylation to allow 
formation  of  the  SNARE  complex  [405].  Priming  also  consists  of  an  ATP-
dependent step which involves the activation of the SNARE complex by binding 
of  soluble  protein  α-SNAP  (NSF  attachment  protein)  [402].  The  α-SNAP- 
SNARE complex then binds soluble NSF ATPase, an interaction that induces the 
hydrolysis of ATP [402]. NSF is considered to be the molecular motor of fusion 
since the energy from ATP hydrolysis is used for the dissociation of the SNARE 
complex, leading to the close apposition of the vesicle with the plasma membrane, 
proposed  as  a  zippering  effect  occurring  from  the  N-terminus  of  the  SNARE 
motifs to the C-terminal membrane anchors of opposing membranes. This pulls 50 
the membranes close together overcoming the energy barrier, the proximal lipid 
leaflets interact and an aqueous fusion pore opens [406]. Figure 1.4 illustrates a 
schematic  of  the  classical  SNARE  fusion  machinery  however  it  is  not  known 
whether WPBs or non-WPBs undertake this pathway of fusion. After fusion the 
SNARE  complex  dissasembles  so  that  the  individual  SNARE  proteins  can  be 
recycled.  Calmodulin  (CaM)  has  been  found  to  bind  several  proteins  of  the 
SNARE complex [125, 126] and has been implicated in regulation of exocytosis. 
The triggering step of exocytosis can be Ca
2+-driven or GTP-driven. Ca
2+-
triggered exocytosis involves Ca
2+ sensor proteins such as synaptotagmins [407] 
and annexins [408, 409]. Synaptotagmins are found in excitable cells on vesicles 
at subplasmalemmal regions of high local [Ca
2+]i, rich in voltage operated Ca
2+ 
channels (VOCs) [280]. VOCs bind t-SNARES and this allows direct access of 
Ca
2+  to  the  SNARE  complex.  Synaptotagmins  bind  to  phospholipids  in  the 
SNARE  complex  and  couple  [Ca
2+]i  rises  to  exocytosis  [410].  Annexins  are 
heterologously expressed in all cell types and are abundantly found in EC [411]. 
The annexins are a family of proteins that can bind to the plasma membrane and 
coordinate fusion events in a Ca
2+ dependent manner [412, 413]. 
The  GTP-dependent  form  of  regulated  exocytosis  uses  a  distinct  set  of 
molecules including Ral GTPases [414, 415]. RalA is activated by cAMP- and 
Ca
2+-  raising  agents,  although  more  efficiently  by  the  latter,  to  coordinate  the 
assembly of a complex called the exocyst that is composed of small GTPases 
thought  to  be  involved  in  directing  vesicles  to  their  precise  site  of  fusion 
(reviewed  in  [416]).  Guanine  exchange  factors  (GEF)  enhance  the  conversion 
from the inactive GDP-bound to the active GTP-bound form of RalA on the donor 
membrane where Rabs orchestrate the recruitment of effectors. Activated RalA 51 
interacts with several protein effectors such as Sec5 and Exo84 [417], via binding 
and activating phospholipase D1 [418]. The Rab27a effector MyRIP has been 
shown  to  associate  with  the  exocyst  [419].  After  fusion,  GTPase  activating 
proteins promote the GTP hydrolysis to inactivate and dissociate Rabs from the 
respective membranes and to initiate a new cycle of fusion. A binding site for 
calmodulin on Ral has been detected, and calmodulin has been shown to enhance 
the binding of GTP to Ral [124, 420]. Figure 1.4 includes a schematic of the 
exocyst mode of exocytosis.  
It is not clear whether WPB exocytosis is regulated by the SNARE complex 
or the exocyst as evidence exists to support both routes. Regarding the SNARE 
complex, one report has identified t-SNARE syntaxin4 to be involved in WPB 
exocytosis  [421],  for  which  likely  binding  partners  are  SNAP23  and 
synaptobrevin3 (SNAREs expressed in endothelial cells) [422, 423]. The same 
group proposed that PKCα is responsible for the phosphorylation of syntaxin4 and 
Munc18c, thereby facilitating the formation of the SNARE complex and allowing 
WPB exocytosis [421]. Moreover there is evidence that NSF plays a role in WPB 
exocytosis [423], from work that showed NO S-nitrosylation and H2O2 inhibited 
the ATPase activity of NSF and this led to an inhibition of WPB exocytosis [422]. 
The  Ca
2+-triggering  step  of  WPB  SNARE-mediated  exocytosis  could  involve 
synaptotagmins or annexins. Although a vesicular synaptotagmin for the WPB has 
not  been  established,  synaptotagmin1  was  recruited  to  rod-shaped  pseudo-
granules  in  vWF  expressing  AtT-20  cells  [424].  Annexins,  have  also  been 
implicated in a role in EC exocytosis [412] and in particular WPB exocytosis [55]. 
There is also some evidence linking the exocyst with WPB exocytosis [124, 420, 52 
425]. The Guanine exchange factor (GEF) for RalA for WPB exocytosis has been 
reported to be Ral-GDP dissociation stimulator (RalGDS) [124].  
1.8.2  Constitutive exocytosis 
Constitutive secretion is thought to use a similar molecular mechanism to 
the SNARE machinery [426]. However constitutive secretion is thought to follow 
vesicle  docking  without  delay,  subtracting  the  priming  step.  Fusion  of 
reconstituted synaptic vesicles from neurons is shown to involve the formation of 
the SNARE complex in a Ca
2+-independent manner, despite the presence of Ca
2+ 
sensors on the vesicles [427]. The molecular machinery of constitutive exocytosis 
remains mainly elusive.  
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Figure 1.4 Possible secretory pathways of the WPB 
VWF  undergoes  post-translational  modifications  in  the  ER  and  Golgi  before 
driving the formation of WPBs at the TGN. The exocytotic machinery of WPBs is 
not yet established. In A the classical neuronal SNARE exocytosis is described. 
Synaptobrevin3  has  been  reported  on  the  WPBs  and  syntaxin4,  SNAP23  and 
Munc-18 on the plasma membrane of endothelial cells. B The exocyst complex 
recruited by RalA-activated PLD1 may represent an alternative mechanism by 
which WPB exocytosis is controlled. The inactive GDP-bound form of RalA is 
converted to its active GTP-bound form via an interaction involving Ca
2+-bound 
Calmodulin and a guanine exchange factor (GEF) thought to be RalGDS.   54 
1.8.3  Modes of fusion 
Granule  exocytosis  can  be  separated  into  full  fusion  during  which  all 
contents are released or incomplete fusion in which partial or selective release of 
cargo may occur. In the latter a transient fusion pore forms that can readily reseal 
and  retract  from  the  plasma  membrane  [428]  known  as  “kiss-and-run”  fusion 
[429].  This  type  of  fusion  was  originally  observed  in  neuroendocrine  cells  as 
flickering of the fusion pore [430] and later on in mast cells [431], chromaffin 
[432], eosinophils [433] and neutrophils [434]. Kiss-and-run events are thought to 
be a mechanism of regulating the amount and species of cargo released depending 
on their size [435-437]. These events support the existence of a reversible fusion 
machinery  temporally  coupled  to  the  highly  stable  SNARE  complex  [438]. 
Although  WPBs  can  undergo  kiss-and-run  fusion  they  also  display  long  lived 
fusion pores through which small chemokines can exit while pro-coagulant vWF 
and proregion are retained in the granule [435]. A similar selective mechanism of 
release of small transmitters is thought to take place in neuroendocrine cells [439].  
1.9  Haemostatic and inflammatory responses of the endothelium  
The  process  of  exocytosis  of  von  Willebrand  Factor  (vWF)  and  tissue 
plasminogen activator (t-PA) was studied here. A brief description of haemostatic 
and inflammatory responses and the involvement of vWF and t-PA are described 
below and illustrated in Figure 1.5. 
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1.9.1  Involvement  of  WPB  protein  Von  Willebrand  Factor  (vWF)  in 
Haemostasis 
Haemostasis is the cessation of blood loss from a damaged blood vessel that 
can be triggered by a physical or a chemical injury to the vessel. The process of 
haemostasis is often categorised into two phases termed primary and secondary 
haemostasis. 
1.9.1.1   Primary Haemostasis 
Primary  haemostasis  is  characterised  by  platelet  adhesion  to  the  sub-
endothelium,  a  process  that  is  facilitated  by  binding  to  recruited  vWF,  their 
subsequent activation and formation of a platelet plug. VWF was discovered in 
1971 as a Factor VIII binding antigen [440] and named after Professor Erich von 
Willebrand who first described the bleeding disorder von Willebrand disease in 
1926 [441]. VWF is synthesized by EC [442] and secreted constitutively in small 
dimers  [95]  or  by  regulated  secretion  of  WPBs  where  it  is  stored  in  large 
multimers  [25].  It  is  also  secreted  by  regulated  exocytosis  of  α-granules  in 
platelets  [44,  443]  or  constitutively  from  megakaryocytes  [444,  445].  Upon 
vascular injury EC are stimulated to secrete WPBs which release high molecular 
weight multimers of vWF. Under conditions of high shear WPB derived vWF can 
unravel revealing multiple interaction sites and increasing its binding potential 
[446].  The  A3  domain  of  vWF  contains  a  binding  site  for  collagen  that  may 
facilitate its adhesion to the exposed subendothelium and the C1 domain contains 
a binding site for the vitronectin receptor (ανβ3) on the EC membrane [24, 37-39] 
that strengthens the attachment of endothelial cells to the basement membrane, 
forming a seal  around the vascular injury [447]. Although WPB-derived large 56 
multimers of vWF can bind more efficiently to the exposed subendothelium than 
constitutively  secreted  dimers  that  circulate  in  the  plasma  [448],  the  latter  are 
essential for both primary and secondary haemostasis as seen by treatments of 
vWF disease [449] such as blood replacements [450, 451]. Binding of vWF to the 
subendothelium via the A3 domain triggers a conformational change that exposes 
the A1 domain containing the sequence Arg-Gly-Asp (RGD) that recognises the 
Glycoprotein  (GP)  Ib  component  of  the  integrin  GPIb-IX-V  receptor  complex 
found on the platelet membrane [30, 452] promoting platelet adhesion at the site 
of vascular injury. The integrin receptors on resting platelets have high affinity for 
the corresponding ligands on vWF adherent on the basement membrane [453], 
extracellular matrix [454] or incorporated into a forming clot [455]. The initial 
platelet GPIb interaction with vWF A1 elicits platelet signals including [Ca
2+]i 
rises and activation of PKC and tyrosine kinases [456, 457] that lead to activation 
of  integrin  GPIIb-IIIa  (αΙΙbβ3)  on  the  platelet  surface  [458].  This  interaction 
induces  platelet  activation  [459],  shape  change  by  cytoskeletal  rearrangements 
and secretion of their α-granules which store ADP, vWF [460] and thromboxane 
A2  (TXA2),  molecules  required  for  further  platelet  activation  and  aggregation, 
forming  a  primary  haemostatic  plug  [461,  462].  The  GPIIb-IIIa  integrin  is  a 
receptor  for  further  agonists  such  as  plasma  vWF  [463,  464],  fibrinogen  and 
fibronectin  [465,  466],  adhesive  proteins  found  in  the  extracellular  matrix  or 
released  from  the  α-granules.  Figure  1.5  illustrates  platelet  rolling  on  WPB-
secreted  vWF  and  platelet  aggregation  at  the  exposed  subendothelium  in  a 
schematic of the inside of a vessel. 57 
1.9.1.2  Secondary Haemostasis 
Activated  platelets,  monocytes,  EC  and  lymphocytes  expose  negatively 
charged phospholipids on their surface where circulating proteins in a precursor 
form are converted to active serine proteases in the presence of Ca
2+, during a 
series of stepwise proteolytic events [467, 468]. This is called the coagulation 
cascade, part of secondary haemostasis which leads to the formation of a fibrin 
clot that reinforces the platelet aggregate. Circulating low molecular weight vWF 
derived from either constitutive or basal secretion from EC [371], plays a role in 
secondary haemostasis by stabilizing coagulation Factor VIII in the circulation 
[469], binding with high affinity via domain D’ to form a tight, non covalent 
complex  that  protects  FVIII  from  proteolytic  degradation  [470,  471].  The  end 
reaction of the coagulation cascade is the activation of factor Xa which assembles 
into a complex responsible for cleaving pro-thrombin (factor II) into thrombin 
(factor IIa) [472]. Thrombin is the most potent physiological activator of human 
platelets  [473].  Thrombin  also  cleaves  the  soluble  plasma  protein  fibrinogen 
(factor  I)  into  insoluble  fibrin  monomers,  which  stick  together  to  form  fibrin 
polymers that form the scaffold of a developing clot [474, 475]. A forming fibrin 
clot is illustrated in Figure 1.5. 
Haemostasis is tightly controlled by the endothelium through secretion of a 
combination of positive and negative regulatory molecules. Anticoagulant tissue 
factor pathway inhibitor (TFPI) is secreted by activated platelets and Thrombin-
stimulated  endothelial  cells,  to  limit  thrombin  production  [476,  477].  Also 
activated protein C, secreted by EC, inactivates factors of the coagulation cascade, 
in reactions catalysed by protein S [169, 478].  58 
1.9.2  Tissue-Plasminogen Activator (t-PA)- Fibrinolysis 
Fibrin  clots  are  degraded  by  the  action  of  serine  proteases  including 
urokinase and tissue plasminogen activator (t-PA) [479]. The mature t-PA protein 
contains  5  discrete  structural  domains  including  a  fibronectin-like  domain,  an 
epidermal  growth  factor  EGF-like  domain  and  the  serine  proteinase  catalytic 
domain  [480].  Circulating  t-PA  binds  fibrin  and  is  activated  to  cleave 
plasminogen (incorporated in the newly formed fibrin clot) into the active non-
specific serine protease plasmin which degrades fibrin and consequently dissolves 
the fibrin clot [481]. T-PA is secreted constitutively from endothelial cells, but its 
secretion is increased under conditions of vascular injury, exercise or presence of 
vasoactive substances in vivo [77, 78] and in vitro [84]. This may be a mechanism 
for  delivering  an  additional  pulse  of  t-PA  to  the  site  of  injury  ensuring  its 
incorporation in the forming clot and the dissolution of fibrin at the initial stages 
of fibrin clot formation. In vitro t-PA is more potent in dissolving fibrin when it is 
incorporated  into  a  clot  during  coagulation  [482],  because  it  forms  a  ternary 
complex with fibrin and plasminogen in the locality of the clot therefore the rate 
of activation of plasminogen by t-PA is higher in the presence of the polymerized 
fibrin [483, 484].  
Degraded fibrin no longer binds plasmin or plasminogen, and is eventually 
inactivated by the respective inhibitors. The amounts of t-PA in the circulation are 
carefully balanced by plasminogen activator inhibitors PAI-1 and PAI-2, members 
of the serpin family that are also secreted from EC. These form a covalent bond 
with t-PA leading to its inactivation [485, 486]. PAI-2 is up-regulated in human 
plasma only under certain conditions such as pregnancy [76].   59 
1.9.3  Inflammation  
Endothelial  cells  play  an  important  role  in  inflammatory  processes. 
Stimulated WPB exocytosis from EC, along with vWF, also releases P-selectin on 
the  EC  plasma  membrane.  This  type  1  membrane  protein  is  responsible  for 
mediating the initial adherence and rolling of leukocytes on the surface of the 
endothelium  [487].  Stimulation  of  EC  with  Interleukin-1  (IL-1)  and  TNF-α 
(tumor necrosis factor-a) produced by infiltrating inflammatory cells, results in 
the  up-regulation  and  cell  surface  expression  of  adhesion  molecules  including 
integrins,  selectins,  vascular  cell  adhesion  molecule  (VCAM-1),  intercellular 
adhesion molecule (ICAM-1) and platelet endothelial cell adhesion molecule-1 
(PECAM-1) [488-491]. These facilitate the attachment to the endothelium and 
subsequent trans-migration of leukocytes into inflamed tissue, facilitated by EC 
induced shape change, forming intercellular gaps. Physiological stimuli for EC 
gap  formation  are  thrombin  and  histamine  which  induce  cell  retraction  by 
formation and rearrangement of stress fibers composed of filamentous F-actin and 
myosin  [191].  Moreover,  IL-1  and  TNF-α  up-regulate  EC  expression  of 
chemokines such as the neutrophil chemoattractant interleukin-8 (IL-8), eotaxin-3, 
monocyte chemoattractant protein-1 (MCP-1), growth-related oncogene protein-
alpha (GRO-α) and RANTES (Regulated on Activation, Normal T Expressed and 
Secreted)  which  stimulate  the  chemotaxis  of  lymphocytes,  neutrophils  and 
monocytes to the site of inflammation and potentiate transendothelial migration 
(reviewed in [492]). Chemokines such as IL-8 and eotaxin-3 are reported to be 
sorted in the WPB [67], however, they may also exit the cell through the non-
WPB organelle, along with other chemokines such as GRO-α and MCP-1 [92]. 
Sorting of chemokines to differentially regulated organelles in EC may allow for 60 
their differential release to modulate inflammatory processes. An illustration of 
leukocyte rolling on the endothelium and transmigration to the inflamed tissue is 
shown in Figure 1.5. 
Moreover recent findings that WPBs can be released in response to invading 
bacterial  pathogens  such  as  lipoproteins  activating  Toll-like  Receptors  on  EC 
membrane [493] or by an antibody against human leukocyte antigen (HLA) [494] 
suggest  that  WPB  exocytosis  participates  in  innate  immune  responses  or  the 
pathology of transplant rejection respectively. 
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Figure 1.5 Inflammatory and haemostatic action of the endothelium 
Upon  vascular  injury  which  involves  the  exposure  of  the  subendothelium  to 
plasma,  or  inflammation  which  involves  the  activation  of  leukocytes  and 
subsequent  secretion  of  interleukin-1  (IL-1)  and  tumour  necrosis  factor  α 
(TNF−α);  endothelial  cells  are  stimulated  to  secrete  von  Willebrand  Factor 
(vWF) and P-selectin from their Weibel Palade Bodies (WPB) and up-regulate the 
expression  of  membrane  adhesion  molecules  vascular  cell  adhesion  molecule 
(VCAM-1), intercellular adhesion molecule (ICAM-1) and others. VWF facilitates 
platelet rolling on the endothelium and platelet attachment to the site of injury 
with  subsequent  platelet  activation  and  aggregation  to  form  a  platelet  plug. 
Secreted vWF from α–granules of activated platelets promotes platelet-platelet 
adhesion.  This  process  initiates  the  coagulation  cascade  on  activated  EC  and 
platelet membranes which results in the formation of a fibrin mesh. P-selectin on 
the  activated  EC  membrane  and  adhesion  molecules  VCAM-1  and  ICAM-1 
facilitates leukocyte rolling and attachment to the endothelium and subsequent 
translocation to the site of inflammation. Figure adapted from [487]. 62 
1.9.4  Defects in vWF or t-PA formation/ secretion lead to disease 
Complications in the process of haemostasis (bleeding disorders) can occur 
due  to  defects  or  lack  in  the  elements  making  up  or  regulating  the  processes 
underlying the primary or secondary haemostasis cascades [495, 496]. Here vWF 
and t-PA related diseases will be considered. Von Willebrand disease (vWD) is an 
autosomal dominant mutation which comes in many degrees of severity. In its 
mild form vWD has a 0.8% frequency of occurrence [497]. In its most severe 
form (VWD type III), absence of vWF leads to complications in haemostasis due 
to inability of platelets to adhere to the exposed subendothelium and form the 
platelet plug (primary haemostasis) [498] and a failure of the clotting cascade due 
to lack of factor VIII in the circulation (secondary haemostasis) [32, 499]. On the 
other hand there is evidence that high plasma levels of vWF can cause thrombotic 
complications in the circulation [500, 501]. Such complications may manifest in 
the development of atherosclerosis as shown from experiments on P-selectin and 
vWF-deficient mice that showed delayed onset and reduced extent and severity of 
atherosclerosis when placed on an atherogenic diet [502, 503]. Abnormal vWF 
levels are not only involved in the dysfunction of haemostasis, but it was also 
shown  that  vWF  contains  binding  sites  for  tumour  cell  receptors  such  as 
glycoprotein Ib or the αIIbβ3 and αvβ3 integrins thereby providing a role in tumour 
metastasis [504].  
In terms of the role of t-PA in disease, once coagulation occurs, inadequate 
dissolution of a fibrin deposit by t-PA may result in the obstruction of a blood 
vessel [481]. On the other hand excessive, premature fibrin degradation by t-PA 
can lead to bleeding [505]. T-PA is used clinically as a thrombolytic agent in the 
treatment of acute myocardial infarction and deep vein thrombosis.  63 
1.10  Mitochondria 
1.10.1  Mitochondria structure 
Mitochondria  are  vital,  dynamic  organelles  forming  an  interconnected 
network  as  observed  by  direct  visualization  of  the  organelle  by  specifically 
targeted  GFPs  (reviewed  in  [506]).  The  mitochondrial  network  in  a  single 
HUVEC  expressing  the  mitochondrial  targeted  fusion  protein  mito-DsRed  is 
shown  in  Figure  1.6,  co-expressing  proregion-EGFP  (A)  or  t-PA-EGFP  (B). 
Mitochondria are thought to have evolved from prokaryotic organisms that were 
phagocytosed by a eukaryote, and contain their own circular DNA (mtDNA) in 
their lumen [507]. Mitochondria have genetic continuity inherited maternally and 
are  prone  to  mutations  as  mtDNA  lacks  histones  and  has  limited  capacity  for 
repair  [507].  The  mitochondrial  DNA  is  15.5kb  encoding  13  polypeptides, 
components of the complex inner mitochondrial membrane [508]. Their major 
role is to produce the cells energy (ATP) by oxidative phosphorylation in most 
cell types [509]. Endothelial cells however are mainly glycolytic cells, producing 
75-99%  of  their  energy  by  substrate  glycolysis  [510,  511].  Endothelial 
mitochondria  are  thought  to  be  more  important  for  various  other  functions 
including  O2  sensing  [512],  Ca
2+  sequestration  and  production  of  NO  (Nitric 
Oxide)  and  ROS  (Reactive  Oxygen  Species)  (reviewed  in  [513,  514]).  ROS 
production,  generated  by  a  damaged  respiratory  chain,  triggers  apoptosis  by 
releasing proteins that activate effector caspases in the cytoplasm (reviewed in 
[515]).  
Mitochondria  are  delimited  by  two  membranes,  an  inner  mitochondrial 
membrane (IMM) and an outer mitochondrial membrane (OMM). The OMM is 64 
readily permeable to small molecules (MW<10KDa) thanks to the abundance of a 
large conductance channel known as mitochondrial porin or voltage-dependent 
anion  channel  (VDAC).  Therefore  the  OMM  is  not  a  limiting  factor  to  Ca
2+ 
diffusion. The IMM is an ion-impermeable membrane with much larger surface 
area due to folds extending into the internal space known as cristae [516]. The 
IMM contains the electron transport chain (ETC) or respiratory chain, the ATP 
synthase  and  specific  carriers  for  metabolites  [507].  The  matrix  space  of  the 
mitochondrial contains enzymes of the citrate cycle and β-oxidation [507]. 
 Mitochondria are motile organelles that undergo continual cycles of fusion 
[517] and fission [518, 519] and the balance of these opposing processes regulates 
mitochondrial  morphology,  number  and  function.  When  fusion  is  blocked 
continuous  fission  causes  the  mitochondria  network  to  fragment.  Fusion  in 
mitochondria  is  unique  from  other  organelles  in  that  it  co-ordinates  fusion  of 
OMM, IMM, inter-membrane space and matrix [520]. 65 
 
Figure 1.6 The mitochondrial network in HUVEC 
Single  HUVEC  co-expressing  mito-DsRed  which  fluorescently  labels  the 
mitochondria and (A) proregion-EGFP which fluorescently labels WPBs or (B) t-
PA-EGFP which fluorescently labels the non-WPBs. 
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1.10.2  Oxidative phosphorylation  
The cytosolic process of glycolysis produces a carbon chain substrate such 
as pyruvate that is supplied to the mitochondria to maintain the citric acid cycle 
(or tricarboxylic acid cycle (TCA)) (demonstrated by Denton, McCormack and 
Hansford in 1960s). During the TCA cycle the pyridine nucleotide NAD
+ and 
flavoprotein FAD are reduced to NADH and FADH2 respectively and are then 
provided to the respiratory  chain on the  IMM. Electrons (e
-) from NADH are 
passed to complex I and from FADH2 to complex II. Electrons are successively 
passed from either complex I or complex II via ubiquinone to complex III and via 
cytochrome C to cytochrome C oxidase (complex IV) which ultimately transfers 
e
-  to  oxygen  to  generate  water.  Cytochrome  C  transfers  e
-  in  a  cycle  of  Fe
3+ 
reduction to Fe
2+ when accepting e
- from complex III and a reverse oxidation of 
Fe
2+ when donating e
- to complex IV. During the redox reactions of complexes I, 
III and IV, protons (H
+) are translocated across the IMM to the intermembrane 
space generating an electrochemical proton gradient 150-200mV negative to the 
cytosol (∆Ψm). This potential provides the driving force for proton influx through 
the  F1F0-ATP  synthase  (ATPase)  leading  to  the  phosphorylation  of  adenosine 
diphosphate (ADP) to generate ATP which is then transported to the cytosol [509, 
521]. Figure 1.7 shows a schematic of the oxidative phosphorylation process. 
Thus ATP is synthesized by coupling two reactions, electron transport and 
phosphorylation. Metabolic uncouplers inhibit ATP synthesis by preventing the 
energy produced by redox reactions in the form of proton motive force to be used 
for phosphorylation [509]. Common uncouplers are hydrophobic weak acids such 
as carbonylcyanide-p-trifluoromethoxyphenylhydrazone (FCCP) which transport 
protons  through  H
+-impermeable  membranes.  Also  any  compound  or  physical 67 
force  such  as  osmotic  shock  that  dissipates  the  pH  difference  and  membrane 
potential can cause uncoupling. 
1.10.3  Pathways of mitochondrial Ca
2+ cycling 
Studies in the 1960s on isolated mitochondria in suspension demonstrated 
their extraordinary ability to take up enormous quantities of Ca
2+ when added to 
the  bathing  solution  [522,  523].  Early  experiments  showed  that  isolated 
mitochondria accumulate up to 36mM Ca
2+ without damage and up to 900mM 
Ca
2+ accompanied by irreversible damage and morphological changes [524]. At 
the time the hypothesis existed that uptake was a passive process linked to the 
∆Ψm [525, 526]. Later on a uniporter was identified, an inwardly rectifying Ca
2+-
selective ion channel on the IMM [527]. The driving force for mitochondrial Ca
2+ 
uptake via the uniporter is the ∆Ψm and its action is inhibited by ruthenium red 
and agents that collapse the ∆Ψm such as uncouplers [528, 529]. When [Ca
2+]i is 
above a threshold [530, 531], the uniporter, which has been shown to be half 
maximally activated around 10–20µM Ca
2+,
 can take up Ca
2+ at high rates [311, 
532-534]. Resting values of intra-mitochondrial Ca
2+ are not thought to be much 
different from cytosolic Ca
2+ levels (in the range of 80-200nM) as measured with 
loading dyes in both isolated and cellular mitochondria [535]. 
Ca
2+ is removed from mitochondria at slow rates (30-400 times slower than 
the  uniporter)  by  secondary  transport  [535].  The  physiological  Ca
2+  cycling 
mechanism  is  achieved  by  the  exchange  of  2Ca
2+  for  3Na
+  via  the  Na
+:Ca
2+ 
exchanger (NCE) [536, 537] and consequently the exchange of Na
+ for H
+ via the 
Na
+:H
2+ exchanger (NHE)  [311, 538, 539]. ROS production has been shown to 
inactivate  the  mitochondrial  NCE  and  therefore  cause  [Ca
2+]i  rises  [540].  The 68 
major  mitochondrial  Ca
2+  handling  pathways  (the  uniporter  and  the  NCE)  are 
illustrated in Figure 1.7.  
Other pathways  for mitochondria Ca
2+ handling include the rapid uptake 
mode pathway (RaM) [541] and the permeability transition pore (PTPm) pathway 
(reviewed  in  [542]).  The  latter  consists  of  a  multi-protein  complex  which 
assembles  under  pathological  conditions  such  as  mitochondria  Ca
2+  overload, 
oxidative  stress  or  adenine  nucleotide  depletion  [542].  The  pore  is  a  high 
conductance, non selective channel that allows maximal Ca
2+ flux and initiates 
apoptotic pathways [543].  
1.10.4  Mitochondrial Ca
2+ homeostasis 
The large capacity of mitochondria to sequester Ca
2+ suggested that they 
could be major players in cytosolic Ca
2+ homeostasis. Indeed estimates suggest 
they contribute to 25% of total cellular Ca
2+ storage capacity in bovine aortic 
endothelial cells [209]. Initially it was thought that the sensitivity of the uniporter 
to Ca
2+ was low, so that mitochondria would only participate in Ca
2+ sequestration 
when [Ca
2+]i approached cytotoxic levels (see review [515]), however, it is now 
known that the threshold of activation of the uniporter is much lower (~300nM) 
[544-546]. Mitochondria can form clusters near the mouth of Ca
2+ channels where 
high Ca
2+ concentrations arise following channel activation [532]. While cytosolic 
Ca
2+  near  Ca
2+  channels  can  be  as  high  as  100µM,  these  levels  can  drop 
dramatically  (below  1µM)  even  at  1-2µm  further  from  the  channels  [547]. 
Mitochondrial  clusters  can  form  near  IP3Rs  on  the  ER  or  near  the  plasma 
membrane (at a distance less than 100nm) [548] depending on the cell type [549]. 
In  this  way  mitochondria  are  positioned  to  participate  in  Ca
2+  uptake  when 69 
exposed  to  high  Ca
2+  microdomains.  Data  obtained  using  mitochondrial  Ca
2+ 
indicators showed that  physiological stimuli acting on Gq-coupled  receptors to 
elicit rises in [Ca
2+]i, lead to a large rapid rise in mitochondrial Ca
2+ concentration 
([Ca
2+]m) in a variety of cell types [549, 550](reviewed in [551]). The [Ca
2+]m rises 
are  shown  to  be  significantly  slower  than  the  [Ca
2+]i  rises  and  to  outlast  the 
cytosolic  signal  [535,  552-555].  Mitochondrial  Ca
2+  uptake  is  also  thought  to 
shape the decay phase of agonist-evoked Ca
2+ transients. Evidence for this has 
come  from  studies  in  which  uncoupled  mitochondria  dramatically  prolong  the 
depolarisation-induced [Ca
2+]i rises in chromaffin cells [547, 556-558], neurons 
[553,  559,  560],  and  pituitary  gonadotropes  [552,  561].  However  in  mouse 
skeletal  muscle  fibers,  FCCP  induced  a  drastic  reduction  of  Ca
2+  transient 
amplitude without any effect on the decay phase [562].  
Clusters of mitochondria in the immediate vicinity of IP3R have been found 
to regulate Ca
2+ release from the stores. Ca
2+ uptake into energized mitochondria 
lowers the local free [Ca
2+]i and regulates the Ca
2+-induced feedback activation or 
inhibition  of  IP3R  Ca
2+  release  [563].  In  this  way  mitochondria  control  bulk 
[Ca
2+]i increases and modulate the rate and extent of Ca
2+ signal propagation and 
consequently [Ca
2+]i oscillations [563, 564]. Uncouplers either dramatically slow 
the rate of [Ca
2+]i oscillations (e.g. in pituitary gonadotropes [552], in neurons 
[560, 565], and in rat cortical astrocytes [553]) or completely inhibit regeneration 
of [Ca
2+]i oscillations (e.g. in xenopus oocytes [566]).  
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Figure 1.7 Mitochondrial Metabolism 
A schematic of a mitochondrion illustrating the channels present on the inner 
mitochondrial  membrane,  including  complexes  I-IV  of  the  electron  transport 
chain,  the  F1F0-ATPase,  the  mitochondrial  uniporter  (U)  and  the  Na
+/Ca
2+ 
exchanger responsible for Ca
2+ sequestration.  The figure also highlights drugs 
that can be used for mitochondrial dysfunction including the uncouplers FCCP 
and  antimycin  A  and  the  ATPase  inhibitor  oligomycin.  (IMM=inner 
mitochondrial membrane, IS=intermembrane space, NCE=Na
+/Ca
2+ exchanger, 
OMM=outer mitochondrial membrane, RUR=ruthenium red, U=Uniporter) 
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Mitochondria  clusters  have  been  found  in  close  proximity  to  the  plasma 
membrane Ca
2+ channels in neurons [560], fibroblasts [567], T-cells [568] and 
endothelial cells [569, 570]. Subplasmalemmal mitochondria take up local Ca
2+ 
and form microdomains of low [Ca
2+]i close to the plasma membrane. In this way 
during capacitative Ca
2+ entry (CCE), the gradient for Ca
2+ entry is increased and 
this  is  thought  to  help  accelerate  the  transfer  of  Ca
2+  into  the  cytosol  for  ER 
refilling (see 1.6.1) [570-573]. Inhibition of mitochondrial Ca
2+ flux augmented 
agonist-evoked ER depletion and abolished ER refilling via CCE in endothelial 
cells [229, 568, 569, 573, 574].  
1.10.5  Oscillatory [Ca
2+]m signals  
[Ca
2+]m has been found to oscillate in phase with [Ca
2+]i oscillations in the 
case of anterior pituitary cells [552], xenopus oocytes [566], β-cells [575], adrenal 
glomerulosa cells [576] and hepatocytes [577]. In other cases [Ca
2+]m can increase 
accumulatively during [Ca
2+]i oscillations, due to the slow recovery of [Ca
2+]m 
[578]. In endothelial cells long lasting elevations in [Ca
2+]m are seen [549]. There 
is  evidence  that  [Ca
2+]m  oscillations  are  decoded  into  long  term  activation  of 
dehydrogenases which translates into increased metabolism [577]. 
1.10.6  Mitochondria and secretion 
Elevation  of  mitochondrial  free  Ca
2+  up-regulates  3  major  rate-limiting 
dehydrogenases  of  the  TCA  cycle  (pyruvate,  isocitrate  and  oxoglutarate 
dehydrogenase) which is paralleled by a rise in the reduced form of NADH [575], 
leading  to  an  increase  in  ATP  production  [517,  579,  580].  Increased  energy 
production by mitochondria may match the [Ca
2+]i-triggered energy consuming 72 
processes such as secretion in excitable cells [581], motion or Ca
2+ re-extrusion. 
However this may not be significant in the glycolytic endothelial cells. 
Extensive work has been done on secretion from chromaffin cells during 
inhibition  of  mitochondrial  Ca
2+  uptake.    As  mentioned  above,  clusters  of 
mitochondria have been found concentrated in sub-plasmallemal regions rich in 
Ca
2+ channels. These have been postulated to constitute active secretory zones 
where  mitochondria  buffer  Ca
2+.  Depending  on  the  size  of  the  local  Ca
2+ 
concentration after stimulation, mitochondria serve to limit the diffusional range 
of  [Ca
2+]i  and  localise  the  secretory  response  [578].  It  is  proposed  that 
mitochondria are involved in limiting the propagation of [Ca
2+]i and in controlling 
the traffic of vesicles at the plasma membrane between distinct pools [389, 582]. 
Indeed capacitance measurements of uncoupler treated chromaffin cells [552, 557, 
578,  583,  584]  and  gonadotropes  [552]  showed  no  effect  on  the  immediately 
releasable pool of granules but resulted in an enhancement of recruitment to the 
plasma membrane of granules in the reserve pool and consequently an overall 
increase  in  the  secretory  responsiveness.  In  addition  an  increased  secretory 
response during the interpulse intervals and after cessation of the stimulus train 
was seen only in the presence of uncouplers in those studies. The opposite effects 
of uncouplers were seen in mouse chromaffin cells where a decline in [Ca
2+]i and 
secretion  was  observed  [557].  Therefore,  it  appears  as  though  different 
proportions of Ca
2+ channel subtypes in each species work with mitochondria to 
determine the physiological response. At present there is no evidence to suggest 
that mitochondria play a role in regulating WPB or non-WPB exocytosis from 
EC. 73 
1.10.7  Mitochondria in disease 
Production  of  reactive  oxygen  species  (ROS)  (see  reviews  [585,  586]), 
mitochondrial DNA mutations [508] and inherited mitochondrial genetic defects 
[585,  587]  lead  to  mitochondrial  dysfunction.  These  encompass  dissipation  of 
∆Ψm  and  consequently  impairment  of  the  mechanism  by  which  mitochondria 
participate in Ca
2+ homeostasis. As a result, this may lead to disruption of the fine 
tuning of spatiotemporal patterning of [Ca
2+]i signals by mitochondria, which in 
turn  could  affect  the  secretory  response.  Mitochondria  are  concentrated  in 
neuronal  synapses  and  significant  alterations  to  synaptic  mitochondrial 
localization,  number,  morphology,  or  function  can  be  detrimental  to  synaptic 
transmission  [585].  Dysfunctional  exocytosis  of  neurotransmitters  in  the  CNS 
caused by mitochondrial abnormalities is a common underlying phenomenon in 
the initial stages of some human neurodegenerative diseases [543, 585, 588]. The 
same concept could apply to endothelial cells and thus disruption of the exocytotic 
response  of  WPBs  could  be  the  link  between  mitochondrial  dysfunction  and 
chronic inflammatory diseases [589].  
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1.11  Thesis Aims 
ECs control many important processes through the secretion of a wide range 
of molecules including peptides and proteins. Peptides and proteins are secreted 
by  exocytosis  from  preformed  membrane  bound  secretory  organelles.  In  this 
thesis  optical  methods  have  been  employed  to  fluorescently  label  and  hence 
directly visualise two distinct populations of secretory granules, the WPB and a 
small organelle containing t-PA, the non-WPB. A main focus of this thesis will be 
to  characterise  the  distinct  nature  of  these  two  organelles.  Using  high  speed 
multicolour imaging the kinetics of WPB and non-WPB exocytosis evoked by 
physiological and pharmacological [Ca
2+]i-raising agents have been studied with 
sub second time-resolution. These data provide the first time-resolved analysis of 
the kinetics of secretion of these granule populations revealing new information 
about the inherent delays and rates of WPB exocytosis and their dependence on 
extracellular Ca
2+. Attempts were made to investigate whether [Ca
2+]i oscillations 
in cultured HUVEC might play a role in regulating WPB exocytosis, and whether 
mitochondrial  Ca
2+  uptake  participates  in  shaping  the  [Ca
2+]i  signalling  in 
HUVEC and WPB exocytosis. 
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2  Experimental Methods 
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2.1  Protocols and Reagents 
2.1.1  Tissue culture  
Primary  Human  Umbilical  Vein  Endothelial  Cells  (HUVECs)  were 
purchased from TCS Cellworks, Botolph, Claydon, UK and grown in HUVEC 
Growth  Medium  (HGM)  (M199  +Earle’s,  +L-Glutamine,  Invitrogen,  Paisley, 
UK) supplemented with 20% fetal calf serum, 10 U/ml of heparin (Sigma, Dorset, 
UK), 30 µg/ml of Endothelial Cell Growth Supplement (Upstate, Dundee, UK) 
and  50  µg/ml  Gentamicin  (Invitrogen)  under  5%  CO2  at  37°C  as  previously 
described [59].  
2.1.2  Expression of fusion proteins by Nucleofection 
HUVEC at passage 3 or 4 were transfected with 4-8µg of expression vector 
DNA  using  the  Nucleofection™  device  and  buffers  according  to  the 
manufacturer’s instructions (Amaxa GmbH, Cologne, Germany) and as described 
in Erent et.al 2008. Briefly the cells were trypsinized and centrifuged at 1000rpm 
for  3min.  The  number  of  cells  varied  depending  on  the  experiment.  Roughly 
60.10
6cells/ml were nucleofected per 6-well plate. The pellet was re-suspended in 
100µl HUVEC nucleofector solution OLD and mixed with 4-8µg of the desired 
DNA. The mixture was transferred into a cuvette and placed in the Nucleofection 
device for the DNA to be electroporated to the nucleus of the cells using the 
program  U-01  (appropriate  for  endothelial  cells).  The  cells  were  plated  in 
complete culture medium at confluent density onto 24 x 24mm square uncoated 
glass coverslips (Menzel-Glaser, Menzel GmbH Germany) for live cell imaging 
or onto gelatine-coated (incubate at 37ºC for 20min; 20%w/vol; Sigma fish skin 
gelatine) 9mm diameter glass coverslips (Griffiths & Nielsen, West Sussex, UK) 77 
for  immunocytochemistry.    Cells  were  maintained  without  further  medium 
changes until their use one to two days after Nucleofection. 
Chimeric proteins provided and used for expression were vWF or its pro-
polypeptide (proregion) fused to Enhanced Green Fluorescent Protein (EGFP), t-
PA-EGFP, proregion-monomeric Red Fluorescent Protein (mRFP) and proregion-
mEGFP  made  as  previously  described  [35,  390,  590,  591]  (Figure  2.1). 
Monomeric  Enhanced  Green  Fluorescent  Protein  (mEGFP)  was  made  by 
substituting Alanine at position 206 of EGFP with a lysine (A206K) to prevent 
possible  dimerization  without  altering  its  spectral  properties  [591].  Cells  were 
used  4  or  24hours  post-Nucleofection  for  t-PA-EGFP  and  48hours  post-
Nucleofection for vWF or proregion-EGFP or mEGFP.  
In cells nucleofected with proregion-EGFP or mEGFP, 20-40% of cells had 
detectable EGFP fluorescence. In contrast only 5-20% of cells nucleofected with 
full length vWF-EGFP showed fluorescent WPBs presumably because it is more 
difficult  for  the  cells  to  make  the  much  larger  full  length  vWF  protein  [1]. 
Nevertheless these levels of expression were more than sufficient for single cell 
optical studies of exocytosis and in the case of proregion-EGFP for biochemical 
studies of secreted GFP. 
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Figure 2.1 GFP-tagged constructs 
GFP-tagged constructs were expressed in HUVEC by Nucleofection, including 
vWF-EGFP  (top),  proregion-EGFP  or  mEGFP  (middle)  and  t-PA-EGFP 
(bottom). 
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2.1.3  Constructing mito-EGFP from mito-DsRed 
A  Ca
2+-insensitive  fluorescent  mitochondrial  marker  was  constructed  for 
control  experiments  to  monitor  intra-mitochondrial  pH  changes  during 
pharmacological  collapse  of  the  ∆Ψm.    This  was  achieved  by  exchanging  the 
DsRed2 fluorescent protein of pDsRed2-Mito (BD biosciences Clontech, Oxford, 
UK,  cat.  No.  632421;  see  Figure  1.6)  with  EGFP  (Figure  2.2).  The  vectors 
pEGFP-N1 (BD biosciences Clontech, cat. No. 6085-1) and pDsRed2-Mito (BD 
biosciences Clontech) were digested with BamHI and NotI (Roche, East Sussex, 
UK) according to manufacturer’s instructions to cut out the fluorophores EGFP 
and DsRed2 respectively. The digestion products were separated by Agarose Gel 
electrophoresis as described in Sambrook, J., Molecular cloning 1989 [592]. The 
~700bp  fragment  coding  for  EGFP  and  the  ~4Kb  fragment  comprising  the 
pDsRed2-Mito  vector  with  the  DsRed2  fluorophore  removed  (delta-pDsRed2-
Mito)  were  identified  using  a  100bp  and  1kb  DNA  ladders  (New  England 
BioLabs, Hertfordshire, UK); cut from the gel and purified using a QIAquick Gel 
Extraction  Kit  (QIAGEN,  West  Sussex,  UK)  according  to  manufacturer’s 
instructions. The purified EGFP fragment and the delta-pDsRed2-Mito plasmid, 
in TE solution (Tris-EDTA; 10mM Tris-cl pH8, 1mM EDTA pH8) were ligated 
together using T4 DNA ligase (New England BioLabs cat. No. M0202S) [593]. 
The ligated product was transformed into DH5α competent cells (Invitrogen, cat. 
No.  18263-012)  using  a  45sec  heat  shock  in  a  42ºC  water  bath  according  to 
instructions [594]. The transformed bacteria were plated on an L Agar Petri dish 
supplemented with a 1000 dilution of kanamycin from a stock concentration of 
50mg/ml  using  sterile  conditions  and  incubated  overnight  at  37ºC  in  humid 
conditions.  Colonies  were  picked  after  16hours  and  harvested  in  L  Broth 80 
supplemented with 50µg/ml kanamycin from a stock concentration of 50mg/ml in 
dH2O  for  16hours  [595].  The  cloned  plasmid  DNA  was  isolated  from  the 
transformed bacteria using the Alkali lysis method and dissolved in TE [595]. 
Figure  2.2A  illustrates  the  cloning  process  and  Figure  2.2B  shows  an 
epifluorescence image of a single HUVEC expressing this construct. 
2.1.4  Antibodies, Reagents and Immunocytochemistry 
For immunofluorescence localisation of endogenous vWF immunoreactivity 
in  fixed  HUVEC  a  rabbit  polyclonal  anti-human  vWF  antibody  (Dako  Ltd, 
Cambridgeshire, UK, catalogue number A0082) or a sheep polyclonal anti-human 
vWF  (AbD  Serotec,  Oxford,  UK  cat.  No.  AHP062)  were  used  at  a  1:10000 
dilution.  For  immunofluorescence  localisation  of  endogenous  t-PA 
immunoreactivity a sheep polyclonal anti-t-PA antibody (AbD Serotec, cat. No. 
9020-0809)  was  used  at  a  1:300  dilution.  Secondary  antibodies  coupled  to 
fluorophores were purchased from Stratech scientific, Cambridgeshire, UK and 
used at a 1:200 dilution; donkey Cy-2 anti-rabbit (cat. No. 711-225-152), donkey 
Cy-2 anti-sheep (cat. No. 713-225-147), donkey Red-X anti-rabbit (cat. No. 711-
295-152) and donkey Cy-5 anti-sheep (cat no 713-175-147). Cells were processed 
for immunofluorescence as previously described [35]. Briefly the cells were fixed 
with 3% (w/v) paraformaldehyde
 in PBS for 15min and permeabilized/quenched
 
(Perm/quench)
 with 50mM NH4Cl and 0.2% (w/v) saponin in PBS for 10min at 
room temperature. Perm/quench was replaced with PGAS (comprising of gelatine 
(0.2% (w/v)), saponin (0.02% (w/v)) and NaN3 (0.02% (w/v)) in PBS) for 5min to 
block unspecific antibody binding sites. Cells were then incubated
 with 50µl of 
antibody appropriately diluted in PGAS; 45min in the primary followed by
 40min 
in  the  secondary  antibody.  Coverslips  were  mounted  onto  Mowiol  on  a 81 
microscope slide. The slides were stored for at least 4hours before being viewed 
using a 63x oil objective on a confocal microscope (Leica SP2 AOBS, Milton 
Keynes, UK).  
2.1.5  GFP ELISA 
Proregion-mEGFP  expressing  HUVEC  were  plated  at  confluency  onto 
gelatine  coated  6-well  dishes  (Fisher  Scientific,  Roskilde,  Denmark).  48hours 
post-Nucleofection cells were incubated in serum free M199 Medium (+Earle’s, 
+L-Glutamine,  Invitrogen)  supplemented  with  20mM  HEPES  (Sigma,  Dorset, 
UK) (S/FM199) for 1hour at 37ºC after which the medium was replaced with 
fresh  S/FM199  for  a  further  10min  at  37ºC  (to  ensure  complete  removal  of 
secreted material released over the initial 60min incubation period). The medium 
was  then  changed  to  S/FM199  plus  stimulus  for  5min.  Media  samples  were 
collected and centrifuged for 3min at 13000rpm and the pellet was discarded. The 
cells on the dish were washed with 1ml Lysis buffer made with 1% triton (TX-
100, Sigma, Dorset, UK) in S/FM199 and 1:100 dilution of Protease Inhibitor 
cocktail (Sigma, Dorset, UK, cat no. P8340). Lysis samples were centrifuged for 
5min at 13000rpm and the pellet was discarded. The experimental procedure is 
shown in Figure 2.3. 
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Figure 2.2 Constructing mito-EGFP from mito-DsRed 
DsRed2 from vector pDsRed2-Mito was replaced with EGFP from vector pEGFP-
N1. The bottom image shows a single HUVEC expressing mito-EGFP. 
488 (30)nm 83 
 
 
 
 
 
 
Figure 2.3 GFP ELISA 
Experimental  protocol  for  assessing  stimulated  secretion  of  GFP  tagged 
proregion from HUVECs. 
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ELISA plates were coated overnight with 100µl of sheep anti-GFP antibody 
(AbD Serotec, Oxford, UK cat no. 4745-1051) diluted 1:1000 in PBS. Plates were 
blocked  with  300µl  of  Tween-ELISA  buffer  (TWEB)  (0.1%  Tween-20,  0.2% 
gelatin and 1mM EDTA in PBS) for an hour before the samples were loaded. 
100µl of standards, blanks and neat samples were added in duplicate, covered and 
mixed  for  1hour.  The  standard  curve  was  made  from  1:2  dilutions  of  a 
recombinant bacterially produced GFP in S/FM199 (for the media samples) or in 
lysis buffer (for the lysate samples). The wells were then covered and incubated 
for 1hour on a mixer plate with 100µl of secondary rabbit anti-GFP (Invitrogen, 
Paisley, UK, cat no A11122) diluted 1:5000 in TWEB and then 100µl donkey 
anti-rabbit-HRP  (horse  radish  peroxidase)  conjugate  (Stratech  scientific, 
Cambridgeshire, UK, cat no 711-035-152) diluted 1:1000 in TWEB. The plates 
are washed with TWEB in between antibody incubations and with an additional 
PBS wash after the last incubation. The last wash is flicked off and replaced with 
100µl chromogen O-Phenylediamine dihydrochloride (OPD, Sigma, Dorset, UK, 
cat no P8412) for GFP detection. OPD is prepared by dissolving 1.5mg/ml OPD 
tablets in CPT buffer pH6.2 (100mM citric acid, 0.2M Na2HPO4, 0.1% TX-100) 
for 10min before adding 1:50000 dilution of H2O2 for the colour change reaction 
to initiate. The assay is measured immediately kinetically at 450nm followed by 
an End point assay at 450nm approximately 5min after the H2O2 addition. 
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2.2  Imaging 
2.2.1  Basic epifluorescence imaging apparatus 
For  experiments,  cells  seeded  onto  24  x  24mm  square  uncoated  glass 
coverslips (Menzel-Glaser, Menzel GmbH Germany) were transferred to the stage 
of  an  Olympus  IX71  inverted  fluorescence  microscope  where  they  were 
maintained at between 36-37ºC using a stage heater, an objective heater and an in-
line  solution  heater  (Harvard  apparatus,  Kent,  UK).  The  imaging  system 
comprised a monochromator (Optoscan; Cairn Research, Faversham, UK) capable 
of fast (~1 ms) wavelength switching and able to provide excitation light between 
300–700nm  at  bandwidths  between  2–30nm.  The  excitation  light  was  passed 
through a 50% neutral density filter to reduce fluorophore bleaching before being 
reflected  by  a  chromatic  reflector  onto  the  back  aperture  of  an  Olympus 
UPLSAPO  x100  1.40NA  objective  to  excite  the  specimen.  Emitted  light  was 
transmitted through the chromatic reflector to be selected by an emission filter and 
sent to an Ixon EMCCD camera (Andor, Belfast, UK) operated in frame transfer 
mode at full gain and cooled to -65°C. Wavelength switching was synchronised 
with  image  capture  using  the  free  software  WinFluor 
(http://spider.science.strath.ac.uk/sipbs/page.php?show=software_imaging) by Dr. 
John Dempster of Strathclyde University. Full frame (512 by 512 pixels) images 
were  acquired  as  fast  as  30frames/sec.  A  schematic  of  the  basic  setup 
configuration is shown in Figure 2.4. The filter sets used for each specific imaging 
configuration are illustrated in each following chapters. 
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Figure 2.4 Basic configuration for imaging 
The basic epifluorescence configuration used comprised a monochromator which 
sent the excitation light through a 50% neutral density filter to the chromatic 
reflector to be reflected onto the specimen. Emitted light was transmitted through 
the  chromatic  reflector  and  selected  by  an  emission  filter  before  sent  to  an 
EMCCD camera. The preparation is stimulated by a glass micropipette. 
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2.2.2  Total Internal Reflection Fluorescence Microscopy (TIRFM) 
The  TIRFM  lasers  were  built  around  the  epifluorescence  microscope 
described  above;  a  488nm  laser  (20mW;  I-Flex  2000,  Point  Source,  Hamble 
UK), fitted with an acousto-optical deflector (AOD) allowing computer control of 
the laser power and a 561nm laser (50mW, 10Khz modulation; GLC-050-561, 
CrystaLasers,  Nevada,  USA)  controlled  by  a  pulse  width  modulation  (PMW; 
10KHz) and a range of neutral density filters to achieve optimum excitation with 
minimum  photobleaching.  Switching  between  laser  and  epifluorescence 
illumination  was  synchronized  with  image  capture  using  Winfluor.  Schematic 
Figure 2.5 describes the setup. A small mirror ( 3 mm diameter) was placed near 
the back aperture of the objective lens responsible for directing the laser beams to 
the  specimen  at  a  specific  adjustable  angle  that  will  produce  total  internal 
reflection. The internally reflected beam is projected by another identical mirror, 
on the opposite side of the first one, onto a position-sensitive photodiode used for 
autofocus control. A similar configuration was previously used [596]. TIRFM is 
achieved by hitting the glass (high-refractive medium; n2=1.518) – water (low-
refractive  medium;  n1=1.33-37)  interface  with  excitation  light  at  an  angle  (θ) 
above 61° to the normal which causes the light to undergo total internal reflection 
according to Snells’ law. This produces an evanescence field of excitation with 
depth  of  penetration  depending  on  the  wavelength  of  light  and  the  angle  of 
incidence (the larger the angle the smaller the field penetration). Only material 
that enters the thin plane of the evanescent field is excited, giving rise to a high 
contrast  image  with  minimal  background  fluorescence  and  no  out-of-focus 
fluorescent material [596-598]. 
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Figure 2.5 TIRFM 
The 488nm and 561nm lasers were built around the epifluorescence microscope. 
The laser beam was directed to the specimen at a specific adjustable angle by a 
small mirror near the back aperture of the objective. At the glass- water interface, 
where the refractive index of glass is n2=1.518 and of water n1=1.33-1.37, the 
critical angle (θc) for total internal reflection is θc=61° defined by the equation θc 
= sin
-1(n2/n1). Above that angle an evanescence field of light is produced which excites a 
thin plane of the specimen at high contrast. The internally reflected light is directed by 
another mirror to the position sensitive photodiode for autofocus control. 
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2.2.3  Agonist stimulation of a single HUVEC 
HUVEC  grown  on  24x24  coverslips  were  attached  on  a  laminar-flow 
chamber (specially manufactured in the NIMR workshops) using silicon vacuum 
grease (Beckam cat no 335148-03) and bathed in physiological saline (PS) (140 
mM NaCl, 5 mM KCl, 1.8 mM CaCl2, 2 mM MgCl2, 10 mM glucose, 10 mM 
HEPES-NaOH,  pH  7.40).  Ca
2+-raising  agents  dissolved  in  PS  were  applied  to 
single cells by pressure injection from a glass micropipette (Warner Instruments, 
Kent, UK, cat no. 64-0804) positioned close to the cell (puffer application). A 
perfusion system was used to wash the stimulus off after each puffer application 
preventing stimulation of other cells on the coverslip. Figure 2.6 shows a picture 
of the stimulation configuration. Activation of the puffer controller was monitored 
by a +1V analogue telegraph output recorded simultaneously with image capture 
within the acquisition program WinFluor. Figure 2.7 shows a single proregion-
EGFP  expressing  HUVEC  in  epifluorescence  (A)  and  DIC  (Differential 
Interference Contrast) (B) to illustrate the placement of the puffer. The distance 
between the pipette and the cell (typically 10-15µm), the width of the pipette tip 
(2µm) and the compressed air pressure (1psi) were adjusted to achieve fast agonist 
solution  application  but  such  that  control  solutions  did  not  elicit  a  change  in 
[Ca
2+]i due to fluid shear effects [21, 94]. Figure 2.8 shows an example of an 
experiment where the micropipette contains only PS to control for shear evoked 
elevation of [Ca
2+]i in a single HUVEC.  
For the controlled repetitive puffing experiments, the puffer activation and 
deactivation was controlled with a voltage stimulus protocol within the WinFluor 
programme. For experiments where solutions were continuously perfused onto the 
cells,  a  6  channel  in-line  perfusion  system  (fabricated  by  Dr  Martin  Stopps, 90 
NIMR)  connected to the cell chamber was used. Syringe valve switching was 
digitally controlled and recorded as an analogue signal in Winfluor during the 
experiments. The stimulation solutions passed through the in line solution heater 
(Harvard apparatus, Kent, UK) at about 37 ºC before arriving at the laminar-flow 
chamber. An aspirator on the opposite side of the chamber allowed removal of the 
applied solution. The average perfusion rate used that did not cause a shear [Ca
2+]i 
response was 2.5ml/min. 
2.2.4  Determining the time-point of agonist arrival at the cell 
To  estimate  the  time-course  of  drug  arrival  at  the  cell  during  puffer 
application, experiments were carried out in which 10µM alexa-647 (Invitrogen) 
was included in the puffer pipette solution. A region of interest (ROI) was placed 
over the cell to measure the alexa-647 fluorescence change and the point of drug 
arrival at the cell was taken arbitrarily as the time-point corresponding to the 50% 
rise of Alexa-647 fluorescence. This was ~200ms (2 frames) post-activation of the 
puffer pipette (n=15 cells) (vertical dotted line in Figure 2.9) and was used as 
time=0s for defining subsequent delay times. Figure 2.9 illustrates an example of 
the  temporal  relationship  between  puffer  application  (A)  and  the  detection  of 
Alexa fluorescence (B) offset so that puffer activation occurs at t=0. 
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Figure 2.6 Agonist application setup 
A picture of the cell stimulation setup showing the laminar-flow chamber, the 
puffer micropipette controlled by a micromanipulator, the in-line solution heater 
with  the  perfusion  tubing  leading  to  the  chamber  and  the  stage  heater.  An 
aspirator on the other side of the chamber allows flow of the applied solution. 
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Figure 2.7 Agonist application 
A.  Single  proregion-EGFP  expressing  HUVEC  in  epifluorescence  excited  at 
488nm. B. The same cell in DIC showing the placement of the puffer micropipette 
 
Figure 2.8 Effect of fluid shear due to puff application on resting [Ca
2+]i in 
HUVEC. 
 The  top  trace  shows  the  analogue  output  signal  and  indicates  activation  and 
deactivation  of  the  puffer  micropipette.  The  lower  trace  shows  the  Fura-2 
fluorescence  which  does  not  change  during  puff  application  of  bath  solution 
indicating there is no response due to fluid shear effects. 
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Figure 2.9 Defining the delay in drug arrival 
The  top  panel  shows  the  +1V  analogue  output  from  the  micropipette  solution 
puffer  controller  that  signals  activation  of  the  device.  The  solid  trace  in  the 
bottom panel represents the mean time-course of the fluorescence increase due to 
Alexa-647 in the puffer solution (normalised to the peak steady-state fluorescence 
level, n=15 cells), in a ROI placed over the cell. Dotted lines represent s.e., of 
mean. The time-point of drug arrival at the cell was taken arbitrarily as the 50% 
Alexa fluorescence increase (Vertical dashed line) and was ~200ms. This time-
point was used to define time=0s for subsequent analysis of delay times. 
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2.2.5  Ammonium Chloride (NH4Cl) pulse technique 
NH4Cl, a weak base, completely ionizes in solution to ammonium (NH4
+) 
and Cl
-. NH4
+ reacts with OH
- in solution to form ammonia (NH3) and H2O. NH3 
is cell permeable because it is uncharged and rapidly passes through lipid bilayers  
to bind protons in the lumen of organelles and form NH4
+ until NH3 and NH4
+ 
reach equilibrium in the cell and its organelles (e.g. the secretory granules) [599]. 
This  process  alkalinises  the  granules  transiently  resulting  in  an  increase  of 
granule-targeted  GFP  fluorescence.  The  charged  partner  (NH4
+)  was  originally 
thought to be cell impermeable from the early work by Overton in 1897 and by 
Jacobs in 1922 [599]. Later on it was discovered that NH4
+ also passively enters 
the cell at a slower rate than NH3, dissociating into NH3 and H
+ and causing the 
cell to acidify [600, 601]. A simplified diagram of these reactions is illustrated in 
Figure 2.10A.  
5mM NH4Cl final concentration from 50mM stock in PS made up fresh and 
adjusted to pH7.4 with NaOH was added to the t-PA-EGFP and proregion-mRFP 
co-expressing HUVEC maintained in PS at 37°C. The EGFP fluorescence change 
upon NH4Cl addition is used to calculate the pHt-PA by using the equation in 2.10B 
where the pKa (pH at half-maximal fluorescence) is 5.84 and nH (Hill coefficient) 
is 0.74 as derived from the in vivo pH titration of WPB EGFP fluorescence [1]. F 
represents the steady-state normalised EGFP fluorescence before NH4Cl addition 
and Fmax the peak of the normalised EGFP fluorescence. 95 
  
 
 
Figure 2.10 NH4Cl action on the secretory organelles 
A.  Schematic  diagram  of  the  action  of  NH4Cl  on  secretory  granules.  NH4Cl 
completely  ionizes  in  solution.  Its  charged  moiety  forms  NH3  which  rapidly 
permeates membranes and binds H
+ inside the acidic lumen of secretory granules 
to form NH4
+ until NH3/NH4
+ equilibrium is reached. Extracellular NH4
+ slowly 
permeates the granule to re-acidify the lumen.  
B.  The  equation  used  to  calculate  the  intra-granule  pH  from  the  normalised 
luminal EGFP fluorescence during NH4Cl addition. Where pKa=5.84, nH=0.74, 
Fmax= normalised peak of EGFP fluorescence, F= steady-state normalised EGFP 
fluorescence. 
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2.2.6  Data analysis and measurements 
Image analysis was carried out using custom written plugins and macros in 
ImageJ software (http://rsb.info.nih.gov/ij/). Dataset plotting, fitting and analysis 
were performed in Excel, Microcal Origin 7 and GraphPad Prism. Results are 
expressed as mean±SD unless indicated otherwise. Statistical differences (at 95% 
confidence  limit)  between  2  population  means  were  determined  using  a  non-
paired two way t-test or a one way ANOVA between more than 2 population 
means followed by a Tukey post test which compared all pairs of populations. The 
proportion of WPB that underwent exocytosis was determined in epifluorescence 
experiments. A 5 frame averaged image, taken prior to stimulation, was exported 
to ImageJ for counting WPBs using the Pointpicker plugin. The total number of 
WPBs within the cell were counted manually twice and the mean value taken. The 
number of WPBs that underwent exocytosis was determined (in ImageJ) from the 
time-lapse images. Changes in [Ca
2+]i were calculated as the ratio of background 
subtracted  Fura-2  fluorescence  at  355nm  divided  by  that  at  380nm  within  the 
WinFluor program. The time-point of [Ca
2+]i rise was determined as the first time 
point of the Fura-2 signal that was higher than the mean + 3 times the standard 
deviation of the pre-stimulated signal (>mean+3*SD). 
For  [Ca
2+]m  changes,  the  analysis  was  done  in  ImageJ  using  a  custom 
written  average  background  subtraction  macro  (Nicolai  Kiskin,  NIMR).  The 
average background was subtracted first from the cytosol and then from a ROI 
adjacent to the X-Rhod-1 loaded mitochondrial region that was being analyzed. A 
ROI was then placed over the chosen mitochondrial region to measure the change 
in  X-Rhod-1  fluorescence.  If  the  mitochondria  happened  to  move  during 97 
stimulation  i.e.  contract,  then  a  custom  macro  (written  by  Dr  Victor  Babitch, 
NIMR) was used to track the movement. 
2.3  Description of Imaging 
2.3.1  Imaging [Ca
2+]i  changes with Fura-2  
In order to determine the relationship between elevated [Ca
2+]i and secretion 
it  is  necessary  to  make  simultaneous  measurements  of  changes  in  [Ca
2+]i  and 
WPB  exocytosis.  For  measuring  [Ca
2+]i,  the  UV  light  excitable  Ca
2+  indicator 
Fura-2 (Invitrogen; Paisley, UK, cat. No. F1221) was used [602]. For intact cells 
the acetoxymethyl (AM) ester form was used that can passively diffuse across cell 
membranes where it is cleaved by cytosolic esterases to yield a charged molecule 
that  becomes  trapped  inside  the  cell  (Figure  2.11).  Fura-2  is  a  high  affinity 
ratiometric indicator (Kd=100nM) that allows measurements of [Ca
2+]i changes 
independent  of  variables  such  as  indicator  concentration,  photo-bleaching,  cell 
thickness  and  artefacts  such  as  movement.  Although  this  dye  has  a  similar 
emission wavelength profile to that of GFP it is excited at very much shorter 
wavelengths. These characteristics, in conjunction with suitable optics allowed 
both fluorophores to be imaged within the same cell (setup Figure in chapter 4 
Figure 4.1).  The excitation and emission wavelengths of Fura-2 free of Ca
2+ or 
Ca
2+  bound  are  shown  in  Figure  2.11  along  with  the  wavelengths  chosen  for 
imaging;  355nm  and  380nm.  The  commonly  used  excitation  wavelengths  for 
Fura-2 are 380nm (for which emission light at 520nm is quenched upon Ca
2+-
binding), and 340nm (for which emission light at 520nm increases upon Ca
2+-
binding).  However,  microscope  systems  vary  in  their  optical  transmission 
properties and are often inefficient at transmitting light in the near UV. This is 
illustrated for the transmission properties of the objectives used in these studies 98 
(Figure  2.12).    To  determine  the  optimal  wavelengths  for  ratiometric 
measurements of Fura-2 for our optical setup, spectral imaging experiments were 
conducted using Winfluor software. 1µM Fura-2 loaded HUVEC were imaged at 
30frames/s during which the centre wavelength for excitation light was varied 
frame by frame from 340nm to 400nm in 10nm steps (10nm bandwidth). The cells 
were stimulated with 3µM histamine to elevate [Ca
2+]i. Figure 2.13 shows the 
background  subtracted  fluorescence  at  520±40nm  for  each  of  the  excitation 
wavelengths as a function of time. There was no signal for 340nm excitation light 
consistent with the poor transmission at this wavelength through the microscope 
objective  (Figure  2.12).  From  the  spectral  data  the  wavelengths  of  choice  for 
ratiometric measurements are 355nm, the iso-emissive wavelength (i.e. does not 
change in fluorescence upon binding to Ca
2+) and 380nm. Although at 390nm the 
Fura-2 signal was larger, this wavelength was not chosen in order to minimize 
cross talk with GFP excitation (which can be excited as low as 400nm).   
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Figure 2.11 Chemical and Spectral properties of Fura-2 
A  schematic  of  the  Fura-2/AM  diffusion  through  the  cell  membrane  and 
formation of a charged molecule that becomes trapped inside the cytosol, by 
removal of the ester moieties by cytosolic esterases. The lower panel on the 
right shows the excitation and emission wavelengths of Fura-2 in the Ca
2+-
free and the Ca
2+-bound form. The excitation light for these experiments is 
355nm  and  380nm  (blue  bars)  for  ratiometric  measurements  and  emission 
light  is  selected  at  520±40nm  (green  bar).  The  next  panel  shows  a  single 
HUVEC loaded with 2.5µM Fura-2 imaged with the specific parameters. 
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Figure 2.12 Transmission properties of Olympus UPLSAPO                                        
x100 1.40NA and U-Plan-APO x100 1.35NA objectives 
http://microscope.olympus.com/uis2/UPLSAPO/100XO/ 
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Figure 2.13 Excitation spectral imaging of Fura-2 loaded HUVEC 
HUVEC loaded with 1µM Fura-2 and stimulated with 3µM histamine are imaged 
at  30frames/s  for  wavelengths  between  340nm-400nm  in  10nm  steps  (10nm 
bandwidth).  Each  trace  represents  the  background  subtracted  fluorescence  at 
520±40nm for each of the excitation wavelengths indicated as a function of time. 
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2.3.2  Establishing Fura-2/AM loading conditions 
Due to its Ca
2+ binding properties Fura-2, at high cytosolic concentrations, 
may contribute to buffering, thus limiting the distance over which Ca
2+ can diffuse 
and exert its effects. Changes in intracellular Ca
2+ may be altered sufficiently to 
affect  the  kinetics  of  exocytosis.  To  ensure  that  Fura-2  did  not  interfere  with 
hormone evoked exocytosis, the kinetics of exocytosis of fluorescent WPBs were 
compared between experiments using non-Fura-2 loaded cells (sham loaded) and 
cells loaded with different concentrations of Fura-2/AM (0.5-5µM; for 20min at 
room temperature; see below). Cells were stimulated either with a medium (3µM) 
or high (30µM) histamine concentration applied by pressure injection from a glass 
micropipette.  Alexa-647  was  included  in  the  agonist  solution  in  the  control 
experiments  to  determine  the  time-course  of  drug  arrival  to  the  cell  (2.2.4). 
Concentrations of Fura-2/AM of 2.5µM or less were found not to significantly 
alter the delays and rates of WPB exocytosis for the two concentrations studied. 
Figure 2.14 shows the histograms of WPB exocytotic events between sham loaded 
and 2.5µM Fura-2 loaded HUVEC stimulated with 3µM and 30µM histamine.   103 
 
 
Figure 2.14 Fura-2 loading conditions  
Upper panels show histograms of WPB fusion events, for control unloaded cells, 
offset so that puffer activation occurred at t=0. The lower panels show histograms 
of WPB fusion events and the Fura-2 fluorescence ratio for HUVEC loaded with 
2.5µM Fura-2. Panels on the left are experiments stimulated with 3µM histamine 
and panels on the right 30µM histamine. Unloaded HUVEC histograms represent 
data  pooled  from  17  cells  each  (332  WPB  for  3µM  and  230WPB  for  30µM 
Histamine stimulation). Fura-2 loaded HUVEC histograms represent data pooled 
from 18 cells (244 WPB) and 25 cells (388 WPB), stimulated with 3µM and 30µM 
histamine respectively. 
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For Fura-2 loading, nucleofected cells were transferred into Physiological 
Saline  (PS)  supplemented  with  0.5-2.5µM  Fura-2/AM  diluted  from  a  stock  
solution of 5mM Fura-2/AM in anhydrous DMSO (Dimethyl Sulphoxide; Sigma, 
Dorset,  UK,  cat  no  D2650)  with  2.0%  Pluoronic  F-127  low  UV  absorbance 
(Invitrogen, Paisley, UK, cat no P-6867) a low-toxicity dispersing agent used to 
facilitate the solubilisation of water-insoluble dyes in PS. Cells were incubated at 
room temperature in the dark for 20min, then washed with fresh PS and further 
maintained in the dark at room temperature until use.  
2.3.3  Imaging changes in [Ca
2+]m  with X-Rhod-1  
Changes in mitochondrial Ca
2+ have been directly measured using targeted 
expression  of  Ca
2+  sensitive  photoproteins  such  as  aequorin  [550,  603]  or 
mitochondrial specific fluorescent probes including rhodamine derivatives such as 
the Ca
2+ indicator X-Rhod-1 [604]. X-Rhod-1 (Invitrogen; cat. No. X14210) has a 
Kd for Ca
2+ of 700nM. The cell permeant acetoxymethyl (AM) form is positively 
charged  and  is  preferentially  concentrated  into  polarized  mitochondria  [604]. 
Once in the mitochondrial lumen its ester moieties become hydrolyzed and the 
resulting free acid remains trapped inside the mitochondria where it binds intra-
mitochondrial Ca
2+ and reports increases in [Ca
2+]m as an increase in fluorescence 
intensity  (Figure  2.15).  A  portion  of  X-Rhod-1  fails  to  partition  into  the 
mitochondria and so remains in the cytosol where it reports [Ca
2+]i changes. X-
Rhod-1 was chosen due to its long-wavelength emission characteristics (Figure 
2.15) that allow its simultaneous detection with GFP with minimal crosstalk. In 
order to accommodate the optical arrangements, X-Rhod-1 was excited at 480nm 
to allow simultaneous excitation of GFP (setup Figure in chapter 6; Figure 6.1).  105 
Figure 2.15 shows the X-Rhod-1 excitation and emission wavelengths used (blue 
and red bars respectively). 
To establish localization of X-Rhod-1 in mitochondria, HUVEC were co-
loaded  with  0.2µM  X-Rhod-1  and  50nM  mito-tracker  Green  (Invitrogen)  for 
20min. Mito-tracker Green is a cell-permeant probe that passively diffuses across 
the plasma membrane and accumulates in mitochondria. It is excited at 490nm 
and  emits  light  at  516nm.  Figure  2.16A  shows  co-localization  between  mito-
tracker Green and X-Rhod-1 indicating X-Rhod-1 efficiently partitions into the 
mitochondria. Figure 2.16B shows a single HUVEC expressing construct mito-
EGFP  (2.1.3)  and  loaded  with  X-Rhod-1.  Similarly  X-Rhod-1  fluorescence 
completely coincided with the mitochondrial in cultured HUVEC. In both panels 
2.16  A  and  B,  a  portion  of  X-Rhod-1  remains  in  the  cytosol.  To  remove  the 
contribution of cytosolic changes in X-Rhod-1 fluorescence from mitochondrial 
derived X-Rhod-1 a background subtraction was made from a region adjacent to 
the mitochondrial ROI (2.2.6).  
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Figure 2.15 Chemical and Spectral properties of X-Rhod-1 
The  upper  panel  is  a  schematic  of  the  X-Rhod-1  diffusion  through  the  cell 
membrane and accumulation into the mitochondria where it becomes trapped by 
removal of the ester moieties by mitochondrial esterases. The lower panel on the 
right shows the spectral properties of X-Rhod-1 and the excitation (480nm; blue 
bar)  and  emission  (615±25nm;  red  bar)  wavelengths  used  to  image  X-Rhod-1 
simultaneously with GFP in these experiments. The lower panel on the left shows 
a  single  HUVEC  loaded  with  0.2µM  X-Rhod-1  imaged  with  the  specific 
parameters. 107 
 
Figure 2.16 X-Rhod-1 co-localizes with mito-tracker Green and mito-EGFP  
Live HUVEC were recorded at 6.6frames/s; excited at 480nm and emitted light 
was separated using an optical splitting device to be collected at 520±20nm and 
615±25nm. A shows single HUVEC co-loaded with 0.2µM X-Rhod-1 and 50nM 
mito-tracker Green and B shows single HUVEC nucleofected with mito-EGFP 
24hours prior loading with 0.2µM X-Rhod-1. Left panel in A shows mito-tracker 
Green emission and left panel in B shows mito-EGFP. Middle panels in A and B 
show X-Rhod-1 emission and right panels the overlay. 0.2µM X-Rhod-1 efficiently 
labels the mitochondria with some dye remaining in the cytosol. 
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2.3.4  Establishing dual-loading conditions for X-Rhod-1/AM and Fura-
2/AM  
X-Rhod-1  and  Fura-2  are  both  Ca
2+  buffers  and  their  combined  use  for 
monitoring  Ca
2+  changes  may  interfere  with  physiological  Ca
2+  signalling  and 
consequently with the kinetics of WPB exocytosis. Experiments were carried out 
to  establish  co-loading  conditions  that  did  not  affect  the  kinetics  of  WPB 
exocytosis. The delay between [Ca
2+]i rise and the first exocytotic event and the 
maximal rate of WPB exocytosis stimulated with 30µM histamine was compared 
between HUVEC loaded with 2.5µM Fura-2 alone and HUVEC co-loaded with 
different concentrations of X-Rhod-1 and Fura-2. Data obtained from HUVEC co-
loaded with 0.2µM X-Rhod-1 and 0.5µM Fura-2 were not significantly different 
from that obtained with 2.5µM Fura-2 loaded HUVEC (Figure 2.17).  
The stock solution of X-Rhod-1 was made up to 1mM in DMSO (Sigma) 
with 2.0% Pluoronic F-127 (Invitrogen). HUVEC were co-loaded in 0.2µM X-
Rhod-1 and 0.5µM Fura-2 in PS at room temperature in the dark for 20min and 
then washed with fresh PS and further maintained in the dark at room temperature 
until use.   
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Figure 2.17 Establishing appropriate Fura-2 and X-Rhod-1 co- loading 
conditions. 
Histograms of WPB fusion events and the Fura-2 fluorescence ratio for HUVEC 
stimulated with 30µM histamine; offset so that the Ca
2+ rise occurred at t=0. Left 
panel are HUVEC loaded with 2.5µM Fura-2 and in the right panel HUVEC co-
loaded  with  0.5µM  Fura-2  and  0.2µM  X-Rhod-1.  Histograms  represent  data 
pooled from 25 cells (388 WPB) for single loaded HUVEC and from 12 cells (379 
WPB) for double loaded HUVEC 
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2.3.5  Imaging ∆Ψ ∆Ψ ∆Ψ ∆Ψm Collapse with TMRE  
The  potentiometric  dye  tetramethylrhodamine  ethyl  ester  (TMRE)  is  a 
fluorescent lipophilic cation widely used for ∆Ψm measurements as it accumulates 
in mitochondria in proportion to the standing electrochemical membrane potential 
gradient. The fluorescence change in response to ∆Ψm changes depends on the 
specific dye loading conditions and is reviewed in detail in [521]. Briefly as the 
dye reaches high concentrations inside the mitochondria its fluorescence becomes 
quenched.  This  auto-quenching  of  fluorescence  is  due  to  the  individual  dye 
molecules  coming  so  close  to  one  another  at  high  concentrations  that  emitted 
photons from one molecule are absorbed by adjacent molecules. Depolarisation of 
∆Ψm drives the dye out of the mitochondria, causing the molecules to separate, 
de-quench and increase in fluorescence. This leads to an abrupt increase in both 
mitochondrial and cytosolic TMRE fluorescence as the dye exits the mitochondria 
and enters the cytosol. The concentrations and loading times for reaching auto-
quenching concentrations vary between cell types due to variability of the plasma 
and mitochondrial membrane potential [605]. This first method was called the de-
quenching method and changes in TMRE fluorescence can be measured from the 
whole cell, as previously used in gonadotrope cells [552], chromaffin cells [584] 
and  in  neurons  [553].  However  if  the  dye  is  loaded  in  mitochondria  at  low 
concentrations,  where  it  does  not  reach  auto-quenching  levels,  upon  ∆Ψm 
depolarisation and exit of the dye from mitochondria, the mitochondrial TMRE 
fluorescence signal decreases whereas the cytosolic signal increases as the dye 
enters  the  cytosol.  We  called  this  second  method  the  redistribution  method. 
Measurements of the TMRE signal in this case requires high resolution imaging to 
allow single mitochondrion fluorescence measurements as previously described in 111 
endothelial cells [606, 607]. The basic principles of these two different loading 
methodologies are summarised in Figure 2.18. One potential problem of the high 
concentration,  de-quenching  method  is  that  excitation  of  TMRE  can  lead  to 
excessive ROS production that can damage the mitochondria leading to openings 
of the permeability transition pore (PTPm) [608].  
The concentration at which TMRE undergoes auto-quenching in our cells 
was determined by perfusing onto cultured HUVEC increasing concentrations of 
TMRE.  Recordings  were  taken  using  a  confocal  Olympus  BX50WI  upright 
microscope with a 60x objective, in order to minimise the TMRE background 
fluorescence. TMRE was excited with a 543nm laser and collected using a 555-
565nm emission filter at 0.4frames/s. The fluorescent signal measurements were 
analysed in Image J. In Figure 2.19A the cells were initially loaded with 0.01µM 
TMRE for 10min in the dark and then imaged for about 4min while perfused with 
0.01µM TMRE (to prevent exit of the dye from the cell). The solution was then 
switched to 0.3µM TMRE, recorded for 4min, left to incubate for further 5min 
and  then  recorded  again  for  another  4min  before  switching  to  the  next 
concentrations;  1µM  and  3µM  TMRE,  following  the  same  protocol.  This 
experiment shows the increase in mitochondrial TMRE fluorescence when a low 
concentration of TMRE is used (0.3µM) and a subsequent decrease (due to auto-
quenching)  as  the  concentration  of  TMRE  is  increased  further  to  3µM.    To 
confirm  that  the  dye  was  auto-quenched  at  3µM  TMRE,  cells loaded  in  3µM 
TMRE (for 10min in the dark) were imaged for 5min during perfusion with 1µM 
FCCP and 2.5µg/ml oligomycin to collapse the ∆Ψm. There was an increase in 
TMRE  fluorescence  during  application  of  the  inhibitors  consistent  with  de-
quenching of TMRE fluorescence (Figure 2.19B).  Although both methods were 112 
attempted, we in the end used the second, redistribution method to avoid possible 
problems associated with photo-toxicity. Details of the redistribution method are 
described in more detail in chapter 6. Briefly cells were loaded in 0.3µM TMRE 
(Sigma, cat no 87917) from a stock of 100mM in DMSO, for 20min in the dark at 
room temperature before the start of the experiment and maintained in 0.3µM 
TMRE thereafter. TMRE is excited in epifluorescence at 480(7) and emitted light 
is collected at 615±25nm. 
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Figure 2.18 Loading conditions for TMRE 
The panel on the left demonstrates the redistribution method for measuring TMRE 
fluorescence and on the right demonstrates the de-quenching method. In the first 
method TMRE is loaded at low concentrations (upper panel) and distributes (middle 
panel) in the mitochondrial lumen. Upon collapse of the ∆Ψm the dye exits the lumen 
into  the  cytosol  therefore  the  TMRE  fluorescence  increases  in  the  cytosol  and 
decreases in mitochondria (lower panel). In the second method TMRE is loaded at 
high  concentrations  (upper  panel)  reaching  auto-quenching  levels  in  the 
mitochondrial lumen (middle panel). Upon ∆Ψm collapse TMRE molecules enter the 
cytosol de-quenching therefore increasing in fluorescence both in the mitochondrial 
lumen and the cytosol (bottom panel).  
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3  GFP as a tool to probe changes in 
secretory granule pH and to determine 
the time of fusion pore formation 
during exocytosis of the non-WPB 
secretory organelle 
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3.1  Introduction 
A  major  aim  of  this  thesis  was  to  characterise  in  detail  the  kinetics  of 
exocytosis of two distinct secretory organelles found in endothelial cells (EC); the 
Weibel-Palade-Body (WPB) and the non-WPB  organelle (Introduction  1.3).  In 
order to study the kinetics of exocytosis as directly as possible both organelle 
populations  needed  to  be  visualised  in  living  cells  such  that  the  fusion  of 
individual granules could be determined accurately at high time resolution. To 
achieve this we used green fluorescent protein (GFP) targeted specifically to the 
two distinct secretory granule populations, taking advantage of the pH-dependent 
properties of this fluorescent protein to determine the point  of  granule fusion. 
Here I discuss the properties of GFP that make it suitable for this application and 
show that GFP tagged proteins targeted to endothelial secretory granules can be 
used to determine and compare the intra-granule pH and changes in this pH at 
different stages of organelle maturation.  
3.1.1  GFP Structure  
GFP is a fluorescent protein first identified in the hydroid jellyfish Aequorea 
Victoria as an accessory protein of the bioluminescence protein aequorin [609]. It 
absorbs blue light and emits green light [610] (Figure 3.1A). Cloning of GFP in 
the  1990s  showed  it  to  be  a  single  238  amino  acid  protein  [611]  of  27kDa 
molecular  weight  [612],  that  retains  its  fluorescence  when  heterologously 
expressed  in  prokaryotic  and  eukaryotic  organisms  [613].  GFP  folds  into  a 
cylindrical structure composed of 11 stranded β-sheets linked together by proline-
rich loops [614, 615]. Through the barrel runs an α –helix and both ends of the 
barrel are closed by short α –helices [614, 615] (Figure 3.1B). In the middle of the 118 
central  α  –helix  is  the  chromophore,  formed  by  spontaneous  cyclization  and 
oxidation  of  3  amino  acids,  Serine65-  Tyrosine66  and  Glycine67  occurring 
autocatalytically after the tertiary structure is formed (maturation) [611, 616, 617]. 
Moreover inside the barrel the chromophore is surrounded by 4 water molecules 
that  participate  in  a  hydrogen-bond  network  which  permits  proton  transfer 
between  the  chromophore  and  the  surrounding  molecules  [618,  619].  The 
configuration surrounding the chromophore is important for the fluorescence of 
GFP and its stability, rendering it a protease-resistant molecule only denatured 
under  extreme  conditions  [620-622].  Variations  in  the  configuration  of  the  β-
barrel or the chemical or physical interior environment can change the spectral 
characteristics of the protein [623]. Directed mutagenesis of the primary structure 
of GFP yielded various fluorescent molecules, with different properties including 
enhanced GFP (EGFP) [616, 624, 625]. GFP has a weak tendency to dimerise 
[626],  however,  mutations  of  any  or  all  of  3  aa  (Serine65,  Tyrosine66  and 
Glycine67) removes this tendency giving rise to monomeric GFP (mGFP) that has 
essentially identical spectral properties to EGFP [591]. In these studies EGFP or 
mEGFP (obtained from EGFP mutations; see 2.1.2) were used as the fluorescent 
tags for WPB and non-WPB targeted proteins. No differences in the secretory 
kinetics of WPBs were observed with granules tagged with either GFP variant.  
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Figure 3.1 The GFP molecule 
A.  Graph  of  the  excitation  (dotted  green  trace)  and  emission  (green  line) 
spectra  of  EGFP  in  pH7  buffer  (taken  from 
http://www.invitrogen.com/site/us/en/home/support/Research-
Tools/Fluorescence-SpectraViewer.html). 
B.  A  three-dimensional  demonstration  of  the  tertiary  structure  of  GFP 
illustrating  the  GFP  barrel  formed  by  11  β-  sheets  (green)  arranged  in  a 
cylindrical  order  surrounding  a  middle  α-  helix  (red)  which  contains  the 
chromophore consisting of 3 amino acids (ball-and-stick model). Both ends of the 
barrel are closed by short α-helical sections. The Figure is taken from BREJC, K 
1997 [618] and was produced by RASTER3D [627].  
A 
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3.1.2  The pH-sensitivity of GFP 
The pH-sensitivity of GFP fluorescence was first noted by Ward in the early 
1980s [620, 622] and characterised further by Verkman [628].  Verkman showed 
that the pH dependence of purified GFP in vitro and for GFP expressed in cells is 
nearly identical. Therefore GFP could be used as a reliable non-invasive and rapid 
cellular pH indicator capable of being genetically targeted to distinct sub-cellular 
compartments [629], a distinct advantage over other pH sensors such as acridine 
orange that distribute non-specifically into all acidic cellular compartments [630]. 
Cellular compartments to which GFP has been targeted include the cytoplasm, 
ER, Golgi, secretory granules, nucleus and mitochondria of a variety of cell types 
[345]. The GFP pH-sensitivity is thought to be due to protonation of the phenol 
group on the aromatic ring of tyrosine of the chromophore [622] at pH>5 and 
additional conformational changes below pH5 [628]. The two ground states of 
EGFP; protonated and uncharged states display different spectral characteristics 
and pH changes shift the equilibrium between the two states [631, 632]. 
3.1.3  pH in the secretory pathway 
It is known that as soluble secreted proteins pass through the lumen of the 
secretory pathway there are progressive decreases in the intra-luminal pH that are 
thought  to  be  important  in  facilitating  protein  aggregation  and  condensation 
(reviewed in [633, 634]). The pH of the ER is ~pH7.2-7.4 [634], similar to the cis- 
Golgi, while  the medial compartments of the Golgi apparatus are thought to be 
mildly more acidic and at the TGN the pH drops to ~pH 6.2-6.58 [344-347]. This 
low pH is known to be important for the association of proregion and mature 
vWF, vWF condensation and multimerization and WPB formation [24, 34, 334, 121 
635] (see introduction 1.7.1.1). Studies in endocrine cells indicate that secretory 
granules budding off the TGN undergo further acidification as they mature [343, 
344, 636]. Average values of intra-luminal resting pH of secretory granules were 
determined using GFP targeted to immature granules of insulin-secreting cell lines 
(pH  6.22)  [637]  and  in  mature  granules  of  PC12  cells  (pH5.5)  [638];  by 
determining the H
+ leak rates of secretory granules of the pituitary cell line AtT-
20  cells  (pH5.5)  [344]  and  by  loading  mast  cells  with  a  pH-sensitive  granule 
probe (pH5.5) [639]. In most studies the fluorescence measurements were taken 
from mean intensity levels of regions of interest as the density of granules and 
their small size precluded the possibility of determining the pH within individual 
granules [344, 637, 638]. However single granule pH (pHg) measurements were 
possible in mast cells with very large granules [639]. 
3.1.4  GFP as a pH indicator in the secretory pathway of HUVEC 
Based  on  pH  studies  on  secretory  organelles  it  has  been  speculated  that 
WPBs would also acidify as they mature allowing progressive vWF condensation 
to form the highly ordered tubule like structures comprised of proregion and vWF 
[26, 27]. The pH-sensitivity of the EGFP fluorescence fused to vWF or proregion 
was determined in WPBs in living HUVEC and compared to that for the purified 
protein in vitro [1]. The pH titration of EGFP fluorescence in vivo was obtained 
from experiments where calibration solutions at different pH were perfused onto 
vWF-EGFP or proregion-EGFP expressing HUVEC cultures (Figure 3.2B). The 
EGFP  fluorescence  was  normalized  to  that  obtained  with  the  pH8  calibration 
solution [637]. An example of such an experiment is shown in Figure 3.2B. The 
EGFP calibration curve derived from data such as that shown in Figure 3.2B is 
summarised  in  Figure  3.2A,  fitted  by  a  modified  Hill  equation  [628].  The 122 
behaviour  of  EGFP  fused  to  either  full  length  vWF  or  proregion  alone  was 
essentially  identical  to  that  of  purified  EGFP  [1].  This  suggested  that  the 
properties of EGFP (pH-sensitivity of fluorescence) are largely independent of 
what EGFP was fused to. From the information obtained in those experiments it 
was possible to use EGFP to measure the pH within the secretory pathway of 
HUVEC. The large size of the WPB allowed their pH to be determined (pHWPB) 
in individual granules permitting the distribution of pH values within a secretory 
granule  population  to  be  determined  for  the  first  time  (Figure  3.3).  Using  a 
morphological  pulse  chase  approach,  in  which  cells  were  imaged  at  different 
stages  after  expression  of  WPB  targeted  EGFP,  it  was  possible  to  follow  the 
changes in pHWPB from newly formed immature granules through to fully mature 
organelles. These data show that WPBs, like secretory granules in other cells, 
undergo  a  time-dependent  acidification  of  their  lumen  from  pH6.2  for  newly 
formed granules to 5.4 for the mature organelle (Figure 3.3) (pooled data from the 
secretion and NH4Cl method, see below).    
In contrast to the WPB, the intra-granule pH of the non-WPB (pHnon-WPB) is 
not known. If this organelle is a true regulated secretory organelle it might be 
expected that the intra-granule pH might change in a generally similar fashion as 
described for the WPB.  
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Figure 3.2 In vitro and in vivo pH titration of EGFP fluorescence (Adapted 
from Erent, M. et al. 2007)[1] 
Panel A shows the relationship between EGFP fluorescence and pH. The filled 
circles  represent  the  fluorescence  of  purified  EGFP  in  a  SPEX  fluoromax 
fluorimeter under different pH values. The dotted lines represent the fluorescence 
of EGFP in vivo; vWF-EGFP  (open circles) and proregion-EGFP  (triangles). 
Briefly  HUVECs  expressing  vWF-EGFP  or  proregion-EGFP  were  perfused 
sequentially with cell-permeabilizing calibration solutions, titrated to different pH 
values, allowing sufficient time for fluorescence intensity to stabilize at each pH 
and  imaged  using  epifluorescence  imaging.  A  representative  example  of  an 
individual WPB in a cell is shown in panel B. In each case (in vitro and in vivo), 
the EGFP fluorescence was normalized to that at pH8.0 (corresponding to Fmax 
for EGFP) and plotted against the pH of the solution to generate the calibration 
curve in panel A. The data was fitted by a modified Hill equation with in vitro pKa 
and nH for purified EGFP of 5.88 and 0.9 and in vivo (intra-WPB) mean pKa and 
nH values of 5.84 and 0.74 respectively. 
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Figure 3.3 pHWPB during maturation (Adapted from Erent, M. et al.2007)[1] 
The two panels show the pHg distributions of the immature WPB (4-8 hrs post-
Nucleofection with proregion-EGFP) (upper panel) and the mature WPB (24-48 
hrs  post-Nucleofection  with  proregion-EGFP)  (lower  panel).  The  mean  pH 
decreased during WPB maturation from pH6.16±0.45 (n=101 WPBs; mean±s.d.) 
to pH5.45±0.27 (n=303 WPBs; mean±s.d.). 
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3.1.5  GFP as a marker of fusion 
The  pH-sensitivity  of  GFP  and  the  acidic  lumen  of  secretory  granules 
permits GFP targeted to the granular lumen to act as a marker of exocytosis. This 
is achieved due to the pH change during the formation of the fusion pore resulting 
in an abrupt increase in GFP fluorescence or ‘flash’ of light. Previous studies 
utilised GFP fusion proteins targeted to secretory granules to study exocytosis in 
PC12 cells [640, 641], insulinoma cells [642-644], chromaffin cells (see review 
[645]) and endothelial cells [89]. Similar flashes of light are seen on fusion of 
EGFP-tagged WPBs in HUVEC [35]. These ‘flashes’ of light mark the formation 
of the fusion pore and provide a basis for determining accurately the point of 
fusion for the WPB allowing the detailed analysis of the WPB secretory kinetics 
described later in chapter 4. Similar studies of the non-WPB granule have not 
been made. 
3.1.6  Aim 
In this chapter I describe experiments in which the pH within individual 
non-WPB organelles was determined using EGFP fused to t-PA. A morphological 
pulse  chase  experiment  was  carried  out  to  determine  the  intra-granule  pH  at 
different times post Nucleofection and the data is compared to those previously 
determined for the WPB [1]. The data shows that the distribution of pH in the 
non-WPB organelle differs from that for WPBs in that there is no time-dependent 
acidification,  characteristic  of  the  maturation  of  regulated  secretory  granules. 
However, the changes in florescence seen on fusion of the non-WPB organelles 
can be used in the same way as for WPB-targeted GFP to mark the point of fusion 
of these organelles for kinetic studies (see chapter 5).   s 126 
3.2  Methods and Results 
3.2.1  Targeted expression of EGFP or mEGFP to WPBs in living cultured 
HUVEC 
WPBs in living cells were fluorescently labelled by Nucleofection™ with 
C-terminal  fusion  proteins  of  full  length  vWF  or  the  vWF  pro-polypeptide 
(Proregion) fused to EGFP [35] or mEGFP [591] (2.1.2). Figure 3.4 A and B 
show  examples  of  HUVEC  expressing  proregion-EGFP  or  proregion-mEGFP 
counter stained with an antibody for vWF, an endogenous WPB marker. Some ER 
staining is also apparent. The red arrow in Figure 3.4B points to an example of a 
WPB  that  is  not  labelled  with  EGFP.  During  trypsinisation  of  HUVEC,  a 
procedure carried out prior to Nucleofection, many, but not all WPBs are secreted 
[646, 647]. The non-fluorescent WPBs seen in cells expressing the fluorescent 
constructs  most  likely  represent  the  small  population  of  granules  not  released 
during  the  trypsinisation  and  Nucleofection  process.  These  comprised 
~22.2±16.1% of the total WPBs present in Nucleofected cells 24-48hours post 
Nucleofection [1].  
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Figure 3.4 Expression of proregion-mEGFP and proregion-EGFP fluorescently 
label WPBs in cultured HUVEC 
A and B show endogenously expressed vWF (left panel), proregion-mEGFP (A) 
and proregion-EGFP (B) (middle panels), and merge images (right panel). The 
merge  images  confirm  that  the  constructs  when  expressed  in  HUVEC  by 
Nucleofection specifically label the WPB population of granules. The red arrow in 
B top left panel points to a WPB that is not expressing proregion-EGFP. 
B 
A 128 
3.2.2  EGFP Labelling of the non-WPB Organelle in cultured HUVEC 
To fluorescently mark the non-WPB specifically requires a secreted protein 
exclusively  sorted  to  this  organelle  and  not  the  WPB.  One  possible  candidate 
protein is the chemokine GRO-α [92]. GRO-α of the CXC chemokine family, is a 
small heparin-binding cytokine [648] that is not expressed to any extent in resting 
cells but can be up-regulated in HUVEC under inflammatory conditions such as 
following  exposure  to  IL-1β  or  TNF-α  [649]. Expression  of  EGFP-GRO-α  in 
HUVEC  led  to  specific  labelling  of  the  non-WPB  (Figure  I  in  supplementary 
material), however, there were potential problems associated with the use of this 
molecule in these studies. Following secretion from EC GRO-α can act in an 
autocrine or paracrine fashion via the G-protein coupled receptor CXCR2 on the 
cell surface of activated endothelial cells [650]. GRO-α activates CXCR2 by its 
recognition sequence Glu-Leu-Arg [651]. The consequence of activation of this 
receptor is activation of Rac, a small G protein, which regulates the formation of 
polymerized actin and leads to endothelial cell retraction and gap formation [652]. 
Moreover released GRO-α from EC is thought to bind to the surface of EC via the 
heparan sulphate proteoglycans where it serves to bind and/or activate monocyte 
adhesion to the EC surface [649, 653]. Over-expression of such a molecule could 
lead  to  the  endothelial  cells  becoming  ‘activated’.  This  would  make  direct 
comparisons  with  ‘non-activated’  proregion-EGFP  expressing  cells  potentially 
more complex. Ideally a molecule that is normally expressed in resting cells and 
therefore less likely to perturb the resting state of the cells would be preferable. 
For this purpose we decided to use t-PA that is expressed under resting conditions 
in HUVEC [76].   129 
Expression of t-PA-EGFP in cultured HUVEC rapidly labels the non-WPB 
organelle (4hours post Nucleofection). Although t-PA is expressed in non-WPB 
organelles,  it  can  also  sometimes  appear  in  WPBs  [81],  particularly  at  longer 
times  following  over-expression  [70];  at  ~24hours  post-Nucleofection  a  small 
population of t-PA-containing WPBs can sometimes be seen (e.g. Figure 3.5 red 
arrow). Experiments were carried out both at 4hour post Nucleofection at which 
time no WPBs were t-PA-EGFP positive and at 18-28hour post Nucleofection. 
Therefore  we  had  to  develop  a  method  for  differentiating  between  the  major 
population of small non-WPB granules and a variable but small number of WPBs 
labelled with t-PA-EGFP. WPBs that were morphologically distinctive could be 
readily identified and excluded from analysis, however, the distribution of sizes of 
vWF  positive  secretory  organelles  includes  small  almost  spherical  structures 
(<0.5µm diameter) [1] that were much more difficult to distinguish from the small 
organelles simply based on their morphology. To unequivocally distinguish these 
small  ‘WPBs’  from  the  small  non-WPB  organelles,  HUVEC  were  co-
nucleofected  with  t-PA-EGFP  and  proregion-mRFP  [590],  the  latter  of  which 
specifically targets all newly formed WPBs irrespective of their size or shape. 
Figure  3.5  shows  a  single  HUVEC  co-expressing  t-PA-EGFP  and  proregion-
mRFP  and  counter  stained  with  an  antibody  to  endogenous  vWF.  The  Figure 
shows  that  endogenous  vWF  positive  structures  contain  expressed  proregion-
mRFP, and although occasionally they might also contain t-PA-EGFP (arrow), the 
presence  of  proregion-mRFP  allowed  their  identification  as  part  of  the  WPB 
population.   
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Figure 3.5 Co-expression of t-PA-EGFP and proregion-mRFP in single 
HUVEC stained with an antibody for vWF 
From top: overlay of triple imaging, endogenously expressed vWF, proregion-
mRFP and t-PA-EGFP. The red arrow points to an example of a small WPB that 
contains both proregion-mRFP and t-PA-EGFP.  
t-PA-EGFP 
proregion-mRFP 
a-vWF 
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3.2.3  Imaging  
For pH measurements of WPBs and non-WPBs the experimental setup is 
shown  in  Figure  3.6  A  and  B  respectively.  T-PA-EGFP  labelled  WPBs  were 
excited at 488nm in epifluorescence using an endow GFP bandpass emission filter 
set (Chroma, Vermont, USA, cat. no. 41017). For dual excitation of t-PA-EGFP 
and  proregion-mRFP  co-expressed  in  HUVEC,  cells  were  imaged  by  TIRFM 
excited  by  the  488nm  and  561nm  lasers,  passed  through  a  custom  made 
EGFP/DsRed  filter  set  with  a  400DCLP  coating  on  the  reverse  side  of  the 
diachroic  mirror  to  allow  reflection  of  355nm  and  380nm  light  from  the 
monochromator onto the cells for simultaneous Fura-2 imaging (Chroma, cat. no. 
51019+) (set of experiments used for the kinetic studies of the non-WPB; chapter 
5). TIRFM was used as it only excites a thin plane of field providing a better 
contrast imaging of the non-WPB granules against a high ER fluorescence signal 
[598, 654]. 
3.2.4  Determining the intra-granule pH of the non-WPB organelle. 
The pH sensitivity of EGFP fluorescence for purified EGFP in vitro [628], 
EGFP alone targeted into cells [345] or when fused to a wide range of different 
cellular  proteins  expressed  in  cells  (including  vWF  and  Proregion  [1])  is 
remarkably similar. This led us to think that the pH sensitivity of EGFP fused to t-
PA would be essentially the same as EGFP fused to either full length vWF or 
proregion within the secretory pathway of living HUVEC. To test this hypothesis 
we made measurements of pHWPB in WPBs expressing t-PA-EGFP (48hours post-
nucleofection when t-PA-EGFP positive WPBs can sometimes be found).  In this 
case WPBs were readily identified by their tubular morphology. Using EGFP to 132 
calculate  the  resting  pH  within  the  WPBs  requires  knowing  1)  the  resting 
fluorescence of EGFP in the organelle, 2) the maximum fluorescence of EGFP 
(obtained at pH≥7.4) and 3) the relationship between EGFP fluorescence and pH. 
The latter has already been determined and is shown in Figure 3.2A [1].  The 
resting  fluorescence  is  readily  measured  by  direct  imaging  of  the  cells.  The 
maximum fluorescence of EGFP can be determined in several ways; either by 
addition of an ionophore calibration solution at pH8.0 as previously described 
[637] or more simply by the addition of a weak base such as ammonium chloride 
(NH4Cl)  [599]  (see  methods  section  2.2.5).  Both  the  ionophore  and  NH4Cl 
approaches  have  been  used  to  determine  the  resting  pH  in  WPBs  containing 
proregion-EGFP and  give identical results [1, 435]. Here we used the simpler 
NH4Cl pulse methodology (acute application of 5-10mM NH4Cl, to the cells see 
methods section 2.2.5) to calculate the pH of the mature WPB containing t-PA-
EGFP  and  compared  this  data  to  the  previously  published  values  for  pHWPB 
obtained using vWF- or proregion-EGFP [1].  Application of NH4Cl led to an 
abrupt  increase  in  WPB  t-PA-EGFP  fluorescence  due  to  alkalinisation  of  the 
granule (Figure 3.7A). The frame marked with a red square indicates application 
of NH4Cl. The background subtracted EGFP fluorescence of single WPBs was 
measured in imageJ and normalised to the peak fluorescence (Fmax) (Figure 3.7A). 
From the normalised EGFP fluorescence the pHWPB can be calculated using the 
equation in Figure 3.7B taking the previously determined values for pKa (pH at 
half-maximal fluorescence) and nH (Hill coefficient) of 5.84 and 0.74 respectively 
[1]. Figure 3.7C upper and lower panels show histograms of the pH distributions 
for  t-PA-EGFP  and  proregion-EGFP  labelled  WPBs  respectively.  The  mean 
pHWPB determined using EGFP fused to t-PA was identical to that obtained using 133 
proregion-EGFP  supporting  the  idea  that  the  target  protein  to  which  EGFP  is 
coupled has little influence on the pH-sensitivity of EGFP itself.  
Taking this to be the case the resting pH in the t-PA-EGFP positive non-
WPBs was determined at early (4-8hours) and late (18-28hours) time-points post-
Nucleofection using the ammonium chloride pulse methodology. At early times 
the pH in newly formed non-WPBs (pH6.10±0.32; n=89 non-WPBs) was similar 
to that of the immature WPBs (pH6.16±0.45; n =101WPBs [1]) and corresponds 
to values close (but slightly lower than) to those determined for the TGN [34, 
344-347]. However, at later times, where WPBs are more acidic (pH5.45±0.27 
n=303  WPBs  [1]),  the  pH  within  the  non-WPBs  organelles  was  unchanged 
(pH6.11±0.25; n=52 non-WPBs). Figure 3.8 compares the pH distributions of the 
WPB  and  non-WPBs  at  early  and  late  time-points  after  Nucleofection  of  the 
EGFP-tagged proteins.  
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Figure 3.6 Optical arrangements for single granule fluorescent measurements 
A.  For  single  t-PA-EGFP  expressing  WPB  fluorescent  measurements  an 
endow GFP bandpass emission filter set was used. 
B.  For  HUVEC  co-expressing  t-PA-EGFP  and  proregion-mRFP  the 
fluorophores were excited with a 488nm and 561nm lasers in TIRF configuration. 
The  emitted  light  passed  through  an  EGFP/DsRed  filter  set  with  a  400DCLP 
coating on the reverse side of the diachroic mirror to allow excitation of Fura-2. 
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Figure 3.7 Measuring the pHWPB using the NH4Cl technique 
A.  A montage of 2 t-PA-EGFP expressing WPBs 48hours post-Nucleofection 
subjected to 5mM NH4Cl as indicated with the red square. The granules were 
imaged  with  an  endow  GFP  bandpass  emission  filter  at  33ms  a  frame  and 
averaged  twice.  The  plot  below  follows  the  normalised  EGFP  fluorescence 
measurements also plotted on a pH axis. 
B.  The  equation  used  to  calculate  the  pHWPB  from  the  normalised  luminal 
EGFP  fluorescence  during  NH4Cl  addition,  such  as  in  A.  Where  pKa=5.84, 
nH=0.74,  Fmax=  normalised  peak  of  EGFP  fluorescence,  F=  steady-state 
normalised EGFP fluorescence. 
C.  The panel shows the pH distributions in Histograms of the mature WPBs at 
24-48hours post-Nucleofection with t-PA-EGFP (pH5.27±0.23; n=56WPBs from 
10 cells) (top panel) and proregion-EGFP (pH5.45±0.27; n=303 WPBs from 23 
cells) (bottom panel).The vertical dotted lines pass through the mean pH of the 
two histograms and are colour coded. The pHWPB of proregion-EGFP expressing 
WPBs  was  pooled  from  experiments  using  the  chemical  alkalization  and  the 
secretion method (see Figure 3.9). 
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Figure 3.8 pH distributions of the WPB compared to the non-WPB organelle 
Panels show the pHg distributions of Ai the immature WPB pH 6.16±0.45 (n=101 
WPBs from 10 cells; mean±s.d.) calculated at 6-7hours post Nucleofection with 
proregion-EGFP; Aii the mature WPB pH5.45±0.27 (n=303 WPBs from 23 cells; 
mean±s.d.) 24-48hours post  Nucleofection; Bi the non-WPB organelle 4-8hours 
post Nucleofection with t-PA-EGFP (distinguished from WPBs by co-expressing 
proregion-mRFP) pH6.10±0.32 (n=89 granules from 11 cells; mean±s.d.) similar 
to  the  pH  of  the  Bii  24-28hours  non-WPB  organelle  pH6.11±0.25;  (n=52 
granules from 4 cells; mean±s.d.). 
 
 
 
Ai 
Aii 
Bi 
Bii 139 
3.2.5  Determining  the  resting  pHnon-WPB  from  fluorescence  changes 
during fusion 
In addition to the NH4Cl pulse methodology (methods 2.2.5) for identifying 
the pHgranule, here the Secretion method was also used for calculating the pHnon-WPB 
as described below. The non-WPB organelle undergoes both unstimulated and 
stimulated exocytosis (described in detail in chapter 5). Following fusion pore 
formation  in  either  case  there  is  an  increase  in  EGFP  fluorescence  that  arises 
because the acidic granule lumen becomes exposed to the extracellular solution 
(see  Figure  3.10B).  The  extracellular  solution  is  buffered  to  pH7.4,  and  the 
increase in EGFP fluorescence under these conditions is ~97% of that at pH8.0 
(where EGFP fluorescence is maximal) [1]. Taking the peak fluorescence change 
following granule fusion as a close approximation of the maximum fluorescence 
of EGFP (assuming no loss of EGFP from the granule at the initial point of fusion 
as is the case for the WPB [435]) we can use the equation in Figure 3.7B to 
calculate  the  pre-fusion  resting  pH  within  the  non-WPB  in  the  same  way  as 
described for the WPB (Figure 3.9 top left)[1]. The estimate of the resting pH for 
the non-WPB organelle obtained from analysis of fusion events (pH6.26±0.40, 
n=90 non-WPBs from 16 cells), was essentially identical to that obtained by the 
ammonium chloride pulse technique (pH6.10±0.30; n=141 non-WPBs from 15 
cells pooled from Bi and Bii in figure 3.8) (Figure 3.9). The intra-granule pH of 
the population of non-WPBs undergoing stimulated exocytosis was the same as 
that for the population of organelles that undergo unstimulated fusion in resting 
cells (see chapter 5), suggesting they are part of the same population of organelles. 
In this respect these  granules differ substantially  from the more acidic mature 
WPBs [1] (Figure 3.9 left panels).   140 
 
 
Figure 3.9 The t-PA-EGFP population of non-WPBs undergoing exocytosis 
differs from the mature WPB population in pHg 
Histogram plots of the pHg distributions for proregion-EGFP expressing mature 
WPBs  24-48hours  post-Nucleofection  (left  panels)  and  t-PA-EGFP  expressing 
non-WPBs    24hours  post-Nucleofection  (right  panels)  determined  using  the 
Secretion method (described in 3.2.5) (top panels) or the chemical alkalization 
method  with  NH4Cl  (described  in  2.2.5)  (bottom  panels).  The  pH  of  the  two 
granuls was essentially identical determined with both methods. Top left panel: 
n=159 WPBs from 15 cells; bottom left panel: n=144 WPB from 8 cells; top right 
panel: n=90 non-WPBs from 16 cells; bottom right panel: n=141 non-WPBs from 
15 cells (pooled from Bi and Bii in figure 3.8). 141 
3.2.6  Determining  the  point  of  WPB  and  non-WPB  fusion  for  kinetic 
studies  
In order to analyse the kinetics of WPB and non-WPB exocytosis, the time 
for  fusion  of  each  exocytotic  event  needs  to  be  determined  as  accurately  as 
possible.  The  characteristic  abrupt  increase  in  fluorescence  of  EGFP/mEGFP 
labelled granules (producing a flash of light) upon formation of a fusion pore can 
be utilised as a convenient marker for fusion pore formation during exocytosis. In 
Figure 3.10 an example of such a WPB fusion event is shown (A) in comparison 
to  that  observed  for  the  non-WPB  (B).  The  fluorescence  intensity  plots  are 
normalised to the peak increase. Qualitatively they are similar; in each case there 
is an abrupt increase in fluorescence to a peak followed by a decline as the EGFP 
fusion protein disperses away from the site of fusion; faster for proregion-mEGFP 
than t-PA-EGFP. The most striking difference between the two organelles is in 
the smaller magnitude of the fluorescence increase seen with the non-WPB, as 
illustrated in Figure 3.11. This shows the data in Figure 3.10 superimposed upon 
one another and aligned to the point of fluorescence increase. The smaller non-
WPB fluorescence change upon fusion presumably reflects a smaller difference in 
the pH gradient between the granule lumen and the extracellular solution.  
For the kinetic studies of WPB and non-WPB exocytosis in chapters 4 and 5 
respectively, for each fusion event the mean background subtracted fluorescence 
was measured in ROIs enclosing the whole organelle and the mean fluorescence 
intensity for the organelle was determined prior to and during the fusion event. 
The time-point of fusion was taken as the first frame in which an increase (>3*SD 
of the mean resting fluorescence prior to fusion) in granule-EGFP fluorescence 
occurred (see Figure 3.10).  142 
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Figure 3.10 Determining the time-point of WPB or non-WPB fusion  
The first panel in A and B is a montage of images of a single proregion-mEGFP 
(A)  and  t-PA-EGFP  (B)  containing  WPB  and  non-WPB  respectively  during 
stimulation  with  100µM  histamine  undergoing  exocytosis.  The  non-WPB 
fluorescence was smoothed x5 (adjacent averaging) to reduce noise.  The example 
in A was imaged by epifluorescence at 6.66frames/s whereas the example in B 
was imaged in TIRFM at 5frames/s. The left panel below the montage in A and B 
shows the overall time-course of the normalised EGFP fluorescence change in a 
ROI around the WPB or non-WBP. The bottom panel on the right, in both A and 
B, shows the fluorescence increased on an expanded time-scale. The red arrow 
indicates  the  time-point  taken  as  the  point  of  fusion  and  corresponds  to  the 
montage frame marked with a red box. In B the mean steady-state fluorescence 
(solid line) and 3 times the standard deviation (dotted line) are shown to indicate 
the time-point of fusion is the first time-point above the mean+3*SD of the steady-
state fluorescence. 
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Figure 3.11 Comparison of the EGFP fluorescence between a single WPB and 
non-WPB organelle upon fusion 
The  normalised  mEGFP  fluorescence  of  a  single  mature  WPB  expressing 
proregion-mEGFP, 48hours post-Nucleofection (grey line) and a single non-WPB 
organelle  expressing  t-PA-EGFP,  24hour  post-Nucleofection  (black  line) 
undergoing exocytosis. The black line was smoothed x5 (adjacent averaging) to 
reduce noise.  
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3.3  Discussion 
3.3.1  EGFP as an indicator of exocytosis 
GFP  fusion  proteins  have  been  used  extensively  to  investigate  vesicular 
trafficking in the regulated and constitutive secretory pathways [89, 655, 656], 
exocytosis in neuroendocrine cells [640, 657] and diffusion dynamics of cargo 
proteins after exocytosis [89, 641, 642]. Data in other cell types [641, 658, 659] 
and here show that the abrupt increase in intra-organelle EGFP- fluorescence can 
be attributed to a rise in pH from an initial intra-granule acidic resting level (pH 
5.4 for the WPB [1] and pH 6.2 for the non-WPB) to that of the extracellular 
solution (typically ~pH 7.40) upon formation of a fusion pore.  The less acidic pH 
of non-WPBs gives rise to a smaller increase in intra-EGFP fluorescence upon 
fusion however this is still adequate for distinguishing exocytotic events.  
The increased proregion-mEGFP fluorescence drops down to background 
levels during exocytosis as proregion diffuses  away (Figure 3.10A). Proregion 
associates  non-covalently  with  mature  vWF  inside  WPB,  in  a  pH  dependent 
fashion  [351].  Following  exposure  to  physiological  pH  upon  fusion,  this 
association is lost resulting in the rapid dispersal of proregion from the site of 
exocytosis  [35,  351].  The  fusion-induced  increase  in  t-PA-EGFP  fluorescence 
however does not drop immediately after fusion because its dispersal kinetics are 
slower than for proregion and are dependent on the interaction with plasminogen 
activator  inhibitor-1  (PAI-1)  on  the  EC  plasma  membrane  [89,  641].  During 
fusion events that don’t fully exocytose but maintain an open fusion pore with the 
plasma membrane [429], the increased EGFP fluorescence upon fusion can be 
maintained in a plateau [435]. 146 
3.3.2  WPB fusion pore formation 
The  acidic  lumen  of  secretory  granules,  maintains  cargo  proteins  in  a 
concentrated condensed form for storage [660], however, this packaging structure 
may hinder exocytosis of cargo proteins. Studies in excitable and non-excitable 
cells showed de-protonation is required for efficient release of the intra-vesicular 
contents during exocytosis [638, 661]. An example is the explosive release of 
mucin seen during epithelial Goblet cell exocytosis (reviewed in [662]). Mucins 
are  a  family  of  glycoproteins  evolutionarily  related  to  vWF  [663].  Like  vWF, 
Mucins form large molecular weight polyionic chains highly condensed within 
their storage granule shielded by Ca
2+ [664, 665]. Upon Mucin granule fusion, 
cationic shielding is released and water entry results in a rapid swelling and an 
explosive  release  of  Mucin  untangled  chains  (reviewed  in  [662]).  A  similar 
process is likely to underlie the abrupt disordering of vWF and its subsequent 
explosive discharge.  During WPB exocytosis, an abrupt change in morphology 
follows  the  increase  in  intra-WPB  EGFP-  fluorescence.  Ultrastructural  studies 
show  that  the  major  WPB  core  protein,  vWF,  is  highly  organized,  forming 
discrete rod-like structures [24, 32], and the shape change seen is likely to reflect 
a  change  in  the  organization  of  this  protein  [35].  Although  the  nature  of  the 
shielding species in the WPB are not known, H
+ and Ca
2+ are likely candidates.   
3.3.3  Granular pH 
At  early  times  after  Nucleofection  the  pH  in  WPBs  and  non-WPB 
organelles was similar (~pH6.2) and close to that of the TGN. Newly  formed 
secretory granules are reported to have intra-granule pH close to that of the TGN 
[334, 343, 633, 634] and the data presented here is consistent with this. In mature 147 
regulated secretory organelles, including the WPB, the pH is more acidic (~5.5) 
[638,  658,  659].  The  acidic  environment  is  thought  to  contribute  to  protein 
aggregation and structural organization of major core proteins, and this seems to 
be  the  case  for  vWF  [27,  334].  Protein  condensation  is  optimal  at  an 
environmental pH close to the isoelectric point (pI) of the cargo protein [666]. The 
calculated  pI  values  for  mature  vWF  and  proregion  are  pH5.39  and  pH4.99 
respectively  (predicted  using  the  pI  tool  at  Expasy 
http://us.expasy.org/tools/pi˙tool.html  [1]),  indicating  that  the  WPB  pH5.5  is 
optimal for aggregation of these proteins.  
While the WPB lumen acidified in a time-dependent fashion (pH6.2immature 
WPB and pH5.4mature WPB), the pHnon-WPB was found to be identical when analysed at 
4-6hours  or  24-28hours  after  Nucleofection  with  t-PA-EGFP.  The  most  likely 
reason for this difference is that WPBs are long term storage organelles that are 
designed  to  accumulate  within  the  cell  and  maintain  their  cargo  in  a  highly 
condensed state until released in response to stimuli. In contrast the non-WPB 
organelle is a short lived organelle with a half life of ~15min (T Carter personal 
communication).  Thus at any particular time after Nucleofection the population 
of  small  non-WPB  organelles  represents  a  ‘newly  formed  population’  derived 
from the TGN. The lack of a time dependent acidification provides a further piece 
of evidence that the non-WPB population of granules are distinct from WPBs.  
In conclusion this chapter demonstrates EGFP-fusion proteins targeted to 
WPBs or non-WPBs can be used to identify secretory events as ‘flashes of light’ 
and can be used to track changes in pH through the secretory pathway of these 
cells.  148 
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kinetics of agonist-evoked WPB 
exocytosis 
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4.1  Introduction 
Until  recently  the  only  means  available  to  study  WPB  exocytosis  were 
biochemical assays (e.g. ELISA or RIA) for soluble cargo molecules, principally 
vWF  [97,  107],  or  the  cell  surface  WPB  membrane  protein  P-selectin  [49]. 
However, biochemical assays for these secreted proteins suffer from a number of 
limitations  that  preclude  a  detailed  analysis  of  the  time-course  for  WPB 
exocytosis;  vWF  adheres  strongly  to  the  endothelial  cell  surface  immediately 
following its release from WPB [35, 351, 446], and hence biochemical assays of 
soluble vWF are unlikely to reflect accurately the underlying kinetics or extent of 
WPB exocytosis. Assays based on cell surface P-selectin expression may provide 
more reliable data on the initial onset of WPB fusion [49], but cannot report the 
overall time-course or extent of the secretory response, and lack the sensitivity 
required for precise sub-second kinetic studies. A previous optical study of WPB 
exocytosis,  using  WPB  targeted  vWF-EGFP  [128],  was  limited  to  a  time 
resolution of about 1min, too slow to resolve the detail of individual fusion events 
that  underlie  the  secretory  time-course.  Capacitance  measurements  may  also 
provide  time-resolved  data  [88]  however  it  is  difficult  to  be  certain  about  the 
nature of the organelle undergoing exocytosis. Thus so far the underlying kinetics 
of WPB exocytosis have not been determined accurately. 
In this chapter experiments are described in which the relationship between 
agonist evoked changes in [Ca
2+]i, a major trigger for WPB exocytosis, and the 
onset, frequency and extent of WPB fusion was analysed at high time-resolution 
in single HUVEC by direct optical observation of individual WPB fusion events. 
To  achieve  this,  WPBs  were  specifically  labelled  by  expression  of  EGFP  or 
mEGFP targeted chimeras of the soluble WPB protein proregion. The time-points 150 
of individual WPB fusion events, identified by abrupt increases in WPB-EGFP 
fluorescence (flashes of light that arise due to pH changes within the WPB upon 
fusion-  see  chapter  3),  were  obtained  from  time-lapse  movies  of  EGFP 
fluorescence  in  living  HUVEC.  WPB  exocytosis  was  initiated  by  the 
physiological agents histamine or thrombin and the response was compared to a 
maximal concentration of the non-physiological secretogogue ionomycin, a Ca
2+ 
ionophore. Changes in [Ca
2+]i were measured along with EGFP fluorescence with 
the ratiometric fluorescent Ca
2+-binding dye Fura-2 loaded into the cell using its 
acetoxymethyl ester. The parameters analysed were 1) the delay between agonist 
arrival at the cell membrane and the onset of the rise in free Ca
2+. This reflects the 
time taken for agonist to couple to intracellular Ca
2+ release via the synthesis of 
the second messenger IP3 [118, 267]. 2) The delay from the Ca
2+ rise to the onset 
of WPB exocytosis; this parameter provides information about the coupling (e.g. 
recruitment to the membrane) between Ca
2+ increases and WPB fusion [388, 428, 
667]. 3) The rates of WPB exocytosis and 4) the extent of WPB degranulation. 
Prior to optical studies, the targeting of these constructs to WPBs was confirmed 
(see chapter 3) and the dose-response relation for histamine and thrombin evoked 
secretion  of  WPB-targeted  EGFP  was  characterised  using  biochemical 
approaches. Together with previous biochemical studies of the dose-dependence 
of vWF secretion from WPBs [97, 108, 183] allowed the establishment in advance 
of the agonist concentration ranges needed for the single cell imaging experiments 
described below. 151 
4.2  Methodology 
4.2.1  Epifluorescence imaging of [Ca
2+]i and EGFP 
For  Fura-2/EGFP  imaging  Fura-2  was  illuminated  sequentially  with 
355±10nm and 380±10nm light and EGFP with 480±20nm light. Excitation light 
was reflected onto the specimen using a 500DCXRU dichroic mirror (Chroma) 
and the emitted light passed through a 520±40nm emission filter onto the chip of 
the EMCCD camera. The setup configuration and an example of a single HUVEC 
nucleofected with proregion-EGFP and loaded with 2.5µM Fura-2/AM imaged 
with this optics is shown in Figure 4.1. 
4.2.2  Defining the delays of agonist evoked- WPB exocytosis 
Single cells were stimulated using a puffer micropipette. Simultaneous time-
resolved imaging of Fura-2 and EGFP expressing WPBs allowed for the direct 
analysis of exocytosis correlated with [Ca
2+]i increases. Delays in exocytosis were 
resolved into two components. Delay 1 (D1) which was due to the delay between 
drug arrival at the cell (defined as the 50% rise in Alexa-647 fluorescence; 207ms; 
see methods Figure 2.9) and intracellular Ca
2+ release from Ca
2+ stores, and delay 
2 (D2) between the rise in [Ca
2+]i and WPB exocytosis. A cartoon of delays and 
the signalling cascades associated with them is shown in Figure 4.2D. Figure 4.2 
illustrates an example of the temporal relationship between puffer application (A), 
the  Alexa  fluorescence  (B),  the  evoked  rise  in  [Ca
2+]i,  shown  by  the  Fura-2 
fluorescence ratio, and the first event of WPB fusion (C).  152 
 
Figure 4.1 Setup schematic for simultaneous imaging of Fura-2 and EGFP. 
The excitation light 480±20nm for EGFP and 355±10nm and 380±10nm for Fura-
2, was sent from a monochromator source, through a 50% neutral density filter, 
to  a  500DCXRU  chromatic  reflector  to  be  reflected  onto  a  single  HUVEC 
nucleofected  with  proregion-EGFP  and  loaded  with  2.5µM  Fura-2/AM.  The 
emitted light collected by the objective was passed through a 520±40nm emission 
filter onto the chip of the EMCCD camera. Each image is a single frame imaged 
sequentially at 30 frames/s (corresponding to 10 frames/s per wavelength). 
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Figure 4.2 Defining the delays in drug arrival, Ca
2+ rise and exocytosis. 
 A  Shows  the  +1V  analogue  output  from  the  micropipette  solution  puffer 
controller that signals activation of the device. B The solid trace represents the 
mean time-course (normalised to the peak steady-state fluorescence level, n=15 
cells) of the fluorescence increase due to Alexa-647 in the puffer solution, in a 
ROI  placed  over  the  cell.  Dotted  lines  represent  s.e.,  of  mean.  The  time  of 
application was taken arbitrarily as the 50% fluorescence rise of the Alexa signal 
(Vertical dashed line projecting in C). C shows a representative record of the 
increase in [Ca
2+]i evoked by 3µM histamine (solid trace) and the time for the 
first fusion event detected in this cell (solid circle). The delay between application 
and the rise in [Ca
2+]i was defined as D1 and between the rise in [Ca
2+]i and the 
first WPB fusion event was defined as D2 as indicated by the horizontal bars. A 
schematic of the signalling cascade taking place from hormone binding to a G-
protein coupled receptor to exocytosis is shown in D.  
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4.3  Biochemical  detection  of  agonist-evoked  secretion  of  WPB  targeted 
EGFP 
4.3.1  Secretion  of  WPB  targeted  EGFP  in  proregion-EGFP  expressing 
HUVEC 
A  previous  study  had  shown,  using  optical  approaches,  that  WPBs 
containing  proregion-EGFP  could  undergo  exocytosis  in  response  to  maximal 
concentrations of histamine and the Ca
2+ ionophore ionomycin [35]. However, an 
analysis of the dose-dependence of agonist evoked secretion of WPB-targeted-
EGFP had not been carried out. To establish the dose-dependence of exocytosis of 
EGFP containing WPBs a specific ELISA for GFP that detects the appearance of 
soluble EGFP immunoreactivity in the media of cells expressing proregion-EGFP 
was used.  Proregion-EGFP was chosen as this rapidly and completely disperses 
into the media at physiological pH upon WPB exocytosis [35, 351]. Cells were 
initially  stimulated  by  a  range  of  agonists  that  elevate  [Ca
2+]i,  (histamine, 
thrombin,  the  PAR-2  2f-LIGRLO  peptide  and  ionomycin)  using  maximally 
effective concentrations of these different agonists. In each case these agonists 
strongly  evoked  the  secretion  of  EGFP  immunoreactivity  into  the  cell  media 
(Figure 4.3). The percentage of secreted EGFP from the total EGFP in the cell 
was  34.28±3.30%  for  100µM  histamine,  35.85±3.03%  for  10U/ml  thrombin, 
31.35±1.63% for 10µM 2f-LIGRLO and 46.37±5.83% for 1µM ionomycin (n=2 
experiments in triplicates; mean±s.d.). The most effective secretogogue was the 
Ca
2+ ionophore ionomycin, consistent with previous biochemical studies of WPB 
exocytosis using ELISAs for endogenous vWF [84].  
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Figure 4.3 ELISA detection of secreted EGFP with maximal agonist 
concentration stimulation 
HUVEC  nucleofected  with  proregion-EGFP  were  stimulated  with  maximally 
effective concentrations of histamine (100µM), thrombin (3U/ml), PAR-2 peptide 
2f-LIGRLO  (10µM) and ionomycin (1µM). A  one way ANOVA and a Tukey's 
multiple  comparison  test  showed  that  histamine,  thrombin  and  PAR-2  peptide 
stimulation  were  not  significantly  different  between  them  however  ionomycin 
stimulation was significantly higher than the other secretagogues (*=P<0.0001). 
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4.3.2  Dose-dependence  of  histamine  or  thrombin  -evoked  secretion  of 
WPB targeted EGFP  
Next, the dose-response relationship for agonist-evoked secretion of EGFP 
immunoreactivity was determined for the physiological secretogogues, histamine 
and  thrombin.  Histamine  is  reported  to  evoke  secretion  of  vWF  over  the 
concentration range ~0.5-100µM [97], while thrombin-evoked vWF secretion is 
reported  over  the  concentration  range  0.03U/ml-3U/ml  [84,  183].    Figure  4.4 
shows that the dose-response relation for histamine (A) and thrombin (B) evoked 
secretion of EGFP in proregion-EGFP expressing HUVEC was in the same range 
as  previously  reported  for  vWF  secretion  suggesting  the  expressed  granules 
behave similarly to the endogenous one. This concentration range was used next 
in  the  optical  experiments  on  individual  living  HUVEC  in  order  to  determine 
more precisely dose-dependent effects of these agonists on the kinetics of WPB 
exocytosis.  The  EC50  of  histamine  calculated  from  the  dose  response  graph  is 
6.2µM, assuming the maximal response is at 100µM histamine and the EC50 of 
thrombin is 0.09U/ml, assuming the maximal response is at 3U/ml. 
4.4  Histamine-evoked WPB exocytosis. 
4.4.1  Concentration-dependence of histamine-evoked WPB exocytosis 
Using the concentration range determined in biochemical assays the effect 
of  histamine  on  [Ca
2+]i and  WPB  exocytosis  was  determined  in  single  Fura-2 
loaded proregion-mEGFP expressing HUVEC. At 0.1µM histamine 12/14 cells 
studied exhibited a small increase in [Ca
2+]i however no WPB fusion events were 
detected. At 0.3µM histamine, 21/23 cells responded with an increase in [Ca
2+]i, 
of  these  9  cells  underwent  exocytosis.  At  concentrations  >0.3µM  all  cells 157 
responded with both an increase in [Ca
2+]i and exocytosis. The increase in Ca
2+ 
concentration  was  dose-dependent,  however,  absolute  quantification  of  the 
increases in free Ca
2+ were not attempted as it had been shown previously that 
Ca
2+  signals  in  HUVEC  and  other  endothelial  cells  are  large  and  Fura-2  is 
unlikely to report these changes reliably [267, 668]. Examples of single cells are 
shown in Figure 4.5A of the histamine-evoked increase in [Ca
2+]i (upper panel) 
and histograms of the times of WPB fusion, measured from the rise in [Ca
2+]i, 
exposed to either 0.1, 0.3, 1.0, 3.0, 10, 30 or 100µM histamine (lower panel). The 
overall time-course for the WPB secretory response is summarized in Figure 4.5B, 
which shows the first latency distributions of WPB fusion events pooled from 15-
29 cells in each case exposed to the histamine concentrations indicated.  
4.4.2  Delays, rates and extent of histamine-evoked WPB exocytosis 
Figure 4.6A shows examples of the [Ca
2+]i traces for each concentration 
studied on an expanded time-scale to illustrate the dose-dependent delay in rise, 
offset so that the arrival of histamine at the cell surface at each case occurred at 
t=0. Figure 4.6B summaries the delays D1 and D2 for histamine- evoked WPB 
exocytosis. At 0.1µM histamine there was a delay between application and the 
rise in [Ca
2+]i (D1) of  5.80±1.2s (s.e., n=12  cells) and at 0.3µM histamine of 
2.95s±0.46s  (s.e.,  n=9  cells).  D1  shortened  with  increase  in  histamine 
concentration reducing to 0.46±0.04s (s.e., n=15 cells) at 100µM. The D2 delay 
(from  [Ca
2+]i  rise  to  onset  of  exocytosis)  was  also  concentration  dependent 
starting  from  9.93±3.90s  (s.e.,  n=9  cells)  at  0.3µM  histamine  and  reaching 
1.62±0.21s (s.e., n=15 cells) at 100µM histamine.  
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Figure 4.4 Dose response relations for histamine and thrombin evoked 
secretion of soluble EGFP 
HUVEC nucleofected with proregion-EGFP were stimulated with histamine (A) 
or thrombin (B) at the concentrations indicated. Secreted EGFP in the media was 
expressed  as  the  percentage  of  total  EGFP.  Each  point  is  the  mean±s.d.  of 
triplicates from 2 experiments for histamine stimulation and 4 experiments for 
thrombin stimulation. 
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Figure 4.5 Concentration-dependence of histamine-evoked WPB exocytosis 
A  (upper  panel)  shows  representative  records  of  the  changes  in  Fura-2 
fluorescence-ratio  (355nm/380nm)  in  single  HUVEC  during  stimulation  with 
physiological saline (PS)(purple), 0.1 (pink), 0.3 (blue), 1.0 (cyan), 3.0 (orange), 
10 (green), 30 (red) and 100µM (black) histamine. For comparison the Fura-2 
traces were offset so that the increase in [Ca
2+]i in each case occurred at time=0. 
A (lower panel) shows the frequency of WPB fusion (bin width 1s) for each of the 
individual  cells  in  A  (upper  panel).  There  was  no  secretion  at  PS  or  0.1µM 
histamine  stimulation.  Panel  B  Summaries  the  frequency  of  WPB  fusion  (bin 
width 2s) with time (determined from the rise in [Ca
2+]i) evoked by PS (n=10 
cells), 0.1µM (n=14 cells), 0.3µM (n=9 cells, 81 WPB), 1.0µM (n=20 cells, 313 
WPB),  3.0µM  (n=18  cells,  244  WPB),  10µM  (n=15  cells,  515  WPB),  30µM 
(n=29 cells, 654 WPB) and 100µM (n=15 cells, 549 WPB) histamine. 
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Figure 4.6 Delays of histamine-evoked WPB exocytosis. 
 A  Examples  of  the  time-course  of  Fura-2  fluorescence  increases  evoked  by 
0.1µM  (grey  trace),  0.3µM  (pink  trace),  1.0µM  (blue  trace),  3.0µM  (orange 
trace), 10µM (green trace), 30µM (black trace) and 100µM (red trace) histamine. 
Histamine  was  applied  at  t=0.  B  Summarises  the  delays  between  histamine 
arrival at the cell and the rise in [Ca
2+]i (D1; open circles) and between the rise 
in [Ca
2+]i and exocytosis (D2; closed circles) over the histamine concentration 
range indicated. (mean±se; n=9 cells at 0.3µM, and from between 15 to 29 cells 
at each of the higher concentrations). 
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The  exocytotic  response  comprised  an  initial  rapid  increase  in  fusion 
frequency which reached a maximum between 2 to 5 seconds after the rise in 
[Ca
2+]i  before  declining  to  a  lower  frequency  in  the  continued  presence  of 
histamine. Exocytosis ceased by ~500s. Maximal rates were calculated for cells 
that secreted more than 6 WPBs by plotting the number of WPB fusion events 
against the time point of fusion for each cell and taking the steepest slope of the 
graph as the maximal rate of fusion. The maximal rate of WPB fusion increased 
from 1.2±0.16 WPB s
-1 (mean, s.e., n=8 cells) at 0.3µM to 3.66±0.45 WPB s
-1 
(s.e., n=15 cells) at 100µM histamine (Figure 4.7). The highest rate of exocytosis 
recorded for histamine (30µM) was 12WPB s
-1.  
The  percentage  of  EGFP-tagged  WPBs  that  exocytosed  was  analysed  in 
cells exposed to 0.1, 1.0 or 100µM histamine.  The extent of histamine-evoked 
degranulation increased from zero at 0.1µM, to 19.63 ±13.9% (n=20 cells, range 
0.6- 50%) at 1.0µM and to 47.8±21.7% (n=15 cells, range 7.5-90.0%) at 100µM 
(Figure 4.8).  About 90% of the exocytosed WPBs released their contents within 
60s after stimulation. 
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Figure 4.7 Rates of histamine-evoked WPB exocytosis. 
Shows the maximal rates of WPB exocytosis for histamine stimulation over the 
concentration  range  indicated.  The  maximal  rate  at  0.3µM  was  0.87±0.40,  at 
1.0µM 1.65±0.38, at 3.0µM 2.51±1.65, at 10µM 3.22±1.28, at 30µM 3.66±3.00 
and  at  100µM  3.66±1.76  WPB  s
-1  (mean  ±se,  n=8  cells  at  0.3µM,  and  from 
between 15 to 24 cells at each of the higher concentrations).  
 
Figure 4.8 Extent of histamine-evoked WPB degranulation. 
Summaries  of  the  percentage  of  the  total  number  of  fluorescent  WPB  that 
underwent exocytosis in response to histamine at the concentrations indicated. 
There was no exocytosis at 0.1µM, at 1.0µM there was 19.63±13.9% (n=20 cells, 
range 0.6- 50%) and at 100µM 47.8±21.7% (n=41 cells, range 7.5-90.0%).  164 
4.5  Thrombin-evoked WPB exocytosis 
4.5.1  Concentration-dependence of thrombin-evoked WPB exocytosis. 
The  extent  of  secreted  EGFP  in  response  to  1U/ml  thrombin  was  not 
significantly different from that produced by 3U/ml (see Figure 4.4B), suggesting 
that  this  was  a  maximally  effective  concentration.  This  was  consistent  with 
previously  published  biochemical  data  [97].  Therefore  the  dose  range  for  the 
optical  experiments  used  was  limited  to  between  0.03  and  1U/ml.  Thrombin 
evoked [Ca
2+]i increases and WPB exocytosis in a dose-dependent manner. Figure 
4.9A shows representative [Ca
2+]i traces in single cells stimulated with thrombin 
concentrations  0.03,  0.3  and  1U/ml  (upper  panel)  and  their  corresponding 
histograms of the first latency distributions of WPB fusion events (lower panel). 
Figure 4.9B shows the histograms of WPB fusion events pooled data for 0.03U/ml 
(n=5 cells), 0.3U/ml (n=15 cells) and 1U/ml (n=12 cells) thrombin stimulation. At 
0.03U/ml  thrombin  stimulation  there  was  either  no  [Ca
2+]i  change  or  a  small 
increase and only 5 out of 16 cells analysed responded with secretion. Above that 
concentration there was both a [Ca
2+]i response and WPB fusion in all cells.  
4.5.2  Delays, rates and extent of thrombin-evoked WPB exocytosis 
Figure 4.10 summaries the delays in thrombin-evoked WPB exocytosis at 
the concentrations indicated (mean±s.e.). Thrombin evoked a [Ca
2+]i rise with a 
delay D1 of 10.08±4.50s (mean±s.d., n=6 cells) at 0.03U/ml which decreased to 
4.18±1.65s (mean±s.d., n=12 cells) at 1U/ml. The longest delay D2 was seen at 
0.03U/ml  thrombin,  20.93±10.49s  (mean±s.d.,  n=5  cells)  and  decreased  to  a 
minimum of 5.78±2.639s (mean±s.d., n=12 cells) at 1U/ml stimulation. 165 
 
Figure 4.9 Concentration-dependence of thrombin-evoked WPB exocytosis 
A  (upper  panel)  shows  representative  records  of  the  changes  in  Fura-2 
fluorescence-ratio  (355nm/380nm)  in  single  HUVEC  during  stimulation  with 
0.03, 0.3 and 1.0U/ml thrombin as indicated. For comparison the Fura-2 traces 
were offset so that the increase in [Ca
2+]i in each case occurred at time=0. A 
(lower panel) shows the frequency of WPB fusion (bin width 1s) for each of the 
cells in A (upper panel). Panel B Summaries the frequency of WPB fusion (bin 
width 2s) with time (determined from the rise in [Ca
2+]i) evoked by 0.03U/ml 
(n=5 cells, 42 WPB), 0.3U/ml (n=15 cells, 251 WPB) and 1U/ml (n=12 cells, 362 
WPB) Thrombin. 
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Figure 4.10 Delays of thrombin-evoked WPB exocytosis. 
Summaries  the  delays  between  application  and  the  rise  in  [Ca
2+]i  (D1;  open 
circles) and between the rise in [Ca
2+]i and exocytosis (D2; closed circles) on a 
logarithmic scale over the thrombin concentration range indicated. (mean ±se, 
n=5 cells at 0.03U/ml, n=16 cells at 0.1U/ml, n=15 cells at 0.3U/ml and n=12 
cells at 1U/ml). 
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The  gross  time-course  for  the  exocytotic  response  was  similar  to  the 
histamine response however the initial increase in frequency of fusion was not as 
high as with histamine. For 0.03U/ml thrombin the maximum rate of WPB fusion 
was  1.25±0.92WPB  s
-1 (mean±s.d.,  n=3  cells);  for  0.1U/ml  2.27±2.03WPB  s
-1 
(mean±s.d., n=13 cells); for 0.3U/ml 1.54±0.88WPB s
-1 (mean±s.d., n=11 cells) 
and for 1U/ml 3.64±2.28WPB s
-1 (mean±s.d., n=11 cells). Data is summarised in 
Figure 4.11 (mean±s.e.). The highest rate of exocytosis recorded for thrombin was 
7.6WPB s
-1 at 1U/ml. 
The percentage of EGFP fluorescent WPBs that underwent exocytosis was 
determined  for  thrombin  concentrations  0.03,  0.1  and  1U/ml.  At  0.03U/ml 
thrombin there was fusion of 11.96±7.31% of fluorescent WPBs (n=5 cells, range 
3.22-21.74%);  at  0.1U/ml  18.48±8.50%  (n=16  cells,  range  4.42-34%)  and  at 
1U/ml 28.97±13.07% (n=12 cells, range 9.10-53.46%) (Figure 4.12).  
4.5.3  Comparison of histamine and thrombin evoked WPB fusion  
It was found that histamine (100µM) evoked WPB exocytosis with shorter 
delays than thrombin (1U/ml). Representative examples of Ca
2+ traces in single 
cells evoked by 100µM histamine (grey) and 1U/ml thrombin (red) are shown in 
Figure 4.13A upper panel and the corresponding histograms of fusion events in 
the lower panel. Figure 4.13B shows the same examples on an expanded time 
scale,  to  emphasize  the  longer  delay  for  thrombin  (red  trace)  compared  to 
histamine (grey trace), measured from puff application (t=0) to the [Ca
2+]i rise 
(D1) (upper panel); and from [Ca
2+]i rise to the first exocytotic event (D2) (lower 
panel).  168 
Figure 4.11 Rates of thrombin-evoked WPB exocytosis. 
Summaries  the  maximal  rates  of  WPB  exocytosis  for  thrombin  over  the 
concentration range indicated (mean ±se, n=3 cells at 0.03U/ml, n=13 cells at 
0.1U/ml and n=11 cells at 1U/ml). 
Figure 4.12 Extent of thrombin-evoked WPB degranulation. 
Summaries the percentage of the total number of fluorescent WPB that underwent 
exocytosis in response to thrombin at the concentrations indicated. At 0.03U/ml 
thrombin  there  was  11.96±7.31%  (n=5  cells,  range  3.22-21.74%);  at  0.1U/ml 
18.48±8.50% (n=16 cells, range 4.42-34%) and at 1U/ml 28.97±13.07% (n=12 
cells, range 9.10-53.46%). 169 
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Figure 4.13 Comparison of D1 and D2 in representative single cell examples 
stimulated with 100µ µ µ µM histamine and 1U/ml thrombin. 
A  (upper  panel)  Overlay  of  representative  records  of  the  changes  in  Fura-2 
fluorescence-ratio  (355nm/380nm)  in  single  HUVEC  stimulated  with  100µM 
histamine (grey trace) and 1U/ml thrombin (red trace). The Fura-2 traces were 
offset  so  that  puff  application  occurred  at  time=0  (vertical  dotted  line).  The 
corresponding frequency of fusion events determined from puff application for 
each cell are shown in the lower panel in a grey histogram for histamine and in a 
red histogram for thrombin (bin width 1s). B Shows the same graphs as in A on 
an expanded time-scale to highlight the difference in the time-course of action of 
the  two  agonists.The  ensembled  data  of  the  comparison  of  the  histamine  and 
thrombin- evoked  kinetics of WPB exocytosis is shown in figure 4.15.  
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4.6  Time-course and extent of ionomycin-evoked WPB exocytosis 
Ionomycin is a strong secretogogue known to generate large increases in 
[Ca
2+]i  in  HUVEC  [206].  Ionomycin  (1µM)  evoked  a  large,  fast  rising  and 
maintained increase in [Ca
2+]i (Figure 4.14A solid trace) with a mean delay D1 of 
0.10±0.10s (n=6 cells) and delay D2 of 1.67±0.24s (n=6 cells).  The frequency of 
WPB  exocytosis  in  epifluorescence  experiments  was  high  during  the  first  1-3 
seconds after the onset of exocytosis with a mean maximal rate of 10.66±6.59 
WPB s
-1 (range 3.0-22 WPB s
-1
, n=6 cells), before declining over the next 10-20 
seconds  to  a  low  level  that  was  maintained  in  the  continued  presence  of 
ionomycin (Figure 4.14B histogram). In TIRFM experiments the maximal rate 
(10.01±10.67 WPB s
-1, range 0.47-42.50 WPB s
-1
, n=28 cells) and over-all time-
course  of  exocytosis  determined  for  1µM  ionomycin  was  not  significantly 
different from that of epifluorescence experiments [1]. TIRFM data showed that 
ionomycin  released  on  average  66.5±17.6%  (n=25  cells,  range  16-  94%)  of 
fluorescent  WPB,  a  value  significantly  higher  than  that  for  100µM  histamine 
(P=0.0006).   
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Figure 4.14 Time-course and extent of ionomycin-evoked WPB exocytosis 
A  Representative  record  of  a  single  HUVEC  during  stimulation  with  1µM 
ionomycin,  showing  the  change  in  Fura-2  fluorescence-ratio  (355nm/380nm) 
(solid trace) and the frequency of WPB fusion shown as a histogram (bin width 
1s); offset so that the increase in [Ca
2+]i occurred at time=0.. B Summaries the 
frequency of WPB fusion with time, determined from the rise in [Ca
2+]i in 6 cells 
in the epifluorescence experiments (447 WPB, 1s bin widths). 173 
4.7  Comparison of secretagogue-evoked WPB exocytosis  
Even though thrombin evoked WPB fusion was delayed in onset compared 
to  histamine,  the  maximal  rates  of  exocytosis  were  comparable.  The  Ca
2+ 
ionophore  Ionomycin  is  a  stronger  secretagogue  than  both  histamine  and 
thrombin, driving exocytosis with shorter delays, higher rates, and at higher extent 
of  degranulation.  Figure  4.15  summaries  the  delays  D1  (black)  and  D2  (red), 
maximal rates (blue) and percentage of degranulation (green) in WPB exocytosis 
between  maximal  effective  concentrations  of  physiological  secretagogues 
histamine (H) and thrombin (T) and pharmacological secretagogue ionomycin (I).  
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Figure 4.15 Rates, delays and magnitude of WPB release evoked by histamine, 
thrombin and ionomycin. 
Summaries the delays D1 (black bars) and D2 (red bars), maximal rate of WPB 
exocytosis  (blue  bars)  and  extent  of  degranulation  (green  bars)  for  100µM 
histamine  (H)  (n=15  cells),  1U/ml  thrombin  (T)  (n=11-12  cells)  and  1µM 
ionomycin (I) (n=6 cells for D1, D2 and maximal rates and n=25 cells for % 
degranulation). 
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4.8  Discussion 
4.8.1  Biochemical detection of secreted EGFP. 
Data  from  the  GFP  ELISA  illustrates  that  cultured  HUVEC  expressing 
proregion-EGFP respond to stimulation by a range of Ca
2+-elevating agonists with 
EGFP secretion. Secreted EGFP detected during control (unstimulated) conditions 
was low in the range of 2-5% of total GFP. This is likely to be due to basal 
secretion, the spontaneous release of regulated granules, or due to fluid shear-
stimulated secretion of WPBs during media changes in  the experimental protocol 
[94]. For both histamine and thrombin the secretion of GFP immunoreactivity was 
dose-dependent, with  effective  concentrations ranges similar to that  previously 
shown for vWF secretion [97, 108, 183]. We used proregion-EGFP in these pilot 
experiments because this protein, unlike vWF, does not bind strongly to the cell 
surface  after  secretion  but  rather  disperses  readily  into  solution.  The  efficient 
delivery of EGFP into solution provided excellent signal to noise in the assay 
allowing  secretion  to  be  clearly  observed  even  with  short  stimulation  times 
(5min). Does the EGFP ELISA data (Figure 4.3 and 4.4) provide an accurate 
readout of the extent of WPB degranulation? This is unlikely because proregion-
EGFP  is  found  not  only  in  WPBs  but  also  in  the  ER  (the  biosynthetic 
compartment).  A  better  readout  would  be  to  assay  release  of  endogenous 
proregion, as this molecule is found exclusively in the WPB, however, an ELISA 
assay for this molecule was not available at the time these studies were done.  
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4.8.2  Evidence for a threshold for Ca
2+-driven WPB exocytosis 
 Optical imaging experiments on single cells showed that in the absence of a 
rise in Ca
2+ no WPB exocytosis was observed, even over periods of up to 20min 
with or without low concentrations of stimulus (0.1µM histamine). With 0.3µM 
histamine a rise in Ca
2+ was observed, however, not all cells secreted during these 
small  [Ca
2+]i  rises  indicating  that  there  is  a  threshold  for  Ca
2+-driven  WPB 
exocytosis.  However,  a  quantitative  analysis  of  the  Ca
2+-threshold  for  WPB 
exocytosis was not possible with Fura-2 in these experiments as this dye will tend 
to saturate and therefore not provide reliable data on free [Ca
2+]i during hormone 
action [668]. Studies using lower affinity Ca
2+ indicators are needed to directly 
address such questions. Previous biochemical studies in permeabilised HUVEC 
have shown that vWF secretion only occurred when [Ca
2+]i was elevated >0.8µM 
and that secretion increased steeply in the range of 10-20µM free [Ca
2+]i
 [183, 
669] again consistent with a threshold for Ca
2+-driven WPB exocytosis. Similar 
observations were made in studies where secretion was measured as changes in 
membrane  capacitance;  5-20µM  [Ca
2+]i  was  required  to  evoke  exocytosis  in 
HUVEC [88, 103]. Both hormone evoked and direct IP3-evoked Ca
2+ release from 
internal stores can reach between 1 to 30µM free Ca
2+, as shown by quantitative 
Ca
2+  measurements  in  endothelial  cells  from  various  vessels,  using  the  low 
affinity Ca
2+ indicator Furaptra [103, 267, 668] suggesting that this concentration 
range  (>1-30µM)  is  likely  to  be  physiologically  relevant  for  driving  WPB 
exocytosis, with lower levels ineffective.  177 
4.8.3  Kinetics of agonist evoked-elevations of [Ca
2+]i and WPB exocytosis 
4.8.3.1  Delays in agonist evoked WPB exocytosis 
The analysis of the time-course of exocytosis shows that there are distinct 
delays  in  the  secretory  process  and  these  can  be  modified  by  agonist 
concentration. The first step involves the coupling of receptor activation into the 
rise in [Ca
2+]i. Here there was a delay (defined as D1) that most likely represents a 
composite of the times taken for agonist binding to the G-protein coupled receptor 
and the processes that lead to generation of intracellular IP3, followed by the time 
taken  for  IP3  to  induce  Ca
2+  release  from  the  stores  (see  introduction  1.4  for 
details  of  the  signalling  steps).  Flash  photolysis  studies  of  caged-IP3  have 
identified a minimum delay between IP3 generation to [Ca
2+]i rise of <10ms in 
porcine aortic EC [267],  <20ms in cerebellar Purkinje neurones [670] and 25ms 
in Xenopus oocytes [671]. Even low IP3 concentrations produce Ca
2+ release on 
the scale of 100-200ms in endothelial cells [267]. These delays are much shorter 
than  the  0.5s  seen  here  for  maximally  effective  concentrations  of  histamine 
suggesting that slow signalling steps upstream of IP3 action (e.g. coupling between 
receptor and G-protein, coupling of activated G-protein to PLC and the actions of 
PLC on PIP2 to produce IP3) are likely to be responsible for the majority of the 
delay seen between agonist application and the rise in [Ca
2+]i evoked by either 
histamine or thrombin. For both agonists the delays decreased in a concentration 
dependent fashion to a minimum of 0.5s at 100µM histamine and 4s for 1U/ml 
thrombin.   
The  delay  between  thrombin  application  and  the  rise  in  Ca
2+  was  much 
longer than that seen for histamine. Both agonists are thought to couple to IP3 
production through activation of PLCβ.  As already mentioned most of the delays 178 
at this stage in the signalling cascade are likely to arise from processes up stream 
of  IP3 generation [672]. Therefore the longer delay  with thrombin presumably 
reflects even slower process at this stage. This could be due to differences in the 
mechanism  of  receptor  activation  between  histamine  (acting  at  the  HR1)  and 
thrombin (acting at the PAR-1 receptor).  PAR-1 activation requires a proteolytic 
cleavage  of  the  extracellular  amino-terminal  domain  of  the  receptor  following 
Thrombin binding [176] unlike the activation of HR1 by histamine, and this step 
in PAR-1 activation may contribute to the slightly delayed action of thrombin (see 
Figure 1.2 and section 1.5 in the introduction) .  
Following  the  rise  in  Ca
2+  there  was  a  further  delay  of  several  seconds 
before WPB fusion was observed, (defined here as D2). Delays between Ca
2+ 
increase and exocytosis have been observed in many other secretory cell types 
using electrophysiological or optical approaches. Minimum delays evoked by high 
Ca
2+  are  typically  in  the  range  of  milliseconds  to  tens  of  milliseconds;  in 
astrocytes [673], Chinese hamster ovary fibroblasts [674], chromaffin cells [675, 
676], pituitary melanotrophs [677] and in pancreatic β-cells [678, 679]. This data 
suggests that WPB exocytosis is somewhat slower (minimum delay from Ca
2+ rise 
of 1.6s) than vesicle secretion from neuroendocrine cells and this may reflect slow 
steps in recruiting of the granules to the cell membrane by the cytoskeleton [390]; 
in  the  tethering  of  the  large  in  size  WPB  to  the  plasma  membrane  [428]  and 
perhaps in the Ca
2+-sensitivity of the apparatus responsible for these processes and 
fusion itself.  More work is needed to identify the molecular basis for slow steps 
in WPB exocytosis.  179 
4.8.3.2  Maximal rates in agonist evoked WPB exocytosis 
The  maximal  rate  of  WPB  exocytosis  increased  with  increasing  agonist 
concentration, and was associated with an increase in the [Ca
2+]i signal. The rates 
of rise and amplitudes of the Fura-2 fluorescence changes versus WPB fusion 
were not formally analysed due to uncertainties in our ability to interpret the Fura-
2 fluorescence changes reliably (due to dye saturation) in terms of free Ca
2+. The 
highest mean rate of exocytosis was ~4 WPBs
-1 with 30-100µM histamine, but 
was variable between single cells, not inconsistent with previous findings using 
capacitance  recordings  [88].  ~20%  of  the  total  WPBs  in  a  cell  expressing 
proregion-EGFP  are  not  fluorescent  [1]  so  the  measurements  of  the  rates  of 
exocytosis may be modestly underestimated (assuming the non-fluorescent WPBs 
behave the same way as the proregion-mEGFP labelled WPBs). Correcting the 
rates to take account of these non-fluorescent WPBs gives mean maximal rates of 
1.5  WPB/s  at  0.3µM  (rather  than  ~1.2  WPB/s)  and  ~4.7  WPB/s  at  100µM 
histamine (rather than ~3.7 WPB/s).  
Excitable cells show exocytosis of secretory vesicles at much higher rates 
than for the WPB, in the range of hundreds to thousands granules/s in pituitary 
cells [280, 677], pancreatic β-cells [679] depending on the stimulus strength and 
up to 40,000 vesicles/s in chromaffin cells [676] (reviewed in[680]). These very 
high rates may be due to very high local free [Ca
2+]i at release sites on the plasma 
membrane produced by clustering of Ca
2+ permeable ion channels at active zones 
[280, 681]. Alternatively  the Ca
2+ sensitivity of the fusion apparatus  might be 
different between excitable cells and WPBs in HUVEC. Secretory vesicles from 
neuroendocrine cells release their cargo into the circulation to be delivered on 
disparate  tissues  around  the  body  therefore  high  rates  of  secretion  may  be 180 
essential  to  overcome  dilution,  sequestration  and  clearance  effects.  On  the 
contrary,  the  cargo  of  WPBs  acts  locally  once  secreted,  at  the  surface  of  EC 
(vWF, P-selectin) or at the site of vascular injury (cytokines) where exocytosis is 
elicited. Perhaps the large size of WPBs and the highly condensed nature of intra-
granule vWF mean that the slower rates of WPB exocytosis may be sufficient to 
deliver material efficiently to the cell surface to control processes such as platelet 
adherence.   
4.8.4  High concentrations of histamine and thrombin fail to release all 
WPBs 
Neither histamine nor thrombin was effective at releasing more than ~50% 
of  WPBs.  In  contrast  a  maximally  effective  concentration  of  the  receptor-
independent agonist ionomycin (1µM), which acts directly on the ER to release 
Ca
2+  [206]  independent  of  IP3  production  [682],  was  able  to  drive  exocytosis 
significantly  more  efficiently  than  either  agonist  studied.  This  suggests  the 
existence  of  a  reserved  capacity  in  the  secretory  ability  of  endothelial  cells, 
inaccessible to histamine or thrombin, which may come into play under conditions 
of severe [Ca
2+]i elevations such as cell injury. Under such conditions it is likely 
that the cellular free [Ca
2+]i levels rise much higher than those seen during agonist 
action,  suggesting  that  the  Ca
2+-sensitivity  of  WPB  exocytosis  extents  to  high 
levels.  
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5  Optical analysis of exocytosis of the 
non-WPB secretory organelle  
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5.1  Introduction 
The non-WPB organelles are small structures that in the light microscope 
appear as diffraction limited punctae (Figure 1.1B). They lack the major WPB 
cargo  proteins  vWF,  Proregion,  P-selectin  and  CD63  [87](T  Carter  personall 
communication). Data suggests that they undergo continuous release [82] but may 
also undergo regulated exocytosis in response to secretagogues. In some studies in 
which  t-PA  release  was  used  as  a  biochemical  marker  for  release  from  these 
organelles, the secretion of t-PA appeared to be co-ordinated with that of vWF 
[70, 79, 80] while in other studies the time-course differed from that of vWF 
secretion [82-86]. Because t-PA can be present in WPBs under some conditions, 
the precise kinetics of exocytosis of these organelles has been difficult to establish 
using  the  indirect  biochemical  assay  of  t-PA  secretion.  In  addition  the  time-
resolution of biochemical studies of t-PA secretion from HUVEC are typically 
~1min at best [82, 87], a time-course not fast enough to extract the underlying 
rates, delays or extent in stimulated non-WPB organelle exocytosis.  
The aim of the experiments described in this chapter was to define more 
precisely the kinetics of stimulated exocytosis of the non-WPB organelle by direct 
observation of the organelles and their fusion and to compare these kinetics with 
that of the WPB. A time-resolved TIRFM (total internal reflection fluorescence 
microscopy) assay was used to investigate the kinetics of secretion of the non-
WPB organelle population labelled by expression of t-PA-EGFP under resting 
conditions and during stimulation with histamine or ionomycin in single HUVEC. 
Cells were co-transfected with proregion-mRFP to label all newly formed WPBs, 
some of which can, particularly at later times after transfection, contain some t-
PA-EGFP (see chapter 3). 183 
5.2  TIRF  live  cell  imaging  of  t-PA-EGFP  and  proregion-mRFP  co-
expressing HUVEC 
Double  nucleofected  (t-PA-EGFP  and  proregion-mRFP),  Fura-2  loaded 
HUVEC were imaged with TIRFM in conjunction with epifluorescence excitation 
of Fura-2 to monitor [Ca
2+]i changes. For EGFP excitation a 488nm laser was used 
and  for  mRFP  excitation  a  561nm  laser.  Switching  between  laser  and 
epifluorescence illumination was synchronized with image capture using Winfluor 
software. Figure 5.1 shows a schematic of the setup described. The dichroic used 
was  a  custom  made  GFP/DsRed  dual  band  dichroic  mirror  with  a  400DCLP 
coating on the reverse side to allow reflection of 355nm and 380nm light from the 
monochromator on the cells (Chroma, cat. no. 51019+). The emission light was 
selected through an EGFP/DsRed emission filter (Chroma). Figure 5.1 shows an 
example of a single HUVEC co-expressing t-PA-EGFP and proregion-mRFP and 
loaded with Fura-2, imaged with this configuration. 184 
 
Figure 5.1 TIRF/EPI setup schematic 
The blue and green laser light is co-aligned and focused into the back aperture of 
the objective so as to produce total internal reflection at an angle of 64
o at the 
glass coverslip-saline interface. A shallow evanescent field excitation is produced 
which excites only fluorophores at or near the basal cell membrane. Fura-2 is 
excited  (purple)  by  epifluorescence  illumination.  The  laser  beam  bypasses  the 
chromatic reflector and a dual band emission filter selects for GFP (green) and 
mRFP (red) emission wavelengths. HUVEC co-nucleofected with t-PA-EGFP and 
proregion-mRFP loaded with 0.5µM Fura-2/AM are imaged sequentially at 30 
frames/s (corresponding to 10frames/s per wavelength). 185 
5.3  Spontaneous  fusion  of  the  non-WPB  organelles  in  unstimulated 
HUVEC 
Initially Fura-2 loaded HUVEC co-expressing t-PA-EGFP and proregion-
mRFP  were  recorded  for  2-4min  under  resting  non-stimulated  conditions  to 
determine the unstimulated rate of non-WPB exocytosis. A representative resting 
[Ca
2+]i trace and the histograms of non-WPB fusion events pooled from 14 cells 
are shown in Figure 5.2A. For comparison no unstimulated release of WPBs was 
seen over periods of up to 15min (n=10) (Figure 5.2B). The events appear less 
frequent after the first minute or so because not all recordings were of the same 
length of time. Figure 5.3 shows the recording period of the 14 individual cells.  
The mean rate of the non-WPB spontaneous fusion calculated from individual 
cells was 0.02±0.01 non-WPBs
-1 (n=14). Only 14 out of 25 (56%) cells recorded 
showed unstimulated fusion events.  
5.4  Histamine-evoked non-WPB organelle exocytosis. 
5.4.1  Concentration-dependence of histamine-evoked non-WPB organelle 
exocytosis. 
The  non-WPB  organelle  frequency  of  fusion  increased  during  histamine 
stimulation in a dose dependent fashion. Figure 5.4A shows the [Ca
2+]i traces and 
the  times  of  fusion  events  for  representative  examples  of  single  HUVEC 
stimulated  with  either  1,  10  or  100µM  histamine.  Figure  5.4B  shows  the 
histograms  of  fusion  events  for  data  pooled  from  between  15-18  cells.  The 
frequency of fusion events increased at the highest histamine concentration. The 
vertical  dotted  line  in  Figure  5.4B,  aligned  with  the  [Ca
2+]i  rise,  illustrates 
spontaneous  fusion  events  occurring  before  the  stimulus  application  in  many 186 
cases. At 1µM histamine only 61% of cells studied showed stimulated secretion 
(n=26), while at 10µM this was 54% (n=33) and at 100µM 62% (n=24) of cells. 
The percentage of cells that secreted non-WPBs were not significantly different 
between histamine concentrations.  
5.4.2  Delays and rates of histamine-evoked non-WPB exocytosis 
The delay from the Ca
2+ rise to the onset of exocytosis (D2) for the non-
WPB organelle at 1µM was 8.5±7.0s, at 10µM 5.5±5.0s and at 100µM it was 
4.4±3.4s  (n=15-18  cells  at  each  concentration;  mean±s.d.)  (Figure  5.5A; 
mean±s.e.).  The  delays  of  the  non-WPB  exocytosis  appear  to  decrease  with 
increasing histamine concentration however due to their large variability they are 
not significantly different from one another as calculated by ANOVA (P=0.11).  
The maximal rates of histamine evoked exocytosis for the non-WPB were 
0.6±0.6 non-WPB
 -1 at 1µM, 0.6±0.5 non-WPB
 -1 at 10µM and 2.5±2.4 non-WPB
 -
1  at  100µM  (n=9-12  cells  at  each  concentration;  mean±s.d.)  (Figure  5.5B; 
mean±s.e.). ANOVA calculations show that the mean rate of exocytosis at 100µM 
histamine was significantly different from the mean rate at 10 and 1µM histamine 
(P=0.008), however the rates at 10µM and 1µM histamine were not significantly 
different. 
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Figure 5.2 There is no unstimulated release of WPBs in contrast to the non-
WPB organelle  
Upper  panel  in  A  and  B  shows  a  representative  Ca
2+  trace  for  unstimulated 
HUVEC recorded for approximately 250s (A) or 800s (B). The lower panel in A 
and B shows the histogram of the first latency distributions of fusion events for the 
non-WPB organelle (14 cells; 39 fusion events) (A) and the WPB (10 cells; no 
fusion events) (B), during basal [Ca
2+]i levels.  
A 
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Figure 5.3 Time-course of individual experiments recorded during unstimulated 
conditions 
The first latency distributions of the non-WPB fusion events from the experiments 
pooled in figure 5.2 are plotted separately for the individual cells studied. The 
time at the end of each experiment indicates the time-course of recording of each 
experiment to show the variability and to illustrate the spontaneous non-WPB 
fusion events are arbitrary and sporadic.  
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Figure 5.4 Concentration-dependence of histamine-evoked non-WPB exocytosis 
Each panel in A shows the changes in Fura-2 fluorescence ratio (355/380nm) in 
single HUVEC during stimulation with histamine at the concentrations indicated, 
and the corresponding frequency of fusion events. The Fura-2 traces were offset 
so that the increase in [Ca
2+]i in each case occurred at time=0 and the fusion 
events  are  determined  from  the  rise  in  [Ca
2+]i.  B  shows  the  first  latency 
distributions of pooled events evoked by 1µM (n=15 cells, 217 non-WPB), 10µM 
(n=18 cells, 216 non-WPB) and 100µM (n=16 cells, 200 non-WPB) histamine 
determined from the rise in [Ca
2+]i (vertical dotted line). 
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Figure 5.5 Delays (D2) and maximal rates of histamine-evoked non-WPB 
exocytosis 
A. The non-WPB stimulated exocytosis initiated with a delay from [Ca
2+]i rise of 
8.5±1.8s at 1µM; 5.5±1.3s at 10µM and 4.4±0.9s at 100µM histamine (n=15-18 
cells in each case; mean±se). The delays D2 are not significantly different between 
them (P=0.11). B. The maximal rates of the non-WPB stimulated exocytosis were 
0.6±0.2 non-WPB
-1 at 1µM; 0.6±0.2 non-WPB
-1 at 10µM and 2.5±0.8 non-WPB
-1 at 
100µM histamine (n=9-12 cells in each case; mean±se)(*=P=0.008 compared to 
the other rates). 
A 
B 
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5.5  Ionomycin-evoked non-WPB organelle exocytosis 
In order to examine the secretory behaviour of the non-WPB population of 
granules  during  severe  conditions,  as  might  occur  during  vascular  injury,  the 
kinetics  of  non-WPB  secretion  were  determined  with  ionomycin.    A 
representative  example  of  a  single  HUVEC  co-expressing  t-PA-EGFP  and 
proregion-mRFP stimulated with 1µM ionomycin is shown in Figure 5.6 (upper 
panel).  The  lower  panel  shows  the  first  latency  distributions  of  the  non-WPB 
exocytotic events from 13 cells during ionomycin stimulation.  
Figure 5.7 summaries the maximal rates and delays from the [Ca
2+]i rise to 
the onset of exocytosis (D2) of the non-WPB for 1µM ionomycin and 100µM 
histamine stimulation. The evoked kinetics of non-WPB exocytosis for the two 
secretagogues are not significantly different between them indicating that unlike 
the WPB (see chapter 4) the non-WPB stimulated exocytosis cannot be driven 
faster or at higher rates than a maximally effective hormone concentration.  
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Figure 5.6 Ionomycin-evoked non-WPB exocytosis 
Upper panel shows a representative Fura-2 fluorescence ratio (355nm/380nm) 
and the frequency of non-WPB fusion events, offset so that the [Ca
2+]i rise occurs 
at  t=0,  of  a  single  HUVEC  stimulated  with  1µM  ionomycin.  The  lower  panel 
shows  the  frequency  of  fusion  events  from  the  rise  in  [Ca
2+]i  of  pooled  TIRF 
experiments (13 cells, 198 non-WPB).  193 
 
Figure 5.7 Comparison of the kinetics of non-WPB exocytosis stimulated with 
100µ µ µ µM histamine and 1µ µ µ µM ionomycin 
The  black  bars  represent  delays  (D2)  from  [Ca
2+]i  rise  to  the  first  non-WPB 
fusion  event  stimulated  with  100µM  histamine  (Hist)  4.372±3.37s  (mean±s.d.; 
n=16 cells)  and 1µM ionomycin (Ion) 3.08±2.07s (mean±s.d.; n=13 cells). The 
blue bars represent the maximal rates of non-WPB exocytosis evoked by 100µM 
histamine  2.46±2.38  non-WPB
-1  (mean±s.d.;  n=9  cells)  and  1µM  ionomycin 
2.36±1.92non-WPB
-1(mean±s.d.; n=9 cells). The D2 and maximal rates evoked by 
the two secretagogues were not significantly different.  
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5.6  Discussion 
Previous studies have suggested that t-PA either resides in WPBs [70, 80] or 
in  a  unique  secretory  organelle  [87]  that  we  call  the  non-WPB  organelle. 
Biochemical studies of the secretory kinetics of t-PA in endothelial cells have 
been complicated by the possibility that t-PA could be contained in both granule 
populations. In this work the non-WPB was labelled with t-PA-EGFP and visually 
distinguished from the t-PA-containing WPBs by co-expressing proregion-mRFP 
to enable a kinetic analysis of histamine-evoked non-WPB exocytosis directly.    
5.6.1  Kinetics  of  the  histamine-evoked  exocytosis  of  the  non-WPB 
organelle 
The delay from [Ca
2+]i rise to the first exocytotic event (D2) for the non-
WPB organelle decreased with increasing histamine concentrations, yet due to the 
large variability in the delays, these values were not significantly different from 
each other. An additional complication and one that could account in part for the 
variability seen is that the non-WPB organelle can undergo unstimulated fusion. 
As  a  result  no  clear  conclusions  could  be  drawn  about  the  concentration 
dependence of the delays in histamine evoked non-WPB fusion. The magnitude of 
the  delays  were  however,  significantly  longer  than  those  seen  for  the  WPB, 
particularly at high histamine concentrations (~4.5 s versus 1.6 s for the WPB) 
suggesting  that  the  Ca
2+-dependent  recruitment  and  or  fusion  of  these  two 
organelles differs. Figure 5.8A compares the D2 of the non-WPB to the WPB at 
the histamine concentrations indicated. 
ANOVA analysis showed that the rates of non-WPB fusion stimulated with 
1 and 10µM histamine were not significantly higher than the unstimulated rate of 195 
fusion however the rates increased significantly at 100µM histamine (P=0.0001). 
At 100µM histamine the rates were similar to that seen for the WPB. Figure 5.8B 
compares the maximal rates of non-WPB exocytosis to the WPB at the histamine 
concentrations  indicated.  Despite  taking  great  care  to  ensure  that  WPBs  were 
excluded from this analysis could it be that some of these fusing organelles were 
in fact WPBs? Evidence against this comes from the determination of the resting 
pH within these organelles from intra-granule EGFP-fluorescence changes upon 
fusion (described in detail in chapter 3). The intra-granule pH of the non-WPB is 
~pH6.1  irrespective  of  the  time-point  (4h-24h)  after  which  cells  were 
Nucleofected with t-PA-EGFP. Similarly, the estimate of the resting pH in non-
WPBs  that  underwent  fusion  (either  unstimulated  or  stimulated;  data  obtained 
from the experiments described in this chapter) was also ~pH 6.3, significantly 
higher  than  would  be  expected  for  mature  EGFP  containing  WPBs  (either 
proregion-EGFP or t-PA-EGFP; see chapter 3). 
5.6.2  Extent of stimulated fusion of the non-WPB organelle  
Figure  5.9  compares  the  time-course  of  exocytosis  between  the  two 
granules. The percentage of degranulation for the non-WPB population could not 
be precisely determined because the number of non-WPB organelles in a single 
cell was typically too large to be counted accurately. However, rough estimates of 
the  proportion  of  non-WPBs  exocytosed,  at  100µM  histamine,  indicated  that 
significantly less than 5% of the total number of non-WPBs underwent fusion. 
This compared to ~50% of WPBs fusing with 100µM histamine. Similarly, with 
ionomycin  <5%  of  the  population  of  non-WPBs  appear  to  undergo  fusion 
compared to >60% for WPBs.  196 
 
Figure 5.8 Delays (D2) and maximal rates of the non-WPB and WPB 
histamine-stimulated exocytosis 
A. The delays from the [Ca
2+]i rise to the onset of exocytosis were slower for the 
non-WPB  than  the  WPB  at  the  histamine  concentrations  indicated.  B.  The 
maximal  rates  of  stimulated  exocytosis  for  the  non-WPB  were  lower  than  the 
WPB.  
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Figure 5.9 Comparison of histamine stimulated secretion frequencies between 
WPBs and non-WPB organelles 
Summarises the first latency distributions of WPBs (black histograms) and non-WPB 
organelles  (red  histograms)  determined  from  the  rise  in  [Ca
2+]I,  stimulated  with 
histamine concentrations 1, 10 and 100µM. In each case the histograms represent 
pooled events from 15-20 cells. The top trace represents a Fura-2 Ca
2+ trace offset 
so that the increase in [Ca
2+]i in each case occurred at time=0. The dotted line is 
aligned with the first time-point of Ca
2+ increase  (t=0). Events occurring before 
Ca
2+ increase in the non-WPB population signify spontaneous secretion.  
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5.6.3  Comparison of WPB and non-WPB organelle exocytosis 
The  WPB  and  the  non-WPB  differ  in  their  morphology,  cargo,  and 
intragranular pH (see chapter 3). Here we show that there were also differences in 
the initial kinetics of exocytosis and in the extent of degranulation between the 
two organelles. The differences between the two organelles are summarised in 
table  1.  Data  in  this  chapter  shows,  first;  that  the  non-WPB  undergoes 
spontaneous  exocytosis,  something  that  was  not  detectable  in  optical 
measurements  of  fluorescent  WPBs  (Figure  5.2).  Second,  although  both 
organelles  show  Ca
2+-triggered  exocytosis,  the  onset  for  fusion  for  non-WPB 
organelles  was  slower  than  for  the  WPB  (Figure  5.8A)  and  at  low  histamine 
concentrations the rates of fusion were also lower; although they were similar at 
100µM  histamine  (Figure  5.8B).  Third,  the  extent  of  fusion  was  dramatically 
lower for the non-WPB, and finally, ionomycin was not capable of evoking a 
stronger non-WPB secretory response than 100µM histamine (Figure 5.7). This 
last  piece  of  data  indicates  that  the  two  organelles  may  exhibit  different 
sensitivities to [Ca
2+]i, something that had previously been suggested [82, 84]. Do 
they utilise different molecular machinery of exocytosis? The fusion apparatus of 
the non-WPB can operate at resting [Ca
2+]i levels [82] whereas WPB exocytosis is 
only stimulated above a certain threshold [Ca
2+]i [183, 669]. This indicates that the 
fusion apparatus for the non-WPB is likely to be more sensitive to Ca
2+. The rate 
and extent of stimulated exocytosis of the non-WPB saturates at lower [Ca
2+]i; 
indicated by the inability of ionomycin to evoke a stronger response. This data 
suggests that the two granule populations are likely to contain Ca
2+-sensors with 
different affinities for Ca
2+. Although in other systems, mainly neuroendocrine 
cells, the [Ca
2+]i sensing apparatus has been extensively studied [399, 683-686]; in 200 
endothelial cells it remains unclear. In excitable cells sensor proteins required for 
Ca
2+-triggered  exocytosis  include  the  synaptotagmins  [410,  685]  and  annexins 
[408, 409, 687]. What evidence is there for the molecular identity of the Ca
2+-
sensor in WPB exocytosis? One study identified the recruitment of synaptotagmin 
1 to pseudo-WPBs in vWF expressing AtT-20 cells [424] suggesting a possible 
involvement  of  synaptotagmins  in  WPB  exocytosis,  although  this  could  be  an 
AtT-20 specific effect. Synaptotagmins exist in different isoforms with different 
Ca
2+ affinities [688] suggesting combinations of multiple synaptotagmin isoforms 
could potentially fine tune the Ca
2+ sensing machinery for exocytosis of different 
populations of granules. Annexins are heterologously expressed in all cell types 
and are abundantly found in endothelial cells [411]. They are either found in the 
cytoplasm as monomers or bound to phospholipids on the plasma membrane in a 
heterotetrameric complex [408]. The latter is thought to control Ca
2+ homeostasis 
by controlling Ca
2+ channel trafficking on the plasma membrane in endothelial 
and epithelial cells [411, 689]. Moreover annexins are thought to be involved in 
exocytosis when activated by Ca
2+ in endothelial cells [412] and chromaffin cells 
[413]. Annexins have high affinity  for Ca
2+  [409]. Disruption of the  annexin 
complex  on  the  plasma  membrane  does  not  completely  inhibit  exocytosis  in 
endothelial cells as observed with capacitance measurements [412]. Other work 
showed  that  down-regulation  of  the  annexin  A2  complex  interfered  with  vWF 
secretion  but  not  t-PA  secretion  from  endothelial  cells  when  stimulated  with 
histamine  or  ionomycin  [55].  The  same  group  showed  that  the  GTP-bound 
conformation  of  Rab3D  mutants,  involved  in  the  exocytotic  machinery  [690], 
were recruited to vWF-containing WPBs but not t-PA-containing organelles and 
its over-expression interfered with WPB formation and exocytosis whereas t-PA 201 
exocytosis was unaffected [55]. Other membrane proteins recruited to the WPB 
but not the non-WPB include Rab27a and its effector MyRIP [54], thought to be 
involved in anchoring mature WPBs to peripheral actin and thus preventing WPB 
exocytosis prior to maturation [57]. Further differences identified in the secretory 
pathway of the two organelles come from studies showing that phospholipase D1 
knock down in HUVEC, a molecule shown to  regulate the recruitment of the 
exocyst  complex  (also  reported  to  be  involved  in  WPB  exocytosis  [418]), 
inhibited WPB exocytosis but did not affect t-PA secretion [691]. 
The data presented here strengthen the concept that fusion of the WPB and 
non-WPB organelles are regulated differently. Further work is needed to elucidate 
the  differences  in  the  molecular  machinery  that  give  rise  to  the  formation, 
trafficking and fusion of these two different organelles. 
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Table 1: Differences between WPB and non-WPB 
Feature  WPB  Non-WPB 
Morphology  Small spherical structures 
through to large cigar 
shaped organelles 
Exclusively small spherical 
structures 
Cargo  vWF, proregion, P-selectin, 
CD63, Angiopoietin-2, 
Osteoprotegerin (under 
certain conditions ; IL-8, 
eotaxin-3, t-PA)  [64, 68]                  
t-PA  (under certain 
conditions ; IL-8, eotaxin-3, 
MCP-1, GROα) 
Early pHg  pH6.2  pH6.1 
Late pHg  pH5.4  pH6.1 
Storage  Yes  No 
Molecules 
possibly 
involved in 
exocytosis 
Rab27a and effector 
MyRIP, Rab3D, 
phospholipase D1, 
 annexin A2 
No evidence 
Spontaneous 
release 
No  Yes 
Regulated 
exocytosis 
Yes  Yes 
Kinetics of 
exocytosis 
D2=1.62 ± 0.21s 
Max rate=3.7±1.8 WPBs
-1 
Perc.Degr.=47.8±21.7% 
D2=4.37±0.90s 
Max rate=2.5±0.8nonWPBs
-1 
Perc. Degr.<5% 
Potential Ca
2+-
sensitivity 
Low  High 
Efficiency of 
Histamine vs 
Ionomycin 
evoked 
exocytosis 
Histamine < Ionomycin  Histamine = Ionomycin 203 
 
 
 
 
 
6  Mitochondria and WPB exocytosis 
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6.1  Introduction 
Mitochondria are the major source of energy production in most cells [692], 
however ECs are thought to use the process of anaerobic glycolysis (metabolism 
of glucose in the cytosol) to satisfy their energy demands [510, 511, 513, 514]. As 
a consequence, mitochondria in endothelial cells are thought to be important for 
other processes such as oxygen sensing [512], production of NO and ROS [513, 
514], and intracellular Ca
2+ buffering [571, 573]. How do mitochondria regulate 
cytosolic  Ca
2+?  During  increases  in  cytosolic  [Ca
2+]i  mitochondria  are  able  to 
accumulate Ca
2+ [528, 533, 565] using a high affinity uniporter (Kd=2nM) [527] 
which selectively transports Ca
2+ into the mitochondria [527, 545].  This ability of 
mitochondria  to  sequester  Ca
2+  has  been  shown  to  lead  to  modifications  of 
cytosolic Ca
2+ signaling patterns including Ca
2+ oscillations [552, 553, 566], to 
facilitate  capacitative  (CCE)  Ca
2+  entry  [572,  573],  to  suppress  the  positive 
feedback of local Ca
2+ on the IP3R involved in Ca
2+ propagation [563], and to 
facilitate Ca
2+ clearance from the cytosol [558] in a variety of cell types. Ca
2+ is a 
major second messenger coordinating many cellular functions, including secretion 
[97] and its modulation by mitochondria would potentially have consequences on 
the  secretory  kinetics.  Previous  studies,  using  pharmacological  inhibition  of 
mitochondrial  Ca
2+  uptake,  have  shown  that  stimulated  secretion  of 
catecholamines from chromaffin cells was increased [578, 583, 584] as was the 
release  of  gonadotropins  in  pituitary  gonadotropes  [552].  In  other  instances 
however mitochondrial Ca
2+ uptake inhibition led to a decrease in catecholamine 
secretion from mouse chromaffin cells, suggesting differences between species 
and cell types [557]. 205 
In  this  chapter  the  role  of  mitochondrial  Ca
2+  uptake  in  modifying 
histamine-evoked  [Ca
2+]i  changes  and  the  kinetics  of  WPB  exocytosis  was 
examined by dissipating the mitochondrial membrane potential (∆Ψm), the driving 
force for Ca
2+ uptake via the uniporter, and observing the effects on mitochondrial 
free Ca
2+, cytosolic free Ca
2+ and WPB exocytosis simultaneously in single cells. 
To achieve the collapse of the ∆Ψm, the metabolic uncoupler FCCP (Carbonyl 
cyanide-p-trifluoromethoxyphenylhydrazone)  was  used.  This  drug  transports 
protons across the mitochondrial membrane down the electrochemical gradient 
collapsing  in  this  way  the  ∆Ψm  and  uncoupling  respiration  from  oxidative 
phosphorylation  [509],  leading  to  the  block  of  Ca
2+  uptake  via  the  uniporter 
(reviewed in [693]). Oligomycin was used in combination with FCCP to inhibit 
the consumption of cytosolic ATP as a result of reversal of the  F1F0 ATPase on 
the IMM after dissipation of the membrane potential [694].  
Little work has been done on mitochondrial disruption and WPB exocytosis 
in  endothelial  cells.  Because  there  is  evidence  of  links  between  mitochondrial 
diseases and vascular diseases such as atherosclerosis (for reviews see [513, 589]) 
it  was  of  interest  to  establish  whether  mitochondria  might  play  any  role  in 
modifying Ca
2+ signals and secretion of WPBs. 
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6.2  Epifluorescence imaging of WPB exocytosis and changes in [Ca
2+]i and 
[Ca
2+]m 
For  monitoring  [Ca
2+]m,  the  membrane  permeant  form  of  X-Rhod-1  (X-
Rhod-1/AM) was used in combination with Fura-2 (see methods section 2.3.3). 
Excitation light for Fura-2 380±10nm and 355±10nm and light for exciting both 
X-Rhod-1 and mEGFP 480±20nm was sent to a 500DCXRU dichroic mirror. The 
emitted light was sent to an optical splitting device containing a DC560 dichroic 
mirror that separated the Fura-2 and mEGFP light from that of X-Rhod-1 prior to 
band pass filters centred at 520±40nm and 615±25nm respectively. The imaging 
setup and an example of a single HUVEC expressing proregion-EGFP and loaded 
with Fura-2 and X-Rhod-1 is shown in Figure 6.1.  
6.3  Simultaneous Measurements of [Ca
2+]i and [Ca
2+]m in single HUVEC 
6.3.1  Is X-Rhod-1 measuring changes in [Ca
2+]m? 
X-Rhod-1  is  a  Ca
2+  -sensitive  fluorescent  rhodamine  derivative  that 
becomes selectively trapped in mitochondria due to the highly negatively charged 
inner mitochondrial membrane (IMM) and has been used extensively to report 
changes in [Ca
2+]m [552, 584, 695]. X-Rhod-1 was used here to report changes in 
[Ca
2+]m  during  mitochondrial  inhibition  and  histamine  action.  To  confirm  the 
partitioning of the X-Rhod-1 into mitochondria, HUVEC were co-loaded with X-
Rhod-1  and  mitotracker  green,  a  fluorescent  mitochondrial  marker  that 
preferentially  accumulates  in  mitochondria  regardless  of  the  mitochondrial 
membrane  potential.  In  separate  experiments  HUVEC  expressing  mito-EGFP 
which specifically marks the mitochondria, were loaded with X-Rhod-1. In both 
cases  the  X-Rhod-1  fluorescence  signal  co-localised  with  these  mitochondrial 207 
specific markers (Figure 2.16). X-rhod1 is not a ratiometric Ca
2+ indicator, and as 
such  is  potentially  susceptible  to  movement  artefacts  and  to  changes  in 
mitochondrial  morphology  (e.g.  swelling  /  shrinking)  that  could  give  rise  to 
changes in the optical path length or volume of the organelle. Such morphological 
changes might give rise to spurious changes in fluorescence intensity un-related to 
changes in [Ca
2+]m. To determine if such changes might occur and thus contribute 
to measurements of [Ca
2+]m, mitochondria were labelled with both X-Rhod-1 and 
a second Ca
2+-insensitive fluorescence marker (mito-EGFP or mitotracker green). 
Changes  in  the  fluorescence  of  these  markers  should  report  Ca
2+-independent 
changes in parameters such as swelling. Figure 6.2 shows a typical experiment in 
which the mitochondrial fluorescence change of mito-EGFP, X-Rhod-1 and the 
[Ca
2+]i change reported by Fura-2 were recorded during histamine stimulation. 
The background subtracted (blue ROI in A) EGFP (green trace) and X-Rhod-1 
(red trace) fluorescence were measured from the same region of interest (shown in 
green  and  red  ROIs  in  A).  While  X-Rhod-1  responds  with  an  increase  in 
fluorescence, mito-EGFP fluorescence remained stable, suggesting changes in X-
Rhod-1 fluorescence reflect changes in [Ca
2+]m, presumably due to mitochondrial 
Ca
2+ uptake.  
 208 
 
Figure 6.1 Setup schematic for imaging Fura-2, EGFP and X-Rhod-1. 
The excitation light sent from the monochromator, 480±20nm for EGFP and X-
Rhod-1 and 355±10nm and 380±10nm for Fura-2, passed through a 50% neutral 
density filter and was then reflected onto the specimen by a 500DCXR chromatic 
reflector. The emitted light was separated using an optical splitting device to be 
collected  at  520±40nm  for  Fura-2/EGFP  and  615±25nm  for  X-Rhod-1.  An 
example  of  the  images  obtained  on  the  EMCCD  camera  of  a  single  HUVEC 
nucleofected  with  proregion-EGFP  and  loaded  with  0.5µM  Fura-2/AM  and 
0.2µM X-Rhod-1/AM is shown. Each image is a single frame imaged sequentially 
at 30 frames/s (corresponding to 10frames/s per wavelength).  
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Figure 6.2 Mito-EGFP signal is independent of histamine stimulation 
A. A single HUVEC expressing mito-EGFP and loaded with 0.5µM Fura-2 and 
0.5µM X-Rhod-1 imaged using the setup described in figure 6.1 and stimulated 
with  100µM  histamine.  B.  The  fluorescent  measurements  of  the  background 
subtracted Fura-2 ratio (black trace), the background subtracted X-Rhod-1 (red 
ROI minus blue ROI in A) and the EGFP fluorescence (green ROI minus blue 
ROI in A).  
A 
B 
480±20nm  Mito-EGFP  X-Rhod-1 210 
Another consideration is that mitochondria contain auto-fluorescent proteins 
such  as  flavoproteins  which  participate  in  oxidative  phosphorylation  and  are 
excited  optimally  at  450nm  and  emit  broadly  with  a  peak  at  ~550nm. 
Flavoproteins  increase  in  fluorescence  when  oxidised  during  increases  in  the 
mitochondrial respiration rate and have been used to measure the up-regulation of 
the  TCA  cycle  [577].    This  will  occur  for  example  during  collapse  of 
mitochondrial  ∆Ψm  by  FCCP.  Since  X-Rhod-1  is  excited  at  475(20)nm  and 
emission light is collected at 615±25nm, there was a small possibility of some 
overlap between the tail end of the flavoprotein autofluorescence emission spectra 
and the emission filter used for X-Rhod-1. To identify if there was any bleed 
through  cells  not  loaded  with  X-Rhod-1  were  imaged  with  the  same  optical 
arrangement  during  incubation  with  uncoupler  FCCP.  During  such  recordings 
there  was  no  detectable  signal  due  to  mitochondrial  autofluorescence  changes 
observed (data not shown). 
6.3.2  Stimulus-evoked [Ca
2+]m changes 
Figure 6.3 shows a representative experiment of a live HUVEC expressing 
proregion-mEGFP and loaded with 0.2µM X-Rhod-1 during stimulation with a 
maximally effective (30µM) histamine concentration. The top panel shows the 
raw  X-Rhod-1  changes  from  a  mitochondrial  region  (red  trace;  red  region  of 
interest  (ROI)  on  the  cell  image),  and  from  a  cytosolic  region  (blue  trace), 
measured  from  a  ROI  adjacent  to  the  mitochondrial  ROI  (blue  ROI  on  cell 
image). The middle panel shows the background subtracted Fura-2 ratio (black 
trace) and the mitochondrial X-Rhod-1 signal from the red ROI after subtraction 
of the background signal and the cytosolic signal from the blue ROI  that includes 
some  cytosolic  X-Rhod-1  (red  trace).  The  black  histogram  in  the  lower  panel 211 
represents the first latency distribution of the fusion events in this cell. This data 
shows that changes in both cytosolic and mitochondrial Ca
2+ could be measured 
along with WPB fusion in single cells.  
At what histamine concentration are mitochondrial Ca
2+ signals observed? 
With  low  histamine  concentrations  (0.3µM)  no  clear  changes  in  X-Rhod-1 
fluorescent were seen despite small increase in [Ca
2+]i (Figure 6.4). However, at 
histamine concentrations ≥ 1µM there was a slow rise in [Ca
2+]m that started with 
a  delay  after  the  [Ca
2+]i  rise.  At  high  concentrations  (30-100µM)  the  delay 
between  [Ca
2+]i  rise  and  [Ca
2+]m  was  on  average  2.06±1.45s  (mean±sd,  n=7)  
(Figure 6.4). To summarise, the [Ca
2+]m signal reported by X-Rhod-1 increased 
with a delay with respect to the [Ca
2+]i signal, it was slower to rise and was more 
prolonged than the [Ca
2+]i. 212 
 
Figure 6.3 Simultaneous monitoring of [Ca
2+]i, [Ca
2+]m and exocytosis. 
An  example  of  [Ca
2+]i,  [Ca
2+]m  and  WPB  exocytosis  monitored  in  a  single 
HUVEC loaded with 0.5µM Fura-2 and 0.2µM X-Rhod-1 and stimulated with 
30µM histamine. The top panel represents the raw X-Rhod-1 measurements from 
a mitochondrial ROI (red trace; red ROI on cell image) and an adjacent cytosolic 
ROI  (blue  trace;  blue  ROI  on  cell  image).  The  middle  panel  shows  the 
background subtracted Fura-2 ratio fluorescence measuring [Ca
2+]i (black trace) 
and the background subtracted X-Rhod-1 signal from the red ROI  (red trace) 
after subtraction of the cytosolic X-Rhod-1 signal from the blue ROI. The lower 
panel shows the histogram of the WPB fusion events.  
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6.4  Action of FCCP 
6.4.1  FCCP collapses the mitochondrial ∆Ψ ∆Ψ ∆Ψ ∆Ψm  
FCCP was used at 1µM in combination with 2.5µg/ml oligomycin. Initially, 
to ensure that this concentration of FCCP efficiently collapsed the ∆Ψm and to 
determine the time-course of its action, changes in ∆Ψm were measured using the 
fluorescent  dye  TMRE  [521].  TMRE  is  a  fluorescent  lipophilic  cation  that 
accumulates  in  mitochondria  in  proportion  to  the  magnitude  of  ∆Ψm.  The 
properties of the dye and how it can be used are described in detail in Methods 
section 2.3.5. The method used here was the “redistribution” method where the 
cells were loaded at low TMRE concentrations that did not reach auto-quenching 
levels.  As  the  mitochondrial  membrane  depolarises,  TMRE  exits  the 
mitochondrial  lumen  and  enters  the  cytosol.  This  results  in  a  decrease  in  the 
specific mitochondrial signal [521]. TMRE was used in combination with mito-
EGFP as described below. 
Mito-EGFP  comprises  a  mitochondrial  targeting  sequence  derived  from 
subunit  VIII  of  human  cytochrome  C  oxidase  (COX)  located  on  the  inner 
mitochondrial  membrane  with  the  EGFP  directed  to  the  mitochondrial  matrix 
[696,  697].  During  oxidative  phosphorylation  the  electron  transport  chain 
provides the energy for proton transport via the complexes I, III and IV on the 
inner mitochondrial membrane (IMM) from the mitochondrial lumen to the inter-
membrane  space  (see  Introduction  Figure  1.7  for  a  cartoon  of  the  electron 
transport  chain  on  the  mitochondria).  The  FCCP  protonophore  carries  protons 
down  their  electrochemical  gradient  from  the  inter-membrane  space  into  the 
mitochondrial lumen leading to a rise in the inter-membrane space pH and a drop 215 
in the luminal pH. The mitochondrial matrix pH is alkaline at ~pH8 [345] and 
FCCP will equilibrate this to the cytoplasmic pH (~pH7.2). This small pH drop is 
not sufficient to give a detectable EGFP fluorescence change as at pH7.2 the GFP 
fluorescence is approaching maximum as described by the pH-GFP fluorescence 
relationship in figure 3.2. Although in this case EGFP cannot be used as a pH 
indicator, it can be used to determine any mitochondrial morphological changes 
due to FCCP perfusion.  
TMRE  fluorescence  (∆Ψm  measurements)  and  mito-EGFP  fluorescence 
(morphological changes) were recorded simultaneously using the same imaging 
configuration as in Figure 6.1. Figure 6.5A shows a single HUVEC expressing 
mito-EGFP and loaded with TMRE, both fluorophores being excited at 480nm, 
perfused  with  FCCP/oligomycin,  and  with  TMRE  present  in  the  perfusate  to 
prevent  any  loss  of  cellular  dye.  The  red  ROI  indicates  the  region  of  the 
mitochondria used for the EGFP and TMRE measurements and the blue ROI the 
region used for background subtraction. A montage of the EGFP fluorescence of 
mitochondria in 6.5B shows an apparent condensation of the mitochondria and 
formation  of  rings  as  previously  reported  with  the  mito-GFP  construct  in 
mammalian cells [696] (upper montage) and the decrease in TMRE fluorescence 
(lower  montage).  The  time-course  of  the  background  subtracted  TMRE 
fluorescence changes are plotted in 6.5C. The gray trace shows the TMRE signal 
decreasing as the uncoupler is perfused on, signalling a drop in the mitochondrial 
membrane  potential.  The  cytosolic  signal  should  increase  in  fluorescence  as 
TMRE  leaves  the  mitochondria,  however  this  signal  was  too  weak  to  be 
measured.  
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Figure 6.5 FCCP collapses ∆Ψ ∆Ψ ∆Ψ ∆Ψm  
A Image of a single HUVEC expressing mito-EGFP 24hours post-nucleofection 
and loaded with 0.3µM TMRE imaged using the configuration in Figure 6.1. Both 
fluorophores were excited at 480(7)nm and emitted light was separated using an 
optical splitting device to be collected at 520±40nm for EGFP and 615±25nm for 
TMRE. The cell was perfused with 1µM FCCP, 2.5µg/ml oligomycin and 0.3µM 
TMRE recorded at a time lapse of 1 second to reduce bleaching. The red diagram 
is the mitochondrial ROI selected for the TMRE and mito-EGFP measurements 
and the blue diagram the background ROI.  
B Montage of the red ROI shown in A, after background subtraction (blue ROI), 
for mito-EGFP fluorescence (top panel) and TMRE fluorescence (bottom panel), 
taken every 80s.  
C Background subtracted time-course of TMRE fluorescence during perfusion of 
inhibitors added as indicated with the arrow.  
 
 
 218 
6.4.2  FCCP causes an increase in proregion-mEGFP fluorescence 
When  cells  become  exposed  to  FCCP,  the  protonophore  collapses  H
+ 
gradients across all membranes. In the case of the WPB the result is a rise in WPB 
lumen pH and consequently a rise in WPB-targeted mEGFP fluorescence. Figure 
6.6 shows an example of a single HUVEC perfused with FCCP /oligomycin for 
1min  prior  to  stimulation  with  1µM  histamine.  The  top  panel  shows  the 
background subtracted Fura-2 ratio (black trace) and the first latency distributions 
of  the  WPB  fusion  events  (histogram).  The  time-course  of  the  background 
subtracted mEGFP fluorescence of a single WPB (indicated by the vertical black 
arrow in A) is measured in Figure 6.6B. The fluorescence was normalised to the 
peak  fluorescence  at  the  point  of  fusion.  As  can  be  seen  the  WPB  associated 
mEGFP signal increases slowly while the cell is exposed to FCCP indicating a 
rise in the WPB pH. This is illustrated in Figure 6.6C which shows the pHWPB 
time-course  derived  from  the  mEGFP  fluorescent  measurements  using  the 
equation in Methods Figure 2.10B. The pHWPB reached during FCCP perfusion 
calculated  between  the  two  black  asterisks  was  pH6.0,  increasing  from  the 
average  resting  pHWPB  of  5.4  [1].  This  value  varied  between  different  WPBs 
presumably due to differences in the buffering capacity of individual WPBs [1]. 
Figure  6.6D  shows  the  same  normalized  mEGFP  fluorescence  trace  on  an 
expanded  time-scale  to  highlight  exocytosis.  A  montage  of  images  of  the 
individual WPB undergoing exocytosis is shown in Figure 6.6E.  Frames marked 
with a number correspond to the numbers with arrows in red in B and the red 
asterisk corresponds to the time-point of fusion indicated with a red asterisk in D. 
Detection of the point of WPB exocytosis relies on the flash of light caused 
by the abrupt increase in mEGFP fluorescence during fusion. Under conditions of 219 
FCCP  exposure,  although  the  mEGFP  fluorescence  change  is  smaller  in 
amplitude, it was still adequate to mark the point of exocytosis. 
6.4.3  FCCP treatment blocks mitochondrial Ca
2+ uptake 
Having established that FCCP efficiently transports protons and collapses 
the ∆Ψm, I then went on to confirm the effect of FCCP on agonist evoked [Ca
2+]m 
changes.  A  short  (1min)  and  a  long  (10min)  duration  of  pre-treatment  with 
FCCP/oligomycin was used prior to histamine stimulation, in order to determine 
the time-course for the effects of these inhibitors on mitochondrial Ca
2+ uptake. 
Figure 6.7 shows the effects of a 1min and 10min pre-treatment period on [Ca
2+]i 
and  [Ca
2+]m.  In  both  cases  (1  and  10min),  the  inhibitors  abolished  the 
mitochondrial Ca
2+ uptake (Figure 6.7). The noisier Fura-2 signal seen with the 
10min recordings was due to a reduction in the bandwidth of the Fura-2 excitation 
light from 10nm to 5nm to reduce Fura-2 bleaching during longer recordings.  
In order to ensure mitochondrial Ca
2+ uptake was blocked throughout the 
cell  the  X-Rhod-1  fluorescence  from  several  different  peripheral  ROIs  were 
selected  within  individual  cells.  Figure  6.8  shows  that  the  mitochondrial  Ca
2+ 
uptake  produced  following  stimulation  with  1µM  histamine  is  inhibited  in  all 
selected ROIs (orange, green and blue trace) in a single HUVEC after treatment 
with the inhibitors for 10min.  Together this data suggests that mitochondrial Ca
2+ 
uptake  was  efficiently  blocked  under  the  conditions  used.  Occasionally  the 
application of inhibitors alone induced some [Ca
2+]i changes (see Figure 6.7B), 
these are discussed in more detail below. 
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Figure 6.6 WPBs undergo pH changes due to FCCP action 
A  single  proregion-mEGFP  nucleofected  HUVEC  recorded  at  20frames/s 
(6.66frames/s  per  wavelength)  perfused  with  1µM  FCCP  and  2.5µg/ml 
oligomycin  and  stimulated  with  1µM  histamine.  A  Background  subtracted 
fluorescent traces of Fura-2 (black) and the first latency distribution of the WPB 
fusion events presented in a histogram. B The normalised mEGFP fluorescence of 
a single WPB fusion event (arrow from A) averaged by 2 and C the corresponding 
intra-WPB pH obtained using the equation described in [1] from the mEGFP 
fluorescence.  The  normalised  mEGFP  trace  slowly  increases  in  fluorescence 
when exposed to FCCP and it reaches a plateau before undergoing exocytosis. 
The mean pHWPB calculated between the two black asterisks is pH6.0. D shows the 
normalised  mEGFP  fluorescence  on  an  expanded  timescale  indicated  by  the 
arrows  from  C.  The  montage  images  of  the  individual  WPB  are  shown  in  E 
averaged by 2 and smoothed. The numbers on the single frames of the montage 
correspond to the time-points indicated with numbered arrows on the fluorescent 
time course in B and the red asterisk indicates the frame of fusion corresponding 
to the time-point marked similarly on the expanded time-scale in D. 
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Figure 6.7 FCCP inhibits mitochondrial Ca
2+ uptake 
Single HUVEC loaded with 0.5µM Fura-2 and 0.2µM X-rhod-1 were stimulated 
with 100µM histamine. The panel on the left shows the un-treated control whereas 
the middle and right panels were treated with 1µM FCCP and 2.5µg/ml for 1 and 
10min respectively before histamine stimulation. The black traces represent the 
background  subtracted  Fura-2  ratio  and  the  red  traces  the  background  and 
cytosol  subtracted  X-Rhod-1  changes.  The  mitochondrial  Ca
2+
  uptake  was 
inhibited in the presence of the drugs.  
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Figure 6.8 The inhibitors prevent mitochondrial Ca
2+ uptake throughout the 
cell network of mitochondria 
Upper panel shows a single HUVEC loaded with 0.2µM X-rhod-1 and 0.5µM 
Fura-2  and  incubated  in  1µM  FCCP  and  2.5µg/ml  oligomycin  10min  before 
stimulation with 1µM histamine. The lower panel shows the Fura-2 fluorescent 
changes  (black  trace)  and  the  background  and  cytosol  subtracted  X-rhod-1 
measurements from the corresponding ROIs shown in the HUVEC picture above 
(orange, blue and green). 224 
6.5  Measuring  [Ca
2+]m,  [Ca
2+]i  and  secretion  under  conditions  of 
mitochondrial Ca
2+ uptake inhibition 
6.5.1  Effect  of  Inhibition  of  mitochondrial  Ca
2+  uptake  on  histamine 
evoked increases in [Ca
2+]i  
The mean Fura-2 ratio change obtained with either 1 or 100µM histamine 
from a number of cells was compared between controls and inhibitor treated cells 
pre-incubated  for  either  1  or  10min.  Figure  6.9  summaries  the  effect  of  the 
inhibitors on the amplitude of the Fura-2 ratio evoked by histamine. For both 1 
and 100µM histamine the amplitude of the Fura-2 ratio change was significantly 
decreased for 10min pre-incubation time in inhibitors.  
6.5.2  Effect  of  Inhibition  of  mitochondrial  Ca
2+  uptake  on  histamine 
evoked WPB exocytosis  
In  ~50%  of  the  cases  application  of  the  inhibitors  alone  caused  a  small 
[Ca
2+]i  change  usually  in  the  form  of  a  brief  [Ca
2+]i  spike  (Figure  6.7  middle 
panel). This was associated with a limited exocytotic response comprising at most 
~5.0±3.4%  (mean±sd,  n=10)  of  fluorescent  WPBs  over  a  10min  pre-treatment 
period. This effect of the inhibitors would reduce slightly the population of WPBs 
available for subsequent release by histamine.  225 
 
Figure 6.9 Presence of inhibitors decreases the histamine induced [Ca
2+]i 
changes 
Pooled ∆(355/380nm) amplitudes of stimulated Fura-2 fluorescent changes with 1 
(upper panel) and 100µM (lower panel) histamine, for un-treated control cells 
and  cells  incubated  in  inhibitors  for  the  indicated  time  prior  to  stimulation 
(mean±sd; n=4-5 cells in each case) normalised to control. There is a significant 
decrease  in  stimulated  [Ca
2+]i  changes  when  pre-treated  with  inhibitors  for 
10min evoked with 1µM (p=0.03) and 100µM histamine (p=0.015). 226 
Figure 6.10 shows histograms of the first latency distributions of the WPB 
fusion events in control cells and cells stimulated with 1µM (A) or 100µM (B) 
histamine  after  1  or  10min  pre-incubation  with  the  inhibitors  to  partially  or 
completely block mitochondrial Ca
2+ uptake respectively. The kinetics of WPB 
exocytosis;  delays  from  the  histamine  evoked  [Ca
2+]i  rise  (D2)  (red  bars), 
maximal rates (blue bars) and the percentage of WPB degranulation (green bars) 
are summarised in the lower panels of Figure 6.10 A and B. Any exocytosis that 
occurred prior histamine stimulation, during pre-incubation in the inhibitors, is 
neglected in these calculations in order to selectively study stimulated exocytosis. 
Following inhibition of mitochondrial Ca
2+ uptake, there was a reduction in the 
extent of WPB exocytosis evoked by 1µM histamine for 10min inhibitors pre-
incubation (p=0.058) and a significant reduction of WPB exocytosis evoked by 
100µM  histamine  for  1  (p=0.015)  and  10min  (p=0.0014)  pre-incubation  in 
inhibitors.  
6.6  Discussion 
In  this  chapter  conditions  for  measuring  [Ca
2+]i,  [Ca
2+]m  and  exocytosis 
simultaneously, and conditions for efficiently blocking mitochondrial Ca
2+ uptake 
have been determined. Preliminary data from the optical imaging assay suggests a 
decrease of the extent of histamine-evoked WPB exocytosis when mitochondrial 
Ca
2+ uptake was disrupted.  227 
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Figure 6.10 Summaries kinetics of stimulated WPB exocytosis during 
mitochondrial Ca
2+ uptake inhibition. 
Summaries  the  kinetics  of  WPB  exocytosis  of  proregion-mEGFP  nucleofected 
HUVEC co-loaded with Fura-2 and X-Rhod-1. The upper panels in A and B show 
the first latency distributions of the WPB fusion events (bin width 1s) for control 
cells (left panels) and cells perfused with  1µM FCCP and 2.5µg/ml oligomycin 
for  1  (middle  panels)  or  10min  (right  panels)  prior  to  1µM  (upper  panel)  or 
100µM  (lower  panel)  histamine  stimulation.  The  lower  panels  in  A  and  B 
summary the corresponding delays (D2) from the histamine-evoked [Ca
2+]i rise to 
WPB  exocytosis  (red  bars),  the  maximal  rates  of  histamine-evoked  WPB 
exocytosis  (blue  bars)  and  the  percentage  of  histamine-evoked  WPB 
degranulation (green bars). In each case the data sets were pooled from 6-16 
cells and represent 100-220 WPBs plotted as mean±se.  
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6.6.1  Using X-Rhod-1 to measure mitochondrial Ca
2+ 
X-Rhod-1  is  a  rhodamine-based  mitochondrial  Ca
2+  indicator,  and  was 
chosen  for  these  studies  because  it  has  a  low  affinity  for  Ca
2+  (Kd=700nm) 
compared to other members of this family of indicators. The lower affinity would 
help to limit buffering of [Ca
2+]m allowing changes in [Ca
2+]m to be more reliably 
tracked.  Moreover  its  spectral  properties  allowed  simultaneous  measurements 
with EGFP and Fura-2 (see X-Rhod-1 spectrum wavelengths in Methods Figure 
2.15). The main disadvantage of using X-Rhod-1 is that it lacks a spectral shift 
upon Ca
2+ binding, precluding ratiometric measurements. Thus the absolute X-
Rhod-1 fluorescence change depends on the amount of dye present in different 
regions of the mitochondrial network, and the thickness of mitochondria. X-Rhod-
1 efficiently enters mitochondria (Figure 2.16), and by background subtraction 
from  adjacent  regions  of  cytosol,  the  [Ca
2+]m  changes  could  be  measured 
independently of [Ca
2+]i changes (Figure 6.3). Using mito-EGFP or mitotracker 
green it was shown that changes in X-Rhod-1 fluorescence were unlikely to be 
due  to  artefacts  such  as  movement  or  volume  changes  (Figure  6.2)  providing 
further evidence that the signals seen reflect changes in [Ca
2+]m. FCCP inhibited  
these [Ca
2+]m changes during agonist stimulation (Figure 6.7). 
6.6.2  Mitochondrial Ca
2+ uptake during histamine action in HUVEC 
The  threshold  for  mitochondrial  Ca
2+  uptake  is  estimated  to  be  ~300nM 
[544-546], with a half maximal (EC50) activation of the uniporter at 10-20µM 
[698]. This is well within the range of [Ca
2+]i elevations evoked by histamine and 
thrombin in HUVEC [97, 103, 105]. During stimulation with histamine, changes 
in [Ca
2+]m  occurred with a distinctive  time-course. The kinetics of the increase in 230 
[Ca
2+]m comprised a delay after the [Ca
2+]i increase, followed by a slow rise to a 
maintained plateau. In most cases the increase in [Ca
2+]m persisted after the [Ca
2+]i 
increase  had  declined  to  pre-stimulated  levels.  Similar  kinetics  for  changes  in 
[Ca
2+]m have been previously observed in a variety of cell types including HeLa 
cells [550], hepatocytes [563], epithelial cells [554], neurons [546, 553], smooth 
muscle cells [555] and endothelial cells [549]. Increases in [Ca
2+]m  have been 
shown to be  dependent on stimulus strength [546], and this was also the case 
here,  with  [Ca
2+]m  changes  increasing  in  amplitude  above  0.3µM  histamine 
(Figure 6.4).  
The sustained [Ca
2+]m signal during stimulation with IP3-elevating agonists 
is thought to reflect the high buffering capacity of mitochondria [552], enabling 
accumulation of large Ca
2+ loads (up to 36mM) without damage [524]. The main 
[Ca
2+]m buffer is thought to be phosphate, which forms insoluble Ca
2+-phosphate 
complexes within the mitochondrial matrix [546, 584, 699, 700].  
6.6.3  Possible effects of mitochondrial inhibitors on cellular ATP levels 
The movement of cellular organelles by molecular motors within the cell, 
requires energy in the form of ATP (reviewed [701]). Complete or partial ATP 
depletion could have consequences on Ca
2+ signalling and the secretory kinetics. 
Although  not  quantified  here,  observation  of  the  motility  of  mito-EGFP 
expressing  mitochondria  or  proregion-EGFP  labelled  WPBs,  suggested  that 
transport  was  not  severely  altered  by  exposure  of  the  cells  to  FCCP  and 
oligomycin, for up to 15min. This suggests that these inhibitors did not cause a 
severe depletion of cytosolic ATP levels during the experiments. A verification of 231 
this would be by direct measurements of cytosolic ATP concentrations; however 
this was not carried out here.  
6.6.4  FCCP and the fluorescence of WPB targeted EGFP 
The fluorescence of EGFP-tagged vesicles and EGFP in the mitochondrial 
matrix  increased  upon  FCCP  exposure  indicating  a  rise  in  pH  within  these 
compartments  (sections  6.4.2  and  6.4.3).  This  provided  a  useful  additional 
indication  that  the  FCCP  had  induced  proton  translocation  across  cellular 
membranes in these experiments. The acidic pHWPB is thought to facilitate protein 
aggregation during granule formation and is important for formation of proregion 
and  vWF  as  tubules  that  are  responsible  for  the  elongated  WPB  shape  [334]. 
Increased pH causes the proregion and vWF to dissociate and collapses the WPB 
shape [35]. FCCP action on the pHWPB did not appear to affect the WPB shape; 
the likely reason for this is that the increases in pHWPB seen (up to ~pH6.0) was 
still  less  than  that  within  the  TGN  (~pH  6.4)  where  vWF  and  proregion  are 
thought  to  associate  [26].    Despite  the  increase  in  pHWPB  the  changes  in 
fluorescence upon WPB fusion were still clearly evident after FCCP treatment and 
could be used to mark the point of WPB fusion.  
6.6.5  FCCP–induced [Ca
2+]i rises 
In ~50% of single cells studied exposure to FCCP and oligomycin alone 
caused a small rise in cytosolic Ca
2+ levels. An example of such experiment is 
shown in Figure 6.11B. Why might this be? This phenomenon has been observed 
in a variety of other cell types  and interpreted as leak of Ca
2+ from mitochondria 
via the mitochondrial Na
+/Ca
2+ exchanger (NCE) [562, 702-706]. For instance, in 
mouse skeletal muscle fibers FCCP caused a continuous increase in basal [Ca
2+]i 232 
independent  of  external  Ca
2+  [562]  whereas  in  endothelial  cells  uncouplers 
showed no effect on the steady state [Ca
2+]i [549]. Other pathways by which Ca
2+ 
may exit mitochondrial during FCCP action is by transient spontaneous openings 
of the mitochondrial permeability transition pore (PTPm) [707]. 
Alternatively  the  small  FCCP-induced  [Ca
2+]i  increases  may  arise  from 
extracellular  Ca
2+  entry.  FCCP  is  reported  to  reduce  cytosolic  pH  [708].  The 
molecule  responsible  for  the  control  of  intracellular  pH  in  EC  is  the  Na
+/H
+ 
exchanger suptype 1 (NHE) [709, 710]. Extrusion of intracellular H
+ by the NHE 
and import of Na
+ is coupled to the activity of the Na
+/Ca
2+ exchanger (NCE) 
[305, 711]. The direction of both exchangers depends on the ion gradient across 
the PM. It has been suggested that during FCCP action, NHE activity is increased 
to extrude excess protons carried inside the cell by FCCP, leading to an increase 
of intracellular Na
+. This in turn leads to an increase in the NCE activity leading 
to an excess influx of extracellular Ca
2+. This hypothesis is consistent with work 
on neurons that showed that FCCP induced an intracellular Na
+ rise [712]. To 
investigate  the  origin  of  the  increased  [Ca
2+]i  seen  during  exposure  to  the 
inhibitors  requires  further  experiments.  The  reason  for  only  50%  of  cells 
responding  in  this  way  is  not  clear,  however  it  may  be  due  to  the  cellular 
heterogeneity in ion channels and [Ca 
2+]i responses of EC [713]. 
6.6.6  FCCP effects on histamine-evoked Ca
2+ signalling.  
The  imaging  experiments  reveal  a  time-dependent  decrease  in  histamine 
evoked [Ca
2+]i responses after pre-incubation in FCCP (Figure 6.9). Inhibition of 
mitochondrial  Ca
2+  uptake  is  reported  to  have  differential  effects  on  [Ca
2+]i 
responses  in  different  cell  types  [557].  The  influence  of  mitochondrial  Ca
2+ 233 
buffering on cytosolic Ca
2+ responses is thought to be dependent on the position 
of  the  mitochondria.  Mitochondrial  Ca
2+  uptake  near  IP3  channels  on  the  ER 
(<700nm) [714] is thought to influence the initial kinetics of the [Ca
2+]i response, 
whereas mitochondrial Ca
2+ uptake in the subplasmallemal regions influences the 
sustained and declining phase of  [Ca
2+]i responses [573].  
At the ER, activation of IP3-gated Ca
2+ channels is facilitated by low local 
Ca
2+ levels and inhibited by high Ca
2+ levels [268, 273, 715, 716]. The threshold 
for activation and inhibition of the IP3R may vary from one cell type to another 
and may contribute to periodic fluctuations in cytosolic Ca
2+ signals such as Ca
2+ 
oscillations  that  are  commonly  observed  in  many  non-excitable  cells  [267]. 
Removal of mitochondrial [Ca
2+]i buffering by uncouplers can lead to an increase 
in agonist-evoked Ca
2+ release from the ER such as is seen in hepatocytes [563], 
pituitary gonadotropes [552] and chromaffin cells [578]; or a decrease in agonist-
evoked Ca
2+ release such as in HeLa cells [564, 717]. These different effects may 
arise due to a two-fold role of mitochondrial Ca
2+ buffering on Ca
2+ signalling 
mediated via the IP3R receptor [532]; local Ca
2+ buffering close to the IP3R can 
both suppress or increase IP3R activation. Suppression of Ca
2+ release may arise 
because Ca
2+ is required for the initial activation of the IP3R. By buffering Ca
2+ to 
very low levels the mitochondria can prevent or reduce the sensitivity of the IP3R 
to activation by IP3.  In contrast an enhanced [Ca
2+]i response may arise if local 
buffering interferes with the mechanism of Ca
2+-inhibition of the IP3R following 
receptor activation.   
At  the  subplasmallemal  level,  mitochondria  are  thought  to  facilitate 
capacitative-Ca
2+-entry by generating low [Ca
2+]i microdomains and directing in 
this way the influx of extracellular Ca
2+ towards the ER for refilling [229, 570, 234 
572, 573]. Depolarised mitochondria may slow the recovery of ER Ca
2+ levels and 
thus affect the amplitude and duration of the agonist-evoked [Ca
2+]i rises [573].  
6.6.7  FCCP decreases stimulated WPB exocytosis 
The  imaging  experiments  described  here  show  a  decrease  in  histamine-
evoked  WPB  exocytosis  following  inhibition  of  mitochondrial  Ca
2+  uptake, 
consistent with the decreased histamine-evoked [Ca
2+]i response. Whether ∆Ψm 
collapse has any effect on the molecular machinery of WPB exocytosis is not 
clear.  Collapsing ∆Ψm increases mitochondrial ROS production [515] including 
H2O2 which is thought to inhibit the ATPase activity of NSF and consequently 
inhibit WPB fusion [422] (see 1.8.1 in Introduction for a review of the fusion 
machinery).  Low  levels  of  ROS  production  have  been  implicated  as 
vasoprotective,  whereas  excess  levels  may  contribute  to  the  pathogenesis  of 
vascular disease in diabetes, hypertension and atherosclerosis [589].  
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Figure 6.11 Perfusion of inhibitors alone induced exocytosis which correlated to 
[Ca
2+]i rises 
Fura-2  ratio  changes  (black  trace)  and  number  of  WPB  fusion  events  (green 
histograms) of proregion-mEGFP expressing cells perfused with 1µM FCCP and 
2.5µg/ml oligomycin for the duration of the recordings and stimulated with 1 or 
100µM histamine as indicated with the arrow. A. Shows a single cell example where 
the inhibitors alone did not elicit a change in the Fura-2 ratio fluorescence or WPB 
exocytosis. B Example where the inhibitors alone elicited an increase in the Fura-2 
ratio fluorescence in the form of a slow rise and WPB exocytosis. 
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7  Ca
2+ Oscillations and WPB exocytosis 
in human endothelial cells 
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7.1  Introduction 
The  agonist-evoked  [Ca
2+]i  response  in  ECs  is  biphasic  consisting  of  an 
initial transient response due to Ca
2+ release from internal stores and a second 
phase, dependent on extracellular Ca
2+ that can be prolonged in the continued 
presence of an agonist [152, 268]. In Chapter 4 and 5 the early kinetics of WPB 
and non-WPB exocytosis were described, that result largely from the initial Ca
2+-
release from the internal stores. During more prolonged exposure to physiological 
agonists  the  patterns  of  Ca
2+  signalling  can  take  a  number  of  different  forms, 
either  a  sustained  [Ca
2+]i  plateau,  a  return  to  basal  [Ca
2+]i  levels,  or  more 
commonly  [Ca
2+]i  oscillations  [152,  215].  [Ca
2+]i  oscillations  can  regulate 
exocytosis in electrically excitable secretory cells [281-283, 718]. In non-excitable 
cells, early work demonstrated [Ca
2+]i oscillations in hepatocytes [227] and later 
on  in  a  variety  of  cell  types  shown  to  regulate  different  cellular  processes 
including  glycogenolysis  in  hepatocytes  [227]  and  cell  contraction  in  smooth 
muscle  cells  [288].  In  endothelial  cells  (EC)  [Ca
2+]i  oscillations,  are  typically 
induced  by  low  to  medium  concentrations  of  [Ca
2+]i-elevating  agents  such  as 
bradykinin [216, 266], histamine [152], ATP [100, 215]  and thrombin [183]. The 
function of [Ca
2+]i oscillations in EC is not clear however it has previously been 
suggested that  secretory events driven by extracellular Ca
2+, such as PGI2, NO 
and endothelin may be regulated by [Ca
2+]i oscillations [289]. A possible role of 
[Ca
2+]i oscillations in the release of secretory granules such as the WPB and the 
non-WPB population has not been carefully analysed. While a large maintained 
increase in Ca
2+ drives WPB exocytosis strongly, brief transient [Ca
2+]i elevations 
may constitute a mechanism to limit WPB exocytosis, either to help maintain the 
secretory  response  for  longer  periods  of  time  in  the  face  of  a  limited  pool  of 238 
secretory granules, or to limit WPB exocytosis altogether. The latter might help to 
prevent excessive release of vWF under conditions of mild stimulation and help 
prevent unwanted haemostasis. In one study an attempt to correlate vWF secretion 
from populations of HUVEC, with single cell measurements from cells within 
those populations, was interpreted as [Ca
2+]i spikes having little role in driving 
WPB exocytosis [183].  
Parameters of [Ca
2+]i oscillations such as spike amplitude, frequency and 
duration may be a mechanism for regulating multiple signals for various cellular 
processes such as observed in other systems [291-294]. In endothelial cells, as in 
many  other  cell  types,  the  frequency  of  [Ca
2+]i  oscillations  is  modulated  by 
agonist  concentration  suggesting  a  possible  role  for  frequency  modulation  of 
Ca
2+-dependent processes [100, 152, 183, 215, 266].  
The aim of this chapter was to use direct optical observation of WPB fusion 
events  to  try  and  determine  whether  [Ca
2+]i  oscillations  might  play  a  role  in 
regulating WPB exocytosis. This was carried out by simultaneously monitoring 
[Ca
2+]i and exocytosis, induced by low to medium concentrations of histamine. 
Technical difficulties in the end meant that a definitive analysis of the relationship 
between [Ca
2+]i spike frequency and WPB exocytosis was not achieved, however, 
conditions were identified that might allow such an analysis in the future. 
 
 
 239 
7.2  Histamine evoked Ca
2+-oscillations in cultured HUVEC 
To observe the patterns of Ca
2+ signalling in HUVEC, Fura-2 loaded, non-
transfected  cells  were  imaged  during  exposure  to  different  concentrations  of 
histamine using the imaging setup described in chapter 4 (Figure 4.1). The cells 
were  sequentially  perfused  with  physiological  saline  containing  increasing 
concentrations of histamine, with ~3min intervals between each exposure during 
which  the  cells  were  perfused  with  stimulus  free  saline  to  recover  the  [Ca
2+]i 
levels.  Examples of [Ca
2+]i responses from three single cells to histamine are 
shown in Figure 7.1 (0.3, 1, 3 and 10µM for A and B and PS, 0.03, 0.1 and 0.3 for 
C). The arrows indicate the application (upwards arrow) and removal (downwards 
arrow) of histamine by perfusion.  
At  0.3µM  histamine  77%  of  cells  studied  (n=70)  exhibited  [Ca
2+]i 
oscillations; 13% showed a sustained response and 10% showed a single transient 
[Ca
2+]i spike that returned to pre-stimulated [Ca
2+]i levels. At 1µM histamine 49% 
of cells (n=70) exhibited [Ca
2+]i oscillations and the remaining 51% exhibited a 
sustained  [Ca
2+]i  response.  The  proportions  of  cells  showing  [Ca
2+]i  spikes 
decreased  further  as  the  histamine  concentration  increased,  reducing  to  26% 
(n=70) at 3µM and 10% at 10µM histamine (n=70). In each case the remaining 
fraction of cells showed a sustained [Ca
2+]i plateau. At 1 and 3µM histamine the 
[Ca
2+]i oscillations were often fast and superimposed on an elevated [Ca
2+]i level; 
for  example  see  graphs  in  Figure  7.1A  at  3µM  histamine  and  7.1B  at  1µM 
histamine.  
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Figure 7.1 [Ca
2+]i patterns generated by continuous stimulation with increasing 
histamine concentrations within individual HUVEC 
Examples A, B and C show individual non-nucleofected cells imaged with a 40 
times objective, perfused with increasing concentrations of histamine to observe 
the [Ca
2+]i responses. A and B are examples of single cells perfused with 0.3µM, 
1µM, 3µM and 10µM histamine as indicated, whereas C shows an example of a 
cell  perfused  with  Physiological  Saline  with  no  stimulus,  0.03µM,  0.1µM  and 
0.3µM Histamine as indicated. Between stimulations the cells were washed with 
no additive physiological saline for a few minutes to bring the [Ca
2+]i levels back 
to  pre-stimulated  levels.  Spikes  were  seen  at  lower  concentrations,  whereas 
increased concentrations of histamine evoked higher frequency spikes and/or a 
sustained  plateau.    Different  patterns  of  [Ca
2+]i  oscillations  were  observed  in 
different cells. The arrows indicate activation (upwards arrow) and inactivation 
(downwards arrow) of perfusion.  
C 242 
Histamine-induced [Ca
2+]i responses recorded by Fura-2 showed a degree of 
concentration dependence as previously observed [100, 152, 183, 215, 266] and 
the individual cell [Ca
2+]i responses were very heterogeneous. This may reflect a 
combination of the source of cells, culture conditions and experimental conditions 
used. 
7.3  Extracellular  Ca
2+-dependence  of  the  prolonged  histamine-evoked 
[Ca
2+]i phase  
The [Ca
2+]i response is biphasic, consisting of an initial phase that reflects 
release of Ca
2+ from internal stores and  a second extracellular Ca
2+-dependent 
phase [100]. To confirm this, experiments were performed at 0mM extracellular 
Ca
2+ in the presence of 0.2mM EGTA, a Ca
2+ chaletor (Figure 7.2). In the absence 
of extracellular Ca
2+ the initial Ca
2+ spike was mainly unaffected however, the 
maintained phase of the [Ca
2+]i response was absent. 
To investigate the contribution of extracellular Ca
2+ in defining the time-
course  of  WPB  exocytosis,  proregion-mEGFP  expressing  HUVEC  were 
stimulated with 30µM histamine in the presence or absence of extracellular Ca
2+ 
(Figure 7.3).  In the absence of external Ca
2+ the delays D1, D2, and the maximal 
rates  of  WPB  exocytosis  were  not  significantly  different  from  those  in  the 
presence of external Ca
2+, suggesting removal of external Ca
2+ had little effect on 
the initial kinetics of WPB exocytosis consistent with the initial burst of secretion 
being  due  primarily  to  release  of  Ca
2+  from  internal  stores.  However,  in  the 
absence of external Ca
2+, following the initial burst of exocytosis, there was a 
more  rapid  termination  (after  approximately  30s)  and  a  reduced  extent  of  the 
secretory response (almost 60% reduction in exocytosis), demonstrating that there 243 
is some dependence on external Ca
2+ for the low level of WPB fusion seen at 
longer times.  
The observation that WPB exocytosis occurred during the brief transient 
rise in Ca
2+ observed in the absence of extracellular Ca
2+ suggested that WPB 
fusion  might  occur  during  Ca
2+  spikes  seen  at  lower  agonist  concentrations. 
Although the HUVEC used here responded to low histamine concentrations with 
[Ca
2+]i oscillations, the patterns of [Ca
2+]i oscillations were very heterogeneous. In 
order to try and study the relationship between Ca
2+ spikes (in particular their 
frequency) and WPB fusion, we tried two separate experimental approaches, the 
first  was  to  simply  observe  different  patterns  of  Ca
2+  signalling  and  to  try  to 
correlate WPB exocytosis with Ca
2+ spiking patterns in single cells. The second 
was to develop a system in which we could simulate Ca
2+ spiking patterns in such 
a way that the inter spike interval could be controlled in a systematic fashion. 
Together it was hoped that these approaches might help shed light on the role, if 
any,  of  Ca
2+  spikes  and  in  particular  the  frequency  of  Ca
2+  spiking  in  the 
regulation of WPB exocytosis. The latter approach was attempted first and will be 
described next. Technical difficulties with both approaches meant that in the end 
few hard conclusions could be drawn from these studies.  
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Figure 7.2 The sustained phase of the histamine-evoked [Ca
2+]i response 
depends on extracellular Ca
2+ 
The  Fura-2  traces  from  two  single  HUVEC  stimulated  with  histamine  in  the 
presence (+Ca; black trace) and absence (-Ca; grey trace) of extracellular Ca
2+.  
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Figure 7.3 Extracellular Ca
2+-dependence of histamine-evoked WPB exocytosis. 
Upper panels in A and B show examples of the changes in Fura-2 fluorescence 
ratio  (355nm/380nm)  (solid  traces)  and  the  frequency  of  WPB  fusion  (solid 
histograms,  bin  width  1s)  evoked  by  30µM  histamine  in  the  presence  (A)  or 
absence (B; plus 0.2mM EGTA) of 1.8mM external Ca
2+  in single HUVEC. The 
Fura-2 traces were offset so that the increase in [Ca
2+]i occurred at time=0. The 
lower panels in A (n=637 WPB) and B (n=232 WPB) summaries the frequency of 
WPB fusion determined from the rise in [Ca
2+]i (2s bin widths) for 28 cells in 
each case. 
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7.4  Simulating Ca
2+ spikes with well defined intervals by controlled puff 
application of histamine  
In order to study the relationship between Ca
2+ spikes (in particular their 
frequency)  and  WPB  fusion  in  intact  cells,  a  system  was  developed  in  which 
transient [Ca
2+]i elevations, mimicking Ca
2+ oscillations in their size and shape, 
could be generated with well defined intervals in different cells. To do this [Ca
2+]i 
spikes were produced by brief periodic application of a [Ca
2+]i-raising agonist by 
a puffer micropipette placed close to the cell. Precise timing for the activation of 
the  puffer  pipette  was  controlled  from  within  WinFluor  using  the  stimulus 
protocol editor (http://spider.science.strath.ac.uk/sipbs/software_imaging.htm). 
Initially  ionomycin  was  used,  first  because  its  action  is  reported  to  be 
readily  reversible  on  removal  (by  perfusion)  and  second,  because  it  bypasses 
hormone signalling pathways and thus its use could avoid complications such as 
receptor  desensitization  that  might  arise  during  hormone  action.  Figure  7.4A 
shows  the  average  of  12  Ca
2+  spikes  from  6  cells  normalised  to  the  peak 
amplitude induced during continuous perfusion of 0.3µM histamine onto a single 
un-transfected  HUVEC  (black  trace).  This  average  time-course  was  used  as  a 
‘reference’  waveform  for  a  typical  Ca
2+  spike  for  comparison  with  a  typical 
averaged  (4  spikes)  time-course  for  the  Ca
2+  spike  produced  by  a  2s  puff 
application of 1µM ionomycin (on a proregion-mEGFP expressing HUVEC (red 
trace)). Ionomycin produced Ca
2+ spikes of longer duration (about 70s) than the 
ones seen with low agonist concentrations (about 20s), even when brief periods of 
puff  application  were  used  (2s)  under  flow  conditions.  As  a  consequence  this 
secretagogue was abandoned. 247 
We then tried histamine although as mentioned above this has the possible 
drawback  of  being  susceptible  to  processes  such  as  desensitization  during 
repeated puff application. Different concentrations of histamine (0.3-3µM) were 
used  along  with  different  durations  of  puff  application  in  order  to  identify 
conditions that would elicit a transient Ca
2+ spike of similar amplitude and time-
course to the ‘reference’ [Ca
2+]i spike (Figure 7.4A). Puff application of 0.3µM 
histamine for 2s to proregion expressing cells generated Ca
2+ spikes of amplitudes 
typically  lower  than  the  ‘reference’  [Ca
2+]i  spike  (data  not  shown).  Higher 
concentrations, 1µM and 3µM histamine were then used. Figure 7.4B shows the 
comparison between the reference Ca
2+ spike and a typical Ca
2+ spike produced 
by a 10s puff application of 3µM histamine (on a proregion-mEGFP expressing 
HUVEC  (red  trace)).  Application  of  3µM  histamine  for  10s  generated  Ca
2+ 
transients of longer duration than the reference Ca
2+ spike, however, a shorter 
period of application, 2s, did produce transient Ca
2+ increases with a similar time-
course to the reference spike (Figure 7.4C). This condition, 2s puff duration of 
3µM  histamine,  was  then  used  in  subsequent  experiments  to  try  and  generate 
repetitive brief Ca
2+ spikes with well defined intervals in the range seen during 
continuous hormone action.  
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Figure 7.4 The time-course of Ca
2+ spikes produced by continuous or puff 
application of ionomycin or histamine 
The black trace in A, B and C is the average time-course of 12 typical Ca
2+ spikes 
from 6 un-transfected HUVEC perfused with 0.3µM histamine, normalised to the 
peak  amplitude  (reference  spike).  This  is  compared  to  the  average  Ca
2+ spike 
produced by 2s puff application of 1µM ionomycin (A; n=4 Ca
2+spikes, 1 cell); by 
10s puff application of 3µM histamine (B; n=4 Ca
2+ spikes, 1 cell) and by 2s puff 
application of 3µM histamine on a single cell (C; n=5 Ca
2+ spikes, 1 cell). The 
Ca
2+ spikes were normalized to the peak fluorescence level and offset so that the 
[Ca
2+]i increase occured at t=0.   
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Examples of 2s puff applications of 3µM histamine are shown in Figure 7.5. 
In this Figure [Ca
2+]i spikes produced during continuous application of histamine 
on un-transfected cells (spikes shown correspond to those produced after the first 
initial release of Ca
2+ from the internal store) are compared with those produced 
by 2s periodic application of histamine by  puffer pipette at 60, 120  and 180s 
intervals onto proregion-mEGFP expressing cells. This demonstrates that with the 
repetitive  puff  application  method,  Ca
2+  transients  can  be  produced  at  similar 
intervals  to  those  produced  during  continuous  hormone  action.  A  feature  in 
experiments  where  histamine  was  applied  by  puffer  was  a  decrease  in  the 
amplitude of the second and subsequent Ca
2+ spikes. This effect was independent 
of the histamine concentration used (Figure 7.5), and was seen in both proregion-
mEGFP expressing and un-transfected cells (Figure 7.6), suggesting the effect is 
unrelated  to  possible  perturbations  in  Ca
2+  signalling  due  to  expression  of 
proregion-mEGFP by Nucleofection.   
It is known that [Ca
2+]i spikes in cells perfused with agonists do change in 
amplitude; typically the first spike is larger than the second, however, subsequent 
spikes are often of similar amplitude [668]. This is shown in Figure 7.7 (black 
squares). Qualitatively, the behaviour of Ca
2+ spikes generated by puff application 
of histamine was similar, although the amplitude of second and subsequent spikes 
was  on  average  smaller  than  those  produced  during  continuous  perfusion  of 
histamine (Figure 7.7). 251 
 
Figure 7.5 Simulating [Ca
2+]i spiking patterns by puff application of hormone. 
Single  cell  representative  examples  of  the  normalised  Fura-2  ratio  changes 
produced by 0.3µM histamine perfused onto un-transfected HUVEC (left panels) 
and by 2s puff application of histamine (3µM for the middle panels and 0.3µM for 
the  right  panel)  onto  proregion-mEGFP  expressing  HUVEC  at  the  defined 
intervals indicated. Ca
2+ spikes shown for histamine perfusion (left panels) do not 
include the initial spike due to release of Ca
2+ from the internal stores.  
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Figure 7.6 Controlled puff application on un-transfected HUVEC is also 
subject to desensitization  
Two representative examples of Fura-2 ratio traces from un-transfected HUVEC 
stimulated with 1µM histamine at 2s puff applications at 60s (left panel) and 120s 
(right panel) intervals.  
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Figure 7.7 Controlled puff application causes a larger drop in the Ca
2+ spike 
amplitude between the initial and subsequent spikes than seen during perfusion 
with histamine 
The Fura-2 traces were normalised to the first spike and the peak amplitude of 
each spike is plotted for cells perfused with 0.3µM histamine (black square; n=9 
cells for spike1 and 2, n=7 for spike3, n=6 for spike4, n=5 for spike5, n=3 for 
spike 6 and n=1 for spike7 and 8); stimulated with controlled puff application of 
3µM histamine at 60s intervals (green triangle; n=15 for spike1-4, n=12 for spike 
5, n=8 for spike 6, n=5 for spike 7 and n=4 for spike8)  and at 120s intervals (red 
circles; n=13 for spike1-4, n=7 for spike 5 and n=4 for spike 6). 
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Having  established  that  puff  application  could  in  some  way  mimic  Ca
2+ 
spikes  produced  by  perfusion  of  histamine  while  allowing  control  over  the 
interval  between  the  spikes  we  next  tried  to  determine  if  WPB  exocytosis 
occurred during these artificial spikes. Figure 7.8 shows a representative example 
of the Fura-2 ratio change and the WPB exocytotic responses pooled from 12 cells 
stimulated with 3µM histamine at 2s puff applications with an interval of 60s (A) 
or  120s  (B),  typical  of  the  intervals  seen  with  continuous  perfusion  with  low 
histamine  concentrations  (e.g.  Figure  7.5).  There  was  a  consistent  burst  of 
secretion correlating with each Ca
2+ spike, however on average the number of 
WPB  fusion  events  decreased  with  successive  periods  of  application.  This  is 
quantified  for  these  experiments  in  panels  Aiii  and  Biii.  The  delay  between 
histamine arrival at the cell and the rise in [Ca
2+]i (D1) was relatively stable with 
repetitive applications of stimulus, as was the delay between the rise in [Ca
2+]i and 
exocytosis (D2), although there was a slight tendency for an increase in D2 with 
each  spike  (panels  Aiv  and  Biv);  an  effect  more  obvious  for  shorter  intervals 
between spikes (60s).  
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Figure 7.8 Pooled secretory responses to controlled puff application of 3µ µ µ µM 
histamine onto proregion-mEGFP nucleofected HUVEC 
Panel I of A and B show a representative example of the Fura-2 ratio changes 
induced by puffing 3µM histamine onto proregion-mEGFP nucleofected HUVEC 
for 2s at 60s intervals (A) and 120s intervals (B). Panel II in A and B show the 
first latency distributions of WPB exocytosis in histograms (bin width 2s) from 12 
cells  in  each  case.  The  pooled  secretory  events  were  offset  so  that  D2  was 
maintained for the representative Ca
2+ response in each case. Panel III in A and 
B  summary  the  pooled  percentage  of  WPB  degranulation  at  each  Ca
2+  spike 
calculated from the initial total number of granules for each cell (mean±se; n 
between 1-12 cells). Panel IV in A and B summary the delays between histamine 
arrival at the cell and the rise in [Ca
2+]i (D1; open circles) and between the rise 
in  [Ca
2+]i  and  exocytosis  (D2;  closed  circles)  for  each  spike  (mean  ±sd;  n 
between 1-12 cells for each value for D1 and D2 in A and B).  
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Although  the  numbers  of  WPBs  that  fused  during  each  Ca
2+  spike 
decreased, on average, with increasing spike number, it was noted that in 4 out of 
12 cells studied with an inter spike interval of 60s, the numbers of WPBs that 
fused during the second application of histamine increased, despite the amplitude 
of the second spike being smaller than the first. Figure 7.9 shows the fusion events 
observed in the 4 experiments with a representative Ca
2+ record as reference for 
the position of the Ca
2+ spikes produced. The delay from [Ca
2+]i rise to exocytosis 
(D2) decreased in the second spike in 2 examples and remained the same in 1 
example out of these 4. Also 3 out of 12 cells studied with a 120s inter spike 
interval were noted with the same WPB secretion kinetics (not shown). 
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Figure 7.9 Individual single cell examples that responded to controlled puff 
application of histamine with a larger exocytotic response during the second 
Ca
2+ spike than the first 
The first panel shows a representative example of the Fura-2 ratio evoked by 2s 
controlled puffs of 3µM histamine at 60s intervals. The panels beneath show the 
first latency distribution of the WPB exocytotic response of 4 individual cells. 
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7.5  Ca
2+ oscillations and WPB exocytosis in proregion-mEGFP expressing 
HUVEC during continuous exposure to histamine   
There  was  considerable  cell  to  cell  variability  in  the  [Ca
2+]i  responses 
produced during continuous exposure to histamine. Despite this an attempt was 
made to determine if WPB exocytosis occurs during Ca
2+ spikes. It was hoped 
that by analysing a sufficient number of cells it might be possible to correlate the 
kinetics  of  WPB  exocytosis  with  Ca
2+  spike  frequency.  This  proved  difficult 
because it turned out that proregion-mEGFP expressing cells were less likely to 
show Ca
2+ oscillation when perfused with low histamine concentrations, than non-
expressing cells. In addition, in the proregion-mEGFP expressing cells that did 
respond with [Ca
2+]i oscillations the shape of the Ca
2+ spikes appeared perturbed. 
Figure  7.10  shows  examples  of  single  Fura-2  loaded  cells  perfused  with 
increasing concentrations of histamine and illustrates the patterns of Ca
2+ spikes in 
a non-expressing cell with that of cells expressing proregion-mEGFP. The Ca
2+ 
spikes in the expressing cells appeared slower to rise, smaller in amplitude, and 
longer lasting than the spikes in non-expressing cells. The mean time-course of 
Ca
2+  spikes,  obtained  from  averaging  Ca
2+  spikes  from  proregion-mEGFP 
expressing cells is shown in Figure 7.11. 
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Figure 7.10 Nucleofected HUVEC respond with perturbed [Ca
2+]i oscillations 
when perfused with increasing histamine concentrations 
Fura-2  loaded  HUVEC  were  perfused  with  increasing  concentrations  of 
histamine; 0.3µM (left panels), 1µM (middle panels) and 3µM (right panels) and 
imaged using a 40 times objective. In each case the stimulus is applied 10-20s 
after the onset of the recordings and removed 10-20 seconds before the end of the 
recordings. The top panels represent an example of a single non-nucleofected 
HUVEC  whereas  the  two  below  panels  represent  examples  of  two  proregion-
mEGFP-expressing  HUVEC.  The  cells  were  washed  with  physiological  saline 
between stimulations to bring the [Ca
2+]i levels back to pre-stimulated levels. 
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Figure 7.11 [Ca
2+]i spikes of proregion-mEGFP nucleofected cells were of 
longer duration and have a slower rate of rise than  non-nucleofected cells 
Averaged Fura-2 ratio Ca
2+ spikes normalised to the peak amplitude and offset so 
that the Ca
2+ rise starts at t=0; for non-Nucleofected cells (black trace; n=12 
typical spikes from 6 cells) and for proregion-mEGFP nucleofected cells (green 
trace; n=7 typical spikes from 5 cells) perfused with 0.3µM histamine. The mean 
duration of the spikes was 22.4s for the non-Nucleofected cells and 60.6s for the 
expressing cells.  
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Why might expression of proregion-mEGFP affect the ability to generate 
Ca
2+  spikes  and  the  shape  of  Ca
2+  spikes?  It  could  be  that  the  procedure  of 
Nucleofection  itself  (irrespective  of  whether  a  protein  is  expressed  or  not) 
somehow disrupts the processes that determine the size and shape of Ca
2+ spikes 
as well as their generation and regulation. To test this HUVEC were nucleofected 
without  plasmid  DNA  (sham  Nucleofection)  and  24  hours  later  cells  were 
perfused with low concentrations of histamine and the ability to produce Ca
2+ 
spikes and the shape of the [Ca
2+]i spikes during oscillations was compared to un-
transfected cells. The [Ca
2+]i oscillations observed in either case were very similar 
(Figure 7.12A; upper panel), and the shape, amplitude and rate of rise were the 
same (Figure 7.12A; lower panel) suggesting that Nucleofection per se was not 
responsible for the changes seen when proregion-mEGFP was expressed.  
This data suggests that protein over-expression is most likely responsible for 
this effect, although it was not clear if this was a general phenomenon of protein 
over-expression or an effect specific for the expression of proteins that enter the 
lumen  of  the  secretory  pathway  (proregion-mEGFP).  To  test  whether  protein 
over-expression per se was responsible for the effects on [Ca
2+]i spikes, HUVEC 
were nucleofected with cytosolic-GFP (pEGFP-N1) (Figure 7.13), a construct that 
does not enter the secretory pathway. Cells expressing cytosolic GFP were able to 
generate [Ca
2+]i oscillations (Figure 7.12B; upper panel) and the shape of the Ca
2+ 
spikes was similar to those seen in sham or non-Nucleofected cells (Figure 7.12B; 
lower panel).  
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A  Non-Nucleofected  
Time (s) 265 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B  Non-Nucleofected  
Time (s) 266 
Figure 7.12 Sham nucleofection and pEGFP-N1 nucleofection do not perturb 
the shape of the Ca
2+ spikes  
The upper panel in A and B shows the Fura-2 ratio traces of single cell examples 
perfused with 0.3µM histamine for sham-nucleofected (A) or nucleofected with 
pEGFP-N1  (B)  cells  compared  to  un-transfected  cells  (top  trace).  The  lower 
panel in A and B shows the averaged Fura-2 ratio of Ca
2+ spikes normalised to 
the  peak  amplitude  and  offset  so  that  the  Ca
2+  rise  starts  at  t=0  for  non-
nucleofected  cells  in  A  and  B  (black  trace;  n=12  spikes  from  6  cells),  sham 
nucleofected  cells  in  A  (red  trace;  n=21  spikes  from  6  cells)  and  pEGFP-N1 
nucleofected  cells in B  (cyan trace; n=18 spikes from 11 cells) perfused with 
0.3µM histamine.  
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Figure 7.13 HUVEC expressing pEGFP-N1 construct 
HUVEC expressing pEGFP-N1 24hours post-nucleofection imaged with a 100x 
objective 
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Together  this  data  suggests  that  over  expression  of  protein  specifically 
within the lumen of the secretory pathway is most likely the cause of the changes 
in Ca
2+ spiking and the shape of Ca
2+ spikes in proregion-mEGFP nucleofected 
cells in response to low histamine concentrations.  The ER, in addition to being 
the first compartment into which soluble proteins destined for secretion enter, is 
also the main Ca
2+ store within the cell, the compartment from which Ca
2+ spikes 
arise [214, 215]. A large increase in protein expression within this compartment 
during expression of WPB targeted mEGFP constructs may well perturb the intra-
ER environment leading to changes in Ca
2+ storage or the processes that generate 
or regulate [Ca
2+]i spikes (see introduction 1.6.2).  
7.6  Ca
2+  oscillations  in  Cycloheximide  (CHX)  treated  proregion-mEGFP 
expressing HUVEC  
In  an  attempt  to  restore  Ca
2+  spike  shape  and  amplitude  in  proregion-
mEGFP  expressing  cells,  experiments  were  designed  to  try  and  reduce  the 
potential ER stress due to high levels of protein synthesis.  Initial efforts were 
made to circumvent this effect by choosing cells for experiments that had minimal 
ER fluorescent signal; for example at 72hours post-Nucleofection, a time-point 
when expression of the plasmid DNA was declining. These cells however, also 
showed  altered  kinetics  of  the  Ca
2+  signalling  (not  shown).  We  next  tried  to 
reduce protein load on the ER using a reversible inhibitor of protein synthesis, 
Cycloheximide  (CHX).  The  strategy  was  to  culture  cells  Nucleofected  with 
proregion-mEGFP for 48hours to allow WPB formation and accumulation, after 
which the cells were exposed to a short period of treatment with Cycloheximide 
(CHX).  Because WPBs are long-lived organelles it was hoped that a short period 
of  protein  synthesis  inhibition  would  not  significantly  affect  the  numbers  of 269 
fluorescent WPBs, but might permit the ER to recover from the stress of over-
expression of the plasmid construct allowing normal Ca
2+ signalling to resume. In 
order  to  minimise  the  effect  of  inhibition  of  protein  synthesis  on  cellular 
processes, including exocytosis, we aimed to treat the cells with CHX for as short 
a time as possible (a few hours, see below). However due to the reversible action 
of CHX, it was kept in solution for the duration of the experiments.  
To check that CHX treatment blocked synthesis of the EGFP-constructs in 
our cells, we monitored the loss of non-WPBs in cells expressing t-PA-EGFP. 
Non-WPBs are made continuously but not stored in these cells, so a block in the 
synthesis of the EGFP construct should result in a total (ER and granule) loss of 
EGFP fluorescence from the cells. We first tried 3-4hour periods of treatment with 
10µM CHX. HUVEC expressing t-PA-EGFP were treated with CHX 4hours post-
Nucleofection for a further 4hour period and then imaged. In sham (no-CHX) 
treated cells a strong ER signal and extensive t-PA-EGFP positive puncta were 
observed while in the CHX treated cells no granules could be seen and the ER 
EGFP signal was absent (Figure 7.14). This data indicated an effective block of 
synthesis of t-PA-EGFP at the CHX concentration and treatment period used.  
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Figure 7.14 Treatment of t-PA-EGFP expressing HUVEC with 10µ µ µ µM 
CHX for 4hours inhibited t-PA-EGFP protein synthesis 
HUVEC  were  Nucleofected  with  t-PA-EGFP  and  4hours  post  Nucleofection 
incubated  with  or  without  10µM  CHX  for  further  4hours  and  then  fixed  and 
imaged. 
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We next determined if this period of treatment altered Ca
2+ spiking or the 
shape of the Ca
2+ spikes in non-expressing cells. Under these conditions, CHX did 
not prevent Ca
2+ spikes evoked by perfusion of histamine and the shape of the 
Ca
2+ spikes was similar to un-transfected non-CHX treated cells (Figure 7.15). We 
next  checked  proregion-mEGFP  expressing  cells  treated  with  CHX;  here  the 
shape  and  time  course  of  the  averaged  Ca
2+  spike  evoked  by  perfusion  with 
histamine was restored close to that of control (non-Nucleofected) cells (Figure 
7.16).  
One  potential  problem  with  this  approach  is  that  inhibition  of  protein 
synthesis could have untoward effects on Ca
2+-driven processes, such as WPB 
exocytosis itself, by, for example, a reduction in the levels of some fast turning 
protein involved in transport, docking, Ca
2+-sensing or fusion of the organelle. To 
test if this were the case, the kinetics of fluorescent WPB exocytosis of proregion-
mEGFP expressing HUVEC treated with CHX for 3-4hours were determined and 
compared to untreated cells, stimulated with a medium (1µM) or high (100µM) 
histamine  concentration.  Figure  7.17  summaries  the  delay  from  [Ca
2+]i  rise  to 
exocytosis  (D2),  the  maximal  rates  of  exocytosis  and  extent  of  degranulation 
under  these  conditions  and  shows  that  3-4hour  treatment  with  CHX  had  no 
significant effect on the initial kinetics of histamine-evoked WPB exocytosis. 
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Figure 7.15 [Ca
2+]i responses between non-nucleofected untreated and CHX 
treated cells were similar 
Non- nucleofected single HUVEC were perfused with 0.3µM histamine to observe 
Ca
2+ signals. CHX un-treated cells (black) were compared to 10µM CHX treated 
cells (blue) for 3hours. The CHX was present in the physiological saline for the 
whole duration of the experiment. 
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Figure 7.16 [Ca
2+]i spike duration in CHX treated cells is similar to control 
The averaged [Ca
2+]i spike induced by perfusion of 0.3µM histamine normalised 
to  the  peak  amplitude  of  non-nucleofected  HUVEC  (black  trace;  12  spikes;  6 
cells); proregion-mEGFP nucleofected HUVEC (green trace; 7 spikes; 5 cells) 
and proregion-mEGFP nucleofected HUVEC treated with 10µM CHX for 4hours 
(blue trace; 5 spikes; 4 cells).  
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Figure 7.17 Kinetics of WPB exocytosis in control and CHX treated HUVEC 
Comparison  of  the  delay  (D2)  between  [Ca
2+]i  rise  and  the  onset  of  WPB 
exocytosis  (black  bars);  maximal  rates  of  WPB  exocytosis  (blue  bars)  and 
percentage of degranulation (green bars) between control (C) and CHX treated 
HUVEC  (10µM  for  3-4  hours)  stimulated  with  1µM  (top)  or  100µM  (bottom) 
histamine.  275 
Having  established  conditions  under  which  cells  expressing  proregion-
mEGFP produced Ca
2+ -spiking patterns similar to those seen in non-transfected 
cells we began to look at the relationship between the pattern of Ca
2+ spikes and 
WPB exocytosis. Due to time limitations I was not able to study this relationship 
in detail, however, examples of [Ca
2+]i and WPB fusion in response to continuous 
perfusion  with  0.3µM  histamine  in  single  CHX  treated  proregion-mEGFP 
expressing  HUVEC  are  shown  in  Figure  7.18.  These  examples  suggest  that 
exocytosis does occur during Ca
2+ spikes; however, not enough data was obtained 
to provide any conclusions about the role of Ca
2+ spikes and the frequency and 
kinetics of WPB exocytosis. 
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Figure 7.18 Examples of Ca
2+ oscillations and WPB exocytosis from CHX 
treated single HUVEC  
Fura-2 ratio traces and histograms of WPB first latency distributions (bin width 
1s) of single HUVEC expressing proregion-mEGFP treated with 10µM CHX for 
4hours  prior  to  perfusion  with  0.3µM  histamine.  CHX  was  present  in  the 
physiological saline at all times. Histamine perfusion was activated 20-50s after 
the  onset  of  recordings  and  inactivated  10-20s  before  the  termination  of 
recordings in each case.  
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7.7  Discussion 
7.7.1  [Ca
2+]i oscillations in non-nucleofected HUVEC 
Consistent with previous studies we showed that the second phase of the 
[Ca
2+]i response in HUVEC was dependent on extracellular Ca
2+ [100, 105, 152, 
183]  and  often  comprised  either  of  a  sustained  plateau  or  [Ca
2+]i  oscillations, 
particularly  at  low  to  medium  histamine  concentrations  (Figure  7.1).  The 
amplitude of the Ca
2+ spikes was variable from cell to cell, but typically, they 
were 70-80% of the initial spike amplitude within any individual cell (Figure 7.7), 
similar to that previously calculated using low affinity Ca
2+ indicators (Furaptra) 
in  EC  of  the  rat  aorta  [668].  The  frequency  of  Ca
2+  spikes  increased  with 
increasing hormone concentration, until at high concentrations they merged into a 
sustained  elevated  plateau,  sometimes  superimposed  with  fast  oscillations.  A 
correlation between agonist concentration and frequency has also been reported in 
epithelial cells [294] and hepatocytes [227, 719], suggesting a role for frequency 
encoded signalling in cell responses including exocytosis. Such a role may be 
potentially carried out by Ca
2+-modulated enzymes such as CaMKII [303, 720, 
721]  and  PKC  [266,  296]  whose  activity  is  shown  to  be  determined  by  Ca
2+ 
oscillation frequency and amplitude. PKC phosphorylation provides a  negative 
feedback for agonist-induced Ca
2+ rises [99, 116] or oscillations [215, 297] in EC. 
Moreover agonist-induced activation of PKC is thought to regulate WPB release 
by phosphorylating proteins of the fusion machinery [421, 722]. Thus CaMKII 
and PKC may be involved in decoding frequency modulated [Ca
2+]i signals to 
regulate cellular processes regulated by Ca
2+ such as exocytosis.  278 
There  was  a  marked  heterogeneity  in  the  pattern  of  [Ca
2+]i  oscillations 
between individual cells as previously noted [152, 723]. None-the-less individual 
cells  can  display  consistent  and  reproducible  [Ca
2+]i  responses  to  the  same 
stimulus  [719,  724].  This  suggests  that  each  cell  may  have  a  unique  "Ca
2+ 
signalling  fingerprint"  [724].  Factors  contributing  to  this  cellular  identity  may 
include the content of agonist receptors (HR1) [139] or IP3R [725]; the extent of 
cell-specific  [Ca
2+]i  buffering  by  cytosolic  Ca
2+-binding  proteins  [726,  727], 
mitochondria [534] or ER [313, 728]; the rate of [Ca
2+]i removal mechanisms by 
pumps  including  the  Na
+/Ca
2+  exchanger  and  the  Ca
2+-ATPase  on  the  plasma 
membrane [304, 312]; the rate of IP3R recovery from inhibition by local IP3 and 
Ca
2+ levels [267, 715] and finally the rate of Ca
2+ ER refilling by SERCA [307]. 
All  these  mechanisms  constitute  the  balance  between  release  of  Ca
2+  into  the 
cytosol  and  clearance  of  Ca
2+  from  the  cytosol  thought  to  shape  the  [Ca
2+]i 
signalling of individual cells. 
In these experiments [Ca
2+]i oscillations in confluent cultured HUVEC were 
typically asynchronous between cells, unless cells were in contact with each other, 
as  previously  shown  in  primary  cultures  of  human  EC  [152].  Synchronized 
oscillatory  activity  has  been  observed  in  cultured  confluent  monolayers  of 
endothelial cells stimulated with bradykinin [266, 729] or mechanical stimulation 
[278].  It  is  thought  that  synchronization  of  Ca
2+  responses  occurs  due  to 
intercellular coupling between confluent cells and depends on culture conditions 
[266]. It is possible that synchronous waves of oscillations across the endothelium 
in vivo would co-ordinate the cellular functions regulated by Ca
2+ (see review 
[730]). 279 
7.7.2  Simulated Ca
2+ spiking and WPB exocytosis  
Biochemical studies have shown that removal of extracellular Ca
2+ reduces 
vWF secretion [84]. Here, experiments in which extracellular Ca
2+ was removed 
confirmed  that  the  Ca
2+-dependent  component  is  responsible  for  a  significant 
fraction of the WPB exocytotic response (up to 60%), although the initial kinetics 
of fusion were determined almost solely by the initial pulse of Ca
2+ from the 
internal stores. This observation led us to investigate more  closely the  second 
phase of the Ca
2+ response, specifically Ca
2+ oscillations, and WPB exocytosis 
during this phase. 
The heterogeneity in [Ca
2+]i responses between individual HUVEC posed a 
problem  for  easy  analysis  of  the  relation  between  [Ca
2+]i  spike  frequency  and 
exocytosis; no two cells produce exactly the same frequency of Ca
2+ oscillations. 
One possible solution to this problem was to impose upon the cell patterns of Ca
2+ 
spiking with well defined frequencies. To do this a method of controlled repetitive 
application of a stimulus at defined intervals was developed. Initially ionomycin 
was used as this agonist bypasses receptors and signalling cascades by forming 
lipophilic complexes with Ca
2+ that act directly on the ER to export Ca
2+ in the 
cytosol [202, 203, 205]. In endothelial cells ionomycin is reported not to activate 
PLC and hence IP3 and DAG production [206]. Thus by bypassing the receptor 
transduction pathways it was hoped that the effect of ‘Ca
2+ spikes’ alone on WPB 
exocytosis could be investigated with fewer complications due to activation of 
other possible signalling cascades (DAG-PKC pathway etc).  It was hoped that 
brief repetitive applications of ionomycin would elicit [Ca
2+]i spikes of similar 
amplitude  and  with  similar  time-course  to  those  produced  during  responses  to 
hormone perfusion. However, the [Ca
2+]i spikes produced were slow to recover 280 
back to pre-stimulated levels and did not mimic the time-course of [Ca
2+]i spikes 
produced  by  hormone  action.  The  slower  decay  phase  for  ionomycin-evoked 
[Ca
2+]i responses is possibly two-fold; first although ionomycin can partition into 
and out of lipid membranes the kinetics of this process may be slow compared to 
the  time-scale  of  the  Ca
2+  spike,  resulting  in  prolonged  periods  of  Ca
2+ 
translocation  after  termination  of  the  puff  application.  Second,  ionomycin  acts 
directly on the internal stores, depleting them from Ca
2+ and this strongly activates 
capacitative Ca
2+ entry into the cell which might result in a tendency to sustain the 
[Ca
2+]i  increase  [206].  Because  of  this  practical  problem  with  ionomycin  this 
secretagogue was abandoned and histamine was used instead. 
Cells  exposed  to  repetitive  brief  applications  of  histamine  showed  brief 
[Ca
2+]i spikes. By adjusting the duration of exposure to histamine the kinetics of 
these  brief  [Ca
2+]i  spikes  were  made  similar  to  those  seen  during  continuous 
perfusion with histamine. A feature of these spikes was a decrease in amplitude 
with successive puff applications. Moreover the delay from agonist application to 
the onset of the [Ca
2+]i rise (D1) increased slightly after the initial spike both for 
short and long application intervals. Possible reasons for this phenomenon include 
desensitization  of  the  HR1  histamine  receptor.  This  has  been  observed  during 
prolonged (hours) or repetitive exposure to high histamine concentrations [147-
151,  695,  731],  however,  low  histamine  concentrations  can  elicit  [Ca
2+]i 
oscillations with a steady spike amplitude for long periods of time (30min) [152], 
well within the time-course of these experiments (10min). Perhaps the periodic 
nature of the application of histamine promoted HR1 desensitization more readily 
compared to what happens during continuous exposure to histamine. Despite the 
tendency  for  a  progressive  decrease  in  spike  amplitude  the  general  pattern 281 
produced by puff application was not entirely dissimilar to that seen with hormone 
action. 
During the first puff application of histamine cells underwent a brief pulse 
of exocytosis that terminated abruptly as the Ca
2+ declined. This was similar to 
what was seen in the absence of extracellular Ca
2+ (Figure 7.3). The percentage of 
WPBs that underwent degranulation was ~15-20% of the initial total number of 
fluorescent  WPBs  counted  in  the  cell.  During  second  and  subsequent  [Ca
2+]i 
spikes, the proportion of WPBs that were released decreased (measured as the % 
of the total number of WPBs at the start), both during short (60s) and long (120s) 
intervals  of  stimulations  (Figure  7.8iii).  The  mean  percentage  of  WPBs  that 
underwent degranulation over the duration of the experiments was~36.5% for the 
60s intervals (8-10 puff applications) and 31.3% for the 120s intervals (4-5 puff 
applications), both well within the capacity of the cell to release, as shown in 
chapter 4 (ionomycin stimulation gave 66.5% degranulation and 100µM histamine 
47.8%). This data suggests the cells were not depleted of the releasable pool of 
WPBs, but rather the decrease in the extent of exocytosis is due to some other 
phenomena. The most likely explanation is the decrease in spike amplitude with 
increasing  number  of  applications.  In  chapter  4  it  was  shown  that  there  is  a 
threshold for Ca
2+-evoked WPB exocytosis and that WPB exocytosis increased in 
a  concentration  dependent  fashion  as  the  size  of  the  Ca
2+  response  increased 
(although we decided that a formal correlation of the rates of rise or amplitude of 
the Fura-2 ratio with WPB exocytosis was likely to be prone to errors due to Fura-
2 saturation (Figure 4.5). A way to confirm whether indeed the single cells did not 
run out of the releasable pool of granules during the course of the experiment (up 
to 10 puff applications), would be to stimulate the cells with Ionomycin at the end 282 
of the hormone stimulations. The strong secretagogue would stimulate the release 
of all the remaining granules of the releasable pool and this would indicate the 
capacity of the cell under study to release.   
We  observe  however,  that  in  some  cells  (4/12  cells  studied  with  60s 
intervals and 3/12 with 120s intervals) there was an increase in fusion frequency 
during the second application of histamine despite a decrease in the Ca
2+ spike 
amplitude.  This  suggests  the  initial  Ca
2+  spike  may  have  primed  or  led  to 
recruitment of granules to the cell membrane ready for release in the event of a 
second Ca
2+ spike. Indeed the  delays from the [Ca
2+]i rise to exocytosis decreased 
for  the  second  spike  in  2  out  of  the  4  examples  and  remained  the  same  in  1 
example, suggesting that granule priming may have taken place to decrease the 
time taken for fusion from the Ca
2+ rise. Evidence for Ca
2+-dependent priming of 
secretory  granules  in  HUVEC  have  come  from  capacitance  recordings  [88]. 
Further studies are needed to examine this in more detail.  
These experiments show that WPB exocytosis can occur during repetitive 
transient pulses of Ca
2+, and that the fusion events are tightly  confined to the 
transient  increase  in  Ca
2+.  Further  experiments  are  required  to  determine  the 
kinetics  of  WPB  exocytosis  as  a  function  of  spike  frequency  and  amplitude, 
perhaps using low affinity Ca
2+ indicators capable of monitoring more reliably the 
kinetics and amplitude of large fast rising Ca
2+ transients that occur in these cells.  
7.7.3  Ca
2+ spiking in proregion-mEGFP expressing HUVEC  
In proregion-mEGFP nucleofected HUVEC the Ca
2+ spiking behaviour was 
less frequently observed. The cells that responded with [Ca
2+]i spikes had lower 
amplitudes, longer durations and slower rise times than non-nucleofected HUVEC 283 
(Figures 7.11). This effect appears to be due to the specific over-expression of a 
protein in the lumen of the secretory pathway. What might be the mechanism for 
this interference? It is possible that the over-expressed protein binds to free Ca
2+ 
in the ER, competing with endogenous buffers to alter the diffusion rate of Ca
2+, 
the  amount  of  Ca
2+  and  the  availability  for  release.  Alternatively  the  excess 
expressed protein may induce a mild stress response [732, 733] resulting in the 
expression of chaperone and other proteins that could alter Ca
2+ handling  and 
regulation of the IP3R [734, 735]. To elucidate the precise mechanism for this 
effect requires further studies.    
To overcome this problem I initially tried to take advantage of the fact that 
we used transient expression of the secreted proteins in these studies. By using 
cells 72hours post transfection, when the levels of expression were falling, we 
hoped that the ER stress due to protein over expression would be reduced. This 
was  judged  by  the  amount  of  ER-mEGFP  fluorescence  which  was  reduced  at 
72hours  and  the  cells  appeared  with  just  granule  staining.  However  we 
encountered the same problems in these cells. 
Brief  CHX  treatment  was  used  to  reduce  ER  stress  without  interfering 
significantly with Ca
2+-driven exocytosis of WPBs. A 3-4hour pre-treatment with 
CHX  did  not  alter  the  initial  kinetics  of  histamine-evoked  WPB  exocytosis 
suggesting  that  the  machinery  for  fusion  is  not  turned  over  (degraded  and  re-
synthesised) on this time scale. Under these conditions the kinetics of Ca
2+ spikes 
were restored close to that in non-Nucleofected cells indicating that the processes 
underlying this phenomena are readily reversible with a reduction in ER load.   
In the limited number of experiments carried out in CHX treated HUVEC 
expressing proregion-mEGFP it was apparent that WPB exocytosis could occur 284 
during [Ca
2+]i spikes, although not all Ca
2+ spikes evoked exocytosis. Indeed very 
few  WPBs  appear  to  fuse  during  these  brief  Ca
2+  spikes  (Figure  7.18).  This 
suggests  that  Ca
2+  spiking  may  indeed  provide  a  mechanism  to  limit  WPB 
exocytosis  while  allowing,  perhaps,  other  Ca
2+-dependent  processes  to  operate 
(e.g. NO production, PGI2 synthesis etc). Further studies are required to establish 
if a relation exists between the amplitude and more specifically the frequency of 
[Ca
2+]i oscillations and the secretion of WPBs. The use of CHX to help restore 
‘normal  Ca
2+  signalling’  in  cells  expressing  fluorescent  fusion  proteins  in  the 
lumen  of  the  secretory  pathway  may  provide  a  potential  system  for  further 
detailed  studies  on  single  cells,  perhaps  in  combination  with  controlled  Ca
2+ 
spikes produced either by agonist application as described above or from flash 
photolysis of intracellular caged Ca
2+ in whole cell patch clamped HUVEC [88, 
103].  
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Optical  studies  of  fluorescent  secretory  granules  in  single  HUVEC 
described  in  this  thesis  provide  a  direct  and  time-resolved  analysis  of  the 
properties  and  exocytosis  of  secretory  granules  in  endothelial  cells.  In 
combination with Ca
2+ sensitive dyes the relationship between [Ca
2+]i signalling 
and secretory granule exocytosis was examined with subsecond time resolution. 
Two distinct granules in EC were investigated; the WPB and the non-WPB. Data 
presented  in  this  thesis  summarises  the  differences  in  cargo,  intragranule  pH, 
sensitivity  of  exocytosis  to  [Ca
2+]i  and  time-course  of  stimulated  exocytosis 
between the WPB and non-WPB organelles, not previously shown. The last two 
chapters of this thesis deal with the role of mitochondria in Ca
2+ signaling in EC 
and  the  potential  regulation  of  secretion  by  Ca
2+  oscillations,  however  data  in 
those chapters is still preliminary; nevertheless the work established experimental 
conditions that show the potential for future work as described below.  
A  major  aim  of  these  studies  was  to  characterise  the  properties  and 
exocytosis of the WPB and the non-WPB granules. The pH sensitive properties of 
EGFP were utilised for this purpose. Using EGFP as an organelle-targeted pH 
indicator, the pH in the lumen of the WPB  and the non-WPB organelle were 
determined  in  chapter  3,  revealing  significant  differences  between  these  two 
organelles.  The  WPB  showed  a  time-dependent  acidification  to  ~pH5.5, 
consistent with true storage organelles in other secretory systems [343, 344, 636]. 
No  such  time-dependent  acidification  was  seen  for  the  non-WPB.  Unlike  the 
WPB, the non-WPB appears to be a transient organelle that is not stored in the 
cell. The half-life has been estimated to be ~15min (T Carter; unpublished data); 
thus following formation at the TGN, these organelles may not have sufficient 
time to fully acidify before they undergo unstimulated exocytosis. This chapter 287 
also  confirms  that  EGFP  targeted  to  secretory  granules  is  a  valuable  tool  in 
exocytosis due to its pH sensitive properties. The higher intra-granule pH in the 
non-WPB leads to smaller increases in EGFP fluorescence upon fusion than the 
WPB, however these were still sufficiently detectable to allow for kinetic studies. 
Results chapters 4 and 5 describe the kinetics of exocytosis of the WPB and 
the non-WPB respectively. Here, taking advantage of the pH-dependent increase 
in  EGFP  fluorescence  upon  vesicle  fusion,  direct  information  about  the  dose-
dependence of delays, rates and extent of the WPB and non-WPB exocytosis for 
histamine and thrombin and the pharmacological agent ionomycin were obtained. 
Ionomycin was the strongest secretagogue as it bypasses cell signalling cascades 
to elevate [Ca
2+]i to high levels whereas histamine was shown to be more potent 
than thrombin in elevating intracellular Ca
2+ and evoking exocytosis in the cells 
used in this study. The reason for the different potency between histamine and 
thrombin summarised in figure 4.15, is not well understood, however it could be 
partly due to differences in receptor activation as illustrated in figure 1.2. The data 
provides additional evidence that a threshold for Ca
2+-evoked WPB exocytosis 
exists,  however  the  identity  of  Ca
2+  sensors  involved  in  regulating  WPB 
exocytosis have not yet been characterised. The long delays from the [Ca
2+]i rise 
to granule exocytosis demonstrate the existence of a slow process (or processes) 
in  Ca
2+-driven  WPB  exocytosis.  This  could  involve  trafficking,  tethering  and 
docking of the granules to the plasma membrane prior to fusion. Experiments to 
address the role of the cytoskeleton in Ca
2+-driven WPB exocytosis might include 
selectively  inhibiting  components  of  the  cytoskeleton  involved  in  trafficking 
(microtubules) and tethering (actin filaments) of the granules and comparing how 
the  delays  and  overall  extent  of  WPB  exocytosis  change.  Data  in  figure  7.9 288 
suggests  the  existence  of  granules  that  are  readily  releasable  or  less  readily 
releasable,  similar  to  that  seen  in  neuroendocrine  granules  [391-395].  It  is 
hypothesised  that  granules  that  are  already  near  or  tethered  to  the  plasma 
membrane, perhaps immobilised by the actin cytoskeleton [57, 390], are the first 
granules available for rapid release upon a stimulus. Granules further away from 
the plasma membrane need to be trafficked to the site of fusion prior to their 
exocytosis introducing a longer delay. Possible experiments to study this may be 
to  disrupt  the  microtubule  network  and  look  to  see  if  the  slow  component  of 
events in the first latency distribution is lost.  
The kinetics of the non-WPB exocytosis differ from the WPB and suggested 
a higher sensitivity to [Ca
2+]i. These differences provide further evidence that the 
two secretory granules are distinct organelles and suggest the two population of 
granules  may  express  different  Ca
2+  sensors  on  their  membranes.  Although 
information  on  the  time-course  of  exocytosis  of  the  two  organelles  was 
determined the molecular mechanisms underlying the exocytotic process are not 
clear.  As  already  discussed  the  granules  could  undergo  fusion  either  via  the 
classical SNARE pathway or via the exocyst (figure 1.4). Future experiments that 
could  identify  whether  the  granules  accomplish  fusion  pore  formation  through 
assembly of the SNARE complex would be by treating the cells with botulinum 
toxins, selective blockers of the SNARE proteins [736, 737]. If botulinum toxin 
treatment  inhibits  or  decreases  agonist-evoked  granule  exocytosis  it  would 
suggest  WPBs  or  non-WPB  depend  on  the  SNARE  complex  formation  for 
exocytosis.  289 
Chapter 6 attempted to address whether mitochondrial Ca
2+ uptake in EC 
contributes to intracellular Ca
2+ hoemeostasis and fine-tunes the kinetics of WPB 
exocytosis.  The  approach  taken  to  address  this  question  was  to  collapse  the 
mitochondrial  membrane  potential  by  treating  EC  with  the  mitochondrial 
uncoupler  FCCP  (in  combination  with  oligomycin  to  prevent  consumption  of 
cellular ATP). The conditions were established for imaging [Ca
2+]i, [Ca
2+]m and 
secretion simultaneously and for blocking mitochondrial Ca
2+ uptake. Initial data 
from optical studies demonstrated that inhibition of mitochondrial Ca
2+ uptake 
decreased  both  the  amplitude  of  the  histamine-evoked  Ca
2+  transient  and  the 
extent of WPB exocytosis. The decrease in the Ca
2+ transient is likely to underlie 
the  reduction  in  the  extent  of  WPB  exocytosis;  however  the  mechanism  that 
results in the decreased Ca
2+ transient is not clear. Mitochondria are reported to 
modulate both IP3R activity at the ER level and extracellular Ca
2+ entry at the 
subplasmalemmal level through their Ca
2+ buffering capacity (see 1.10.4). The 
source of Ca
2+ that is modulated by mitochondria is important in defining the 
pattern of Ca
2+ signalling that results from hormone action. In order to understand 
how mitochondrial Ca
2+ uptake affects Ca
2+ homeostasis in our cells, it would be 
important to identify whether mitochondria are modulating Ca
2+ levels at the ER 
level  or  the  subplasmalemmal  level.  It  is  unlikely  that  the  mitochondria  are 
buffering Ca
2+ entering the cell via CCE at the subplasmallemal level because, as 
seen in figure 7.2 and 7.3, in the absence of extracellular Ca
2+ the initial [Ca
2+]i 
phase and WPB exocytosis is not affected. Such buffering effect may be most 
important during the prolonged phase of the Ca
2+ response, not studied here. In 
order  to  investigate  whether  the  [Ca
2+]i  decrease  induced  by  mitochondrial 
depolarisation is due to mitochondria buffering at the IP3R level, future work can 290 
examine  the  response  of  FCCP  treated  cells  to  flash  photolysis  of  caged-IP3. 
Release of caged IP3 activates the IP3R directly to discharge Ca
2+ from the ER. If 
Ca
2+ signalling was found to differ between control cells and cells treated with 
FCCP, this would indicate a role for mitochondria in buffering Ca
2+ at the IP3R 
level thus affecting the IP3R opening probability and Ca
2+ release from the ER. 
Chapter  7  looked  at  exocytosis  during  the  prolonged  phase  of  the  Ca
2+ 
response. Evidence for Ca
2+ oscillations in non-excitable cells and their potential 
significance  in  regulating  cellular  processes,  led  us  to  investigate  their  role  in 
regulating  Ca
2+-driven  exocytosis  of  WPB  in  EC.  The  approach  taken  was  to 
simultaneously  correlate  naturally  occurring  hormone-evoked  Ca
2+  oscillations 
with  WPB  exocytosis  of  proregion-EGFP  expressing  HUVEC.  In  some 
experiments  Ca
2+  spikes  with  uniform  intervals  were  generated  by  brief 
application of hormone in order to study systematically the relationship between 
spike  interval  and  exocytosis.  Expression  of  fluorescent  fusion  proteins  in  the 
secretory  pathway  of  HUVEC  provides  an  excellent  method  for  visualising 
secretory granules; allowing their trafficking and the early kinetics of Ca
2+-driven 
WPB exocytosis to be investigated, however, this approach is not without any 
problems. This methodology led to a perturbation of prolonged Ca
2+ signalling, in 
particular Ca
2+ spiking and Ca
2+ spike shape in our cells. A simple approach was 
developed using short exposure of proregion EGFP expressing cells to the protein 
synthesis inhibitor CHX that to a large extent ameliorated this problem. Despite 
this,  a  systematic  analysis  of  the  relation  between  spike  frequency  and  WPB 
exocytosis is likely to be difficult in single cells largely because no two cells 
behave alike, and because they have a finite pool of WPBs that do not turn over 
rapidly after agonist stimulation [738]. This makes repeated experiments on the 291 
same cells impossible. Protocols to generate well defined patterns of Ca
2+ spikes 
of known interval may offer a way to investigate the relationship between spike 
frequency and the rate and extent of WPB exocytosis. The approach described in 
chapter 7 suggests that WPB fusion can occur during repetitive brief Ca
2+ spikes 
however, the data is not  yet complete enough for any solid conclusions to be 
drawn. A particular issue needing attention is the gradual reduction in the Ca
2+ 
spike amplitudes during hormone puff application. Data in chapter 4 indicated that 
the  amplitude  of  the  Ca
2+  signal  is  important  in  determining  the  extent  of 
exocytosis. Thus the secretory responses seen may well represent a composite of 
spike frequency and spike amplitude making the interpretation of the role of the 
spike interval itself on WPB fusion difficult.  A way to overcome this problem 
would  be  to  treat  intact  cells  with  CHX  which  might  rescue  normal  Ca
2+ 
signalling  in  transfected  cells  exposed  to  repetitive  hormone  stimulations.  An 
alternative  approach  to  control  [Ca
2+]i
  transients  directly  without  affecting  any 
signalling pathways would be by flash photolysis of caged Ca
2+ in combination 
with a low affinity Ca
2+
 indicators such as Furaptra, as previously shown [88, 
103].  
In conclusion fluorescence microscopy can give us direct measurements of 
the kinetics of exocytosis of secretory granule populations in single HUVEC and 
this will ultimately help us understand the underlying mechanisms that regulate 
release of pro- and anti- coagulant molecules involved in regulating haemostasis 
and inflammation.  
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10Supplementary material 
 
 
 
Figure I. Single HUVEC co-expressing EGFP-GRO-α α α α and proregion-
mRFP 
Proregion-mRFP  specifically  labels  the  WPBs  and  EGFP-GRO-α  specifically 
labels the non-WPB population of granules 
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ATP     Adenosine Triphosphate  
CaM    Calmodulin 
cAMP    cyclic Adenosine Monophosphate  
CHX     Cyclohexaminde 
CRAC     Ca
2+ release activated Ca
2+ 
DAG     Diacylglycerol 
DsRed   Discosoma sp. Red 
EC     Endothelial Cells 
EGFP    Enhanced Green Fluorescent Protein 
ELISA   Enzyme Linked ImmunoSorbent Assay 
eNOS    endothelial Nitric Oxide Synthase  
FCCP    Carbonyl cyanide-p-trifluoromethoxyphenylhydrazone 
GFP    Green Fluorescent Protein 
GPCR    G-protein coupled receptor 
HR     Histamine Receptor 
HUVEC  Human Umbilical Vein Endothelial Cells 
IP3     Inositol 1,4,5-Trisphosphate 
IP3R     Inositol 1,4,5-Trisphosphate Receptor 
mGFP   monomeric Green Fluorescent Protein 
mRFP   monomeric Red Fluorescent Protein 
NCE     Na
+:Ca
2+ Exchanger 
NHE    Na
+:H
2+ Exchanger   
NO    Nitric Oxide 
PAR    Proteinase Activated Receptor 
PGI2    Prostacyclin  
PKA     Protein Kinase A 
PKC     Protein Kinase C 
PLC    Phospholipase C 
PMCA   Plasma Membrane Ca
2+-ATPase  
PS    Physiological Saline 295 
ROS     Reactive Oxygen Species 
SERCA   Sarco/Endoplasmic Reticulum Ca
2+ ATPase  
SNARE   Soluble N-thylmaleimide-sensitive factor (NSF) Attachment 
protein Receptor 
TGN    Trans-Golgi Network 
t-PA    Tissue Plasminogen Activator 
Trp     Transient receptor potential 
vWF     von Willebrand Factor 
WPB     Weibel Palade Body 
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